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The mu opioid receptor (MOR) belongs to the superfamily of G-protein coupled
receptors (GPCRs) and remains an important target in the management of pain
and addiction, with an emerging role in promoting tumour growth.
Understanding of the complex role of the MOR in these signalling pathways
would be aided by further study of receptor-ligand interactions. Development
of fluorescent ligands to target the MOR may provide the necessary tools to
study such receptor pharmacology and localisation in healthy and diseased
tissue.
Previously described high affinity fluorescent MOR ligands have been
unsuitable for confocal imaging studies due to high levels of non-specific
interactions with the cellular membrane. The introduction of amino acid-based
linker moieties to separate the orthostere and fluorophore of fluorescent
ligands has been reported to improve receptor binding affinity, receptor
subtype selectivity and the confocal imaging properties of fluorescent ligands
for various GPCRs.
This thesis describes the development of novel fluorescent MOR ligands based
upon the opioid antagonists naltrexone and alvimopan which also contain
amino acid-based linkers. Evaluation of the reported SAR of small molecule
opioid receptor ligands was used to inform orthostere selection and location of
linker attachment. Different amino acid linker compositions were investigated
through the synthesis and evaluation of MOR binding affinity of non-
fluorescent congeners in a series of TR-FRET competition binding assays.
Coupling of the optimised congeners to red-emitting fluorophores (BODIPY
630/650 or sulfo-Cy5) afforded nine amino acid-linked fluorescent ligands for
MOR. Assessment of MOR binding affinity of the fluorescent ligands was
achieved in TR-FRET saturation binding assays.
Investigation of the linker composition of β-naltrexamine-based ligands did not 
identify any significant differences in MOR binding affinity between non-
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fluorescent congeners containing different amino acid linkers. However, a
subsequent series of BODIPY 630/650-containing fluorescent ligands were
identified to possess sub-nanomolar MOR binding affinities (pKD = 9.20-9.58).
Non-fluorescent derivatives of (3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl)
piperidine displayed improved MOR binding affinity when a phenylalanine
moiety was bound via an N-propanoate, but further elaboration of the linker
was found not to improve binding further. High affinity fluorescent ligands for
the MOR containing the BODIPY 630/650 fluorophore were once more
identified utilising this design approach (pKD = 8.14-8.47).
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1.1 G protein-coupled receptors
G protein-coupled receptors (GPCRs) represent the largest family of cell-
surface receptors and the most frequently targeted receptor family for
pharmaceutical intervention and research.1, 2 Its members display a vast and
diverse range of functions, but all possess a conserved structure and primary
mechanism of action. Structurally, GPCRs consist of seven transmembrane α-
helices arranged in a non-linear barrel shape.1, 3 These helices are connected
by less structured extracellular and intracellular loops with an extracellular N-
terminal region and intracellular C-terminal region (Figure 1-1).1, 3 Regulation
of GPCR signalling is activated endogenously by peptide, hormone and
neurotransmitter agonists, but intervention by exogenous drugs allows
signalling to be manipulated for medical and research purposes.
Receptor activation by orthosteric ligand binding typically occurs within the
transmembrane bundle causing a conformational change in receptor structure
that allows new cytoplasmic interactions to occur.1 Binding of a heterotrimeric
G protein to the intracellular region of a GPCR can occur before or after
receptor activation, with activation resulting in the exchange of a bound
guanosine diphosphate (GDP) molecule for guanosine triphosphate (GTP).4 The
GTP-bound G protein is released from the receptor and the G protein subunits
disperse. The GTP-bound α-subunit can interact with proteins elsewhere in the 
cell, with further signalling induced by hydrolysis of GTP to GDP. In this inactive
state, the α-subunit can reunite with the βγ-subunit complex - which can also 
engage in signalling pathways while separated - and reassociate with the GPCR
(Figure 1-1).
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Figure 1-1: A representation of GPCR activation and G protein signalling.
Source: Sven Jahnichen, 24.04.2006.
The GPCR structure is composed of seven transmembrane helices joined by intracellular and
extracellular loops. They are also characterised by an extracellular N-terminal region and an
and intracellular C-terminal region. (A) An orthosteric agonist can bind to the extracellular
binding site. (B) The bound agonist switches the GPCR into an active conformation. (C) In this
state, the G protein-bound GDP is exchanged for GTP. (D) With GTP bound, the α- and βγ-
subunits dissociate. (E) Signalling interactions made by the α-subunit result in hydrolysis of GTP 
to GDP. The agonist dissociates from the receptor binding site, returning it to the inactive
conformation. (F) The inactive conformation of the GPCR is able to bind to a GDP-bound G
protein heterotrimer.
1.2 Opioid receptors
The opioid family of receptors (ORs) are members of the class A gamma
subgroup of GPCRs which bind a Gi/o trimer via the C-terminus of the active
receptor.5 The dissociated αi/o subunit inhibits adenylyl cyclase activity,
preventing production of cyclic adenosine monophosphate (cAMP) from





channel subfamily V member 1 (TRPV1) ion channel inhibition.6 The βγ subunit 
complex can also interact with various membrane-bound ion channels,
including pre- and post- synaptic Ca2+ ion channels and G protein–coupled
inwardly rectifying K+ (GIRK) channels.7, 8 It is in these ways that the ORs are
able to modulate neuronal excitation and neuropeptide release, resulting in
their antinociceptive effects (Figure 1-2).5, 9
Figure 1-2: Opioid receptor signalling by activated G protein subunits.5
Source: Stein (2016)5
Activation of an OR results in the release of its G protein subunits. The αi/o subunit inhibits
adenylyl cyclase activity, leading to TRPV1 ion channel inhibition due to lower cAMP levels. The
βγ subunit complex can interact with various membrane-bound ion channels either directly, or 
via phospholipase C/phosphokinase C (PLC/PKC) pathways.5
ORs are also able to recruit various kinases to phosphorylate their cytoplasmic
regions, including GPCR kinases (GRK), which can recruit arrestin.9 Once bound,
arrestin desensitises the OR by preventing coupling to G proteins and initiates
receptor internalisation and recycling or degradation.9
Sequence analysis of cDNA in mice with selective deletion of genes confirms
only three OR genes exist: the mu (MOR), delta (DOR) and kappa (KOR)
receptors.10 Other OR subtypes have been proposed, including the
nociception/orphanin FQ (N/OFQ), epsilon and sigma receptors, but none are
widely considered to be “true” ORs due to significant differences in gene
sequence or receptor function.5 For this reason, these additional receptors
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were not considered further in this project. There is some structural variety
amongst the three major ORs due to post-translational modifications and gene
splicing.10 Changes in functionality can also be obtained through the formation
of dimers and oligomers.10 Additionally, different ligands can elicit different
effects at the same receptor through allosteric modulation and biased
signalling.10, 11
ORs are implicated in the regulation of numerous signalling pathways and
physiological responses. Though most commonly known for their role in
nociception and analgesia, OR activation is additionally associated with
constipation, respiratory depression, convulsions, anxiety, diuresis and
reduction of inflammation.5 This results from the wide distribution of ORs in
different cells of the body, including neurons of the peripheral (PNS) and
central (CNS) nervous systems, neuroendocrine cells, immune cells and cells of
the gastrointestinal (GI) tract .5
Endogenous peptidic OR ligands are known to regulate these effects. The
endorphins, enkephalins and dynorphins share the “opioid motif”, a common
N-terminal Tyr-Gly-Gly-Phe-Met/Leu sequence responsible for orthosteric OR
binding. Receptor subtype selectivity is determined by the remaining C-
terminal regions of these polypeptides: β-endorphin and the enkephalins act 
primarily at MOR and DOR, and the dynorphins selectively bind to KOR.5
Endomorphins do not contain the “opioid motif”, but are able to selectively
bind MOR.5
1.2.1 Opioid receptors as therapeutic targets
A broad range of OR ligands have been developed to target the pathways
regulated by ORs for clinical benefit. Some OR ligands, such as the natural
products of Papaver somniferum (opium poppy), morphine (1) and codeine (2),
have been used in medicine for millennia,12 while novel OR ligands continue to
be approved for medicinal use.13
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A range of different opioid agonists are used therapeutically (Figure 1-3) with
differences in prescribing based not only on the level of analgesia required, but
also the route of administration, desired onset and duration, as well as the side
effect profile of the drug.5, 14-16 OR agonists are primarily prescribed for pain;
other effects are usually off-target interactions rather than desired
outcomes.14-16 The most commonly prescribed opioid agonists - morphine (1),
codeine (2), oxycodone (3), tramadol (4), fentanyl (5) and many of their
derivatives - act primarily at the MOR.5, 14, 15
Figure 1-3: Structures of the most commonly prescribed opioid agonist.14
The structures of the most commonly prescribed OR agonist drugs in England. Tramadol is
marketed as a racemic mixture of the 1S,2S and 1R,2R enantiomers.
OR antagonists are commonly prescribed to deal with the side effects of opioid
use or overuse. Clinically approved OR antagonists (Figure 1-4) can be split into
two groups: centrally acting MOR antagonists, which are able to penetrate the
blood-brain barrier (BBB) and act throughout the body, and peripherally acting
MOR antagonists (PAMORAs), whose activities are restricted to peripheral
cells. The peripheral selectivity of PAMORAs results from physicochemical
properties which limit GI absorption and result in poor BBB penetrability.
6
Figure 1-4: Structures of clinically approved opioid antagonists.
Bowel related issues are the most common side effects of opioid use, whether
following surgery or from treatment of chronic cancer pain, and include opioid-
induced constipation (OIC) and postoperative ileus (POI).17 OIC results from
increased intestinal fluid absorption due to alterations to MOR- and DOR-
regulated K+ channel activation in GI cells.17 Methylnaltrexone (MNTX) (11),
naloxegol (8), and the recently approved naldemedine (10) are all approved
opioid antagonists for the treatment of OIC. POI, the loss of coordinated bowel
propulsion following surgery, can be treated by alvimopan (9), another
peripherally acting MOR antagonist. Opioid agonists that are prescribed for
surgical pain act through the MOR to block the release of neurotransmitters
from excitatory motor neurons and stimulate the release of neurotransmitters
from inhibitory motor neurons, causing this lack of GI motility.18 Antagonism of
peripheral ORs can treat these conditions without impacting CNS analgesia by
centrally-acting OR agonists.
Naloxone (6) and naltrexone (7) possess high bioavailability from the gut and
are able to penetrate the BBB and act on the ORs of the CNS.15 They are used
to treat overdose of opioid agonists and in addiction therapy, although
antagonist treatment alone does not prevent the cravings associated with
opioid withdrawal so has poor compliance.15
7
OR ligands with more complex pharmacological profiles have been developed,
such as the mixed agonist/antagonist buprenorphine (12), which is a partial
agonist of MOR that acts as an antagonist of KOR and DOR.19, 20 The high MOR
binding affinity, slow dissociation kinetics, and partial MOR agonist profile of
buprenorphine (12), make it suitable for treatment of opioid dependency,
often in a fixed-dose formulation with naloxone (6), as it prevents other opioids
from eliciting a full effect while decreasing cravings and withdrawal.20
Figure 1-5: Structure of the mixed agonist/antagonist buprenorphine (12)
1.2.2 The mu opioid receptor in cancer
Opioids are commonly used to treat chronic pain in cancer patients, but
evidence has emerged in the past two decades linking the MOR with increased
tumour growth. Morphine (1) has been found to stimulate phosphorylation
and activation of the survival-promoting protein kinase Akt in MOR-expressing
cells,21, 22 stimulate angiogenic cell proliferation in MOR-expressing cells in both
in vitro and in vivo models,22 and reduce time to tumour detection when
treated with morphine (1) in a breast tumour xenograft model in mice.22 The
co-administration of naloxone (6) reduces the rate of tumour growth,
increasing the time to tumour detection by over 50%.22 MOR knockout mice
injected with melanoma cells, present significantly reduced tumour growth,
even in the absence of exogenous opioids.23
Seven weeks of morphine (1) treatment was found to increase the density of
tumour vasculature and cause tumours to increase in size and number,
resulting in shorter survival in transgenic mouse models that developed breast
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tumours from a tumour antigen fusion gene.24 Importantly, morphine (1)
treatment was not found to advance the onset of tumour development,
indicating that opioid use does not increase the chance of an individual
developing cancer.24
Several studies have found that expression of the MOR is higher in both human
tumours and mouse tumour models,24-26 that overexpression of MOR in non-
small cell lung cancer (NSCLC) cells, and that treatment with various MOR
agonists results in changes typical of increased epithelial mesenchymal
transition as well as increased tumour growth rates.27 Clinical studies into
MOR-induced tumour growth, though largely limited to retrospective analyses
and anecdotal evidence, support this hypothesis.28, 29 Furthermore, breast
cancer patients possessing an MOR A118G polymorphism showed a decreased
mortality rate compared to wildtype patients.30, 31
The MOR-activated systems responsible for its role in tumour development are
not yet well understood. Further study of these systems, and continued study
of non-cancer MOR activation are therefore paramount to improve future
treatment methods and aid next-generation drug design.
1.3 Studying ligand-receptor interactions
The study of ligand-receptor interactions, and the signalling pathways activated
or inhibited as a result, is a key way in which cellular functions are understood
in both healthy and diseased states. Different experimental and computational
tools are available to study these interactions.
1.3.1 In silico modelling
Three-dimensional models of GPCRs solved via X-ray crystallography can be
used to aid ligand design. The process of creating high quality crystals of
membrane-bound receptors like GPCRs remains challenging, as the GPCR
structure can become compromised when removed from the cell membrane.32
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However, advances in crystallisation techniques have allowed a growing
number of high quality X-ray crystal structures of GPCRs (including the ORs in
201233-35) to be solved. In some instances, active and inactive conformations of
a receptor can be identified through co-crystallisation with a bound agonist or
antagonist.32
In silico modelling allows chemical structures to be docked into the active site
of the solved x-ray crystal structure of a receptor, predicting individual
interactions between the compound and receptor, as well as the overall
binding affinity. De novo ligand design is then the process of modifying docked
compounds to improve existing predicted interactions or to form new
interactions with the receptor.32, 36 Alternatively, smaller structural fragments
can be docked into optimal positions for receptor interaction. The docked
fragments are then covalently linked into a single structure, while still
maintaining these optimised positions.36-38 A de novo approach to ligand design
is especially valuable when a high degree of concordance is found between in
silico predictions and in vitro results.36
In silico modelling is a useful and promising tool for ligand design which
continues to be improved upon. However, experimental evaluation of
synthesised ligands is still required to fully optimise ligand design.
1.3.2 Radioligand binding assays
Radioligands are simply radiolabelled versions of known ligands – a ligand
which has an atom in its structure exchanged for a radioisotope equivalent,
such as 3H, 125I or 32P. Radioligands have been widely used in pharmacology to
determine receptor binding affinities of either the radioligand – and therefore
the unlabelled version of the ligand – or an unlabelled competitor.39 The
receptor binding affinity (equilibrium dissociation constant - KD) of a
radioligand can be determined in a saturation binding assay by measuring the
specific binding of the radioligand across a suitable range of concentrations in
which specific binding reaches saturation (Bmax). The binding affinity of an
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unlabelled competitor ligand (Ki) can be determined by measuring the
competitive displacement of a fixed concentration of radiolabelled ligand.
Additionally, receptor kinetic assays using radioligands can be used to
determine the association and dissociation rates of either the radioligand or an
unlabelled competitor.39, 40
However, radioligand binding assays require a large cell population (over
10,000 cells) per data point and, unlike fluorescent ligands, cannot be used to
study interactions at a single cell level. Safety while handling radioligands
alongside disposal of the subsequent radioactive waste are additional
disadvantages to radioligand use. These issues are greatly magnified if the
radioligand is not commercially available and must be synthesised.
1.3.3 Fluorescent ligands
Fluorescent ligands have increasingly replaced the use of radioligands in ligand-
receptor binding studies, mostly due to safety and cost considerations – not
only the cost of purchasing radioligands but also equipment for safe handling
and storage. Fluorescent ligands can be used in the same pharmacological
assays as radioligands to determine labelled or unlabelled ligand binding
affinities and kinetics. However, the applications of fluorescent ligands are far
more diverse than this, and through the use of different fluorophores,
orthosteres and linker structures (described below), a diverse range of
fluorescent ligands can be made with different physical and photophysical
properties to study receptor binding, signalling and for cell visualisation.
Radioligands remain useful in the study of specific ligands, as their binding
profile is representative of the unlabelled version of the ligand. While
fluorescent ligands have many benefits, they are considered to be unique
pharmacological entities, which are not representative of their unlabelled
parent compound.41
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1.3.3.1 Principles of fluorescence
Fluorescence occurs in certain molecules in which an electron can be promoted
from the singlet ground state (S0) to the singlet excited state (S1) by the
absorption of a photon. The return of this electron to S0 results in the emission
of a photon as fluorescence. However, due to loss of energy by vibrational
relaxation while in S1 (Stokes shift), the emitted photon has lower energy than
the absorbed photon, resulting in a longer wavelength of emitted light (Figure
1-6).
Intersystem crossing occurs when an excited electron transitions from S1 to the
triplet excited state (T1). In S1 the spin of the excited electron remains paired,
but in T1 these spins are parallel. In T1 energy loss is slower and photon emission
as phosphorescence is greatly delayed compared to fluorescence. Intersystem
crossing is more favourable in molecules which have overlapping S1 and T1
levels, as less energy is required to move between them.
The fluorescence quantum yield (ΦF) of a fluorescent molecule (fluorophore) is
the frequency with which an absorbed photon results in fluorescent emission
of a photon. A fluorophore with a high ΦF will convert a high percentage of
absorbed photons into fluorescence, while a lower ΦF fluorophore will convert
more absorbed photons into phosphorescence.
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Figure 1-6: Jablonski diagram displaying the excitation states of electrons in fluorescent
compounds.
(a) In the singlet ground state (S0) electron spins are paired. When an electron is promoted to
the singlet excited state (S1) it remains paired. In the triplet excited state (T1) the electrons are
parallel. (b) Absorption of a photon by an electron in the singlet ground state (S0) results in
promotion of the electron to the singlet excited state (S1). While in the singlet excited state
vibrational relaxation results in energy loss (Stokes shift). When the excited electron returns to
the singlet ground state, a photon of lower energy is emitted as fluorescence. Intersystem
crossing occurs when an excited proton in S1 transitions to T1. Electrons in T1 can undergo
further vibrational relaxation before returning to S0, emitting energy as phosphorescence.
1.3.3.2 Structure of a fluorescent ligand
In the most basic form, fluorescent ligands are composed of a known receptor
ligand (typically an orthostere) labelled with a fluorophore. The first example
of this was 9-aminoacridine-labelled propranolol (9-AAP) (13), with numerous
other examples described in the literature (Figure 1-7).42-44 Unlike most
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significantly alter the structure of the ligand and its properties. It is important
to avoid fluorophore conjugation onto key functional positions of the
orthostere which would interfere with binding, but direct attachment of a bulky
fluorophore anywhere on a ligand is likely to influence receptor binding.
Figure 1-7: Examples of early directly labelled fluorescent ligands.42-44
Early examples of fluorescent ligands attached a fluorophore to an orthostere directly.
Examples include the 9-aminoacridine-propranolol β-adrenoceptor antagonist 9-AAP (13), The
prazosin-BODIPY FL α-adrenoceptor antagonist QAPB (14) and the histamine-fluorescein
complex (15)
For this reason, the orthostere and fluorophore are now more commonly
separated through a linker moiety. Linkers are typically linear chains, often
composed of a repeated structural subunit, such as the polyethylene glycol
(PEG) linker of 18 or the glycyl linker of 16 (Figure 1-8).45, 46 Linkers typically
possess few structural features to reduce disruption of orthostere binding.
However, even with a well calculated point of attachment and linker design,
fluorescent ligands will possess different properties from their unlabelled
precursor. Detailed reviews covering the past five decades of fluorescent ligand
designs have been published by Baindur et al.,44 Middleton et al.47 and Vernall
et al.41
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Figure 1-8: Examples of fluorescent ligands with differently composed linkers.45, 46, 48
The XAC-based fluorescent ligand (16) utilises a glycyl linker between the orthostere and
fluorescein isothiocyanate (FITC) fluorophore.46 An octanyl linker connects the potentidine
orthostere and nitrobenzofurazan (NBD) fluorophore of 17.48 The BODIPY 558/568 fluorophore
and pirenzepine orthostere of 18 are connected by a PEGyl hexamer linker.45
Choice of fluorophore is a crucial aspect of fluorescent ligand design. Factors
such as fluorophore polarity, solubility, emission wavelength, quantum yield
and stability of fluorescent signal should be considered in relation to the
purpose of the ligand and the experiments it will be used in. In general, low
photobleaching (irreversible loss of fluorescence due to photon induced
chemical damage), high fluorescence intensity, high quantum yield and near-
infrared (NIR) emission spectra (to distinguish the signal from
autofluorescence) are preferred in fluorophores, such as sulfo-Cy5 and some
BODIPY variants.
When investigating a particular receptor system, it is useful to have multiple
fluorescent ligands with different fluorophores available, so that the best
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fluorescent ligand can be matched to the assay. For example, BODIPY 630/650
benefits from superior fluorescence intensity and a longer fluorescence
lifetime compared with other red-emitting fluorophores, while sulfo-Cy5 is a
hydrophilic fluorophore which achieves a better signal to noise ratio due to
fewer non-specific membrane interactions.49
Figure 1-9: Structures of some commonly used fluorophores.
A new approach to linker design has recently been pioneered, incorporating
more complex structural elements. Vernall et al.50 synthesised fluorescent
adenosine receptor ligands using a xanthine amine congener (XAC) orthostere
bound to BODIPY 630/650-X via a peptidic linker. Previous examples of peptidic
linker moieties are composed of unsubstituted glycyl subunits,46 but the linkers
in the Vernall et al.50 study utilised different amino acids to optimise receptor-
ligand interactions. This work expanded upon the observations of Jacobson et
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al.51 that conjugation of amino acids to XAC could influence A1 and A3
adenosine receptor (A1AR and A3AR) binding affinity, with certain amino acid
congeners conferring improvements in receptor subtype selectivity compared
to the non-selective XAC. Vernall et al.50 synthesised a series of terminally
Fmoc-bound (fluorenylmethyloxycarbonyl) dipeptide congeners of XAC (Figure
1-10), incorporating different combinations of amino acids to optimise A3AR
binding and selectivity against A1AR. There was some variation in the adenosine
receptor binding profiles between the non-fluorescent congeners and the
corresponding BODIPY 630/650-X fluorescent compounds, but the study
yielded fluorescent ligands containing a Ser-Tyr dipeptide linker with greatly
improved A3AR binding affinity and receptor subtype selectivity compared to
previous non-peptidic fluorescent ligands (Figure 1-11).50
Figure 1-10: Structures of dipeptide Fmoc XAC congeners with different amino acid
compositions synthesised by Vernall et al.50
A similar approach was taken by this group to synthesise fluorescent ligands
for the histamine H1 receptor (H1R).52 They developed a series of high affinity
mepyramine- and VUF13816-based fluorescent H1R ligands containing a
peptidic linker. The high lipophilicity of the fluorescent mepyramine compound
34a had made it unsuitable for confocal imaging.53 Replacement of the pentyl
linker of 34a with di- or tripeptides yielded compounds 34b-d which, while
resulting in attenuation of binding affinity compared to 34a, exhibited
displaceable membrane binding at H1R, indicating a high degree of specific
binding ideal for confocal imaging.52, 53 Similar structures containing the
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VUF13816 orthostere produced similarly high affinity fluorescent ligands with
favourable imaging properties (Figure 1-12).52 The optimal amino acid linker
composition of these fluorescent VUF13816 ligands continues to be studied
(unpublished).
Compound A3AR pKi A1AR pKi A3AR Ki/A1AR Ki
31 9.12 7.62 31.6
32 7.51 8.03 0.3
33 8.38 7.79 3.9
Figure 1-11: Structures and adenosine receptor binding affinities of XAC-BODIPY 630/650-X
fluorescent ligands with different linker compositions.50
The linker moiety of the fluorescent ligand 31 is composed of a Tyr-Ser dipeptide, resulting
from optimisation of the amino acids in the linker to improve A3AR binding affinity and receptor
subtype selectivity compared to the non-selective fluorescent ligands 32 and 33.50
Recent projects which have developed fluorescent ligands containing peptidic
linkers sought to improve the hydrophilicity and imaging properties of the
ligands, rather than to improve binding affinity through new linker-receptor
interactions. These projects have utilised only simple Ala-Ala linkers rather than
more complex amino acid combinations.54, 55
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Compound H1R pKD Compound H1R pKD
34a 8.9a 35a 7.9-8.6b
34b 7.5-8.3b 35b 7.6-8.1b
34c 7.2-8.2b 35c 7.5-8.0b
34d 7.3-7.8b
Figure 1-12: Structures and H1R binding affinities of mepyramine- and VUF13816-based
fluorescent ligands.52, 53
Incorporation of different peptidic linkers into mepyramine-BODIPY 630/650-X fluorophores
resulted in a loss of binding affinity but improved imaging properties compared to 34a.52, 53
VUF13816-BODIPY 630/650-X peptide-linked fluorescent ligands also possessed high H1R
binding affinities and favourable imaging properties.
a – pKD value determined from the shift in histamine response curve in the presence of 34a in
an intracellular calcium mobilization assay in CHO cells expressing H1R.53
b – range of pKD values determined from three methods: shift in histamine response curve in
the presence of fluorescent ligand in an intracellular calcium mobilization assay in CHO cells
expressing H1R; saturation curve of fluorescent ligand binding in a BRET assay in HEK293 cells
expressing Nluc-H1R; saturation curve of fluorescent ligand binding over time in a BRET assay
in HEK293 cells expressing Nluc-H1R.52
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1.3.3.3 Applications of fluorescent ligands
Fluorescent ligands have been in use since the 1960s, mostly as histological
stains.56 The discovery of selective small molecule fluorescent ligands led to the
development of a growing number of pharmacological assays, which will be
described in this section.
Confocal microscopy
Use of fluorescent ligands in confocal microscopy can produce high-resolution
images of receptor localisation on different scales - from a population of cells
down to single cell level. Automated confocal microscopy has been used in
receptor-ligand binding studies, similar to those described above using
radioligands, to measure the binding affinity of labelled and unlabelled ligands
(Figure 1-13).40, 57
Figure 1-13: Confocal microscopy experiment using fluorescent ligands.
Source: Stoddart et al. (2015)40
A laser beam passes through an adjustable pinhole and is reflected off a dichromatic mirror. It
is then focused by the objective onto a focal plane of the fluorescent ligand-bound specimen.
Emitted fluorescence travels back through the objective, where in focus light is focused
through a different pinhole into the photomultiplier detector.40
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Fluorescence correlation spectroscopy
Fluorescence correlation spectroscopy (FCS) measures fluctuations in the
emitted photons of excited fluorescent ligands as they pass through a small
confocal volume. Time dependent measurement of these emissions using
autocorrelation analysis provides information on the fluorescent ligand’s
mobility (and therefore binding state) and concentration within the confocal
volume.40, 58 FCS can be used in low-expression systems, including native tissue.
The small scale at which FCS operates under allows more detailed
characterisation of receptors, such as the spatial organisation of receptors,
detection of receptor oligomerisation into signalling complexes, and
identification of different receptor conformations.40, 53, 58
Fluorescence polarisation
Fluorescence polarisation (FP) is a simpler method which takes advantage of
differences in the flexible linker region of fluorescent ligands by measuring the
change in polarisation of light emitted from a fluorophore.39 Upon excitation
by polarised light, a receptor-bound fluorophore will emit light that is still
polarised, while an unbound fluorescent ligand will emit depolarised light due
to rapid rotation in the linker region. The differences in fluorescent ligand
mobility and resulting depolarisation of light can be measured to determine
binding affinity of the fluorescent ligand or an unlabelled competitor.39
However, when working with low concentrations, FP suffers from poor
precision compared with other quantitative methods.39
Fluorescence resonance energy transfer
Fluorescence resonance energy transfer (FRET) is a measurement of the non-
radiative transfer of energy between two fluorescent moieties. A lanthanide-
containing donor fluorophore is excited by a photon of a particular wavelength
and emits light at a different wavelength (or wavelengths). A successful transfer
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of energy is dependent on the proximity of the donor and acceptor
fluorophores. If the acceptor is in close proximity to the donor, the energy of
the emitted photon can be transferred to the acceptor, allowing it to fluoresce
at a different wavelength. In a FRET assay, a receptor is labelled with a donor
fluorophore and a fluorescent ligand for that receptor contains an acceptor
fluorophore which is able to absorb the emitted wavelength of the donor
(Figure 1-14).40, 58
Figure 1-14: Principle of FRET using a fluorescently labelled receptor and ligand.40
Source: Stoddart et al. (2015).40
The lanthanide-based fluorophore (donor) of a tagged receptor is excited and emits light as
fluorescence. FRET occurs when the acceptor fluorophore of a bound fluorescent ligand is
excited energy transferred from the donor. FRET can only occur when the ligand is bound as it
requires close proximity between the donor and acceptor fluorophores.40, 58
For example, Lumi4-terbium cryptate (Lumi4-Tb) can be used to fluorescently
label receptors. The receptor is labelled with the donor fluorophore in such a
position that only bound ligands are sufficiently close enough for FRET to take
place. Lumi4-Tb absorbs light at a peak of around 340 nm and emits light at
peaks of 490, 548, 587 and 621 nm. Emitted light in the 621 nm range can be
absorbed by some fluorophores, such as BODIPY 630/650 which emits light at
a wavelength peaking at around 650 nm. In this example, fluorescence is
measured at 620 nm (from the donor) and 665 nm (for the acceptor) to ensure
that there is minimal overlap in emission spectra. The ratio of these emissions
indicates the frequency of FRET occurring, and therefore allows measurement
the binding affinity of the fluorescent ligand.
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Time-resolved FRET (TR-FRET) introduces a short gap (of 50-150 microseconds)
between the energy input and measurement of emission. This allows short-
lived fluorescence from sources other than the donor and receptor to decay,
leaving a clearer signal from the donor and acceptor emissions, which have
longer fluorescence lifetimes.
1.4 Fluorescent opioid receptor ligands
Development of fluorescent opioid ligands was initially limited to fluorescent
conjugates of peptidic OR ligands, mostly enkephalins and their synthetic
analogues.44 Compared to small molecule fluorescent conjugates, the addition
of a fluorophore represents a less significant increase in molecular weight and
often positions the fluorophore further from the ligand binding site, reducing
the likelihood of interfering with orthosteric binding.47 Fournie-Zaluski et al.59
discovered that attachment of a dansyl moiety to the N-terminus of met-
enkephalin (36a) resulted in a loss of OR binding affinity, while C-terminal
dansyl attachment (36b) retained the activity of the unlabelled enkephalin.
Following this, several other C-terminally linked fluorescent peptides were
synthesised, each possessing improved binding affinity compared to their
parent ligands (Figure 1-15).60-62
Peptidic fluorescent OR ligands have remained popular, with structures
developed to incorporate non-naturally occurring amino acids, such as
dimethyl tyrosine (DMT), tetrahydro-isoquinoline-3-carboxylic acid (Tic) and N-
leucine (Nle) (Figure 1-16).63-66
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Figure 1-15: Structures of several early enkephalin-based fluorescent OR ligands.59-62
Figure 1-16: Structures of fluorescent peptidic ligands which utilise unnatural amino acids.63,
64
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The development of non-peptidic fluorescent OR ligands was initially slow, and
those that had been discovered utilised morphinan scaffolds with directly
bound fluorophores, such as the fluorescein-oxymorphone derivatives
developed by Kolb and colleagues (Figure 1-17).67, 68 The close spatial
relationship between the orthostere and fluorophore resulted in greatly
diminished receptor binding, relative to their unlabelled parent compounds.67,
68
Figure 1-17: Fluorescent oxymorphone derivatives with directly bound fluorescein
fluorophores.67, 68
Progress was made by Archer et al.,69 who incorporated a short sarcosine linker
between different orthosteres and a NBD fluorophore (Figure 1-18). The same
group produced a series of BODIPY-labelled ligands, including a MOR-selective
irreversibly binding fluorescent ligand (46).70 Unfortunately, some of these
compounds suffered from significant hydrophobicity or exhibited absorption
and emission wavelengths unsuitable for many modern pharmacological
methods, which typically prefer NIR emitting fluorophores.57, 69, 70
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Figure 1-18: Selection of fluorescent OR ligands.69, 70
6- and 7-position conjugated NBD fluorescent ligands 45 and 47 were synthesised by Archer et
al.69 containing a sarcosine linker. BODIPY-fluorescent OR ligands (43, 44 and 46) were
synthesised by Emmerson et al.70 including the irreversible fluorescent ligand 46.
Since the 1990s, development of fluorescent MOR ligands has been somewhat
neglected compared to advances at other receptors.41 More recently however,
Schembri et al.57 reported the successful synthesis of several oripavine-derived
fluorescent ligands (Figure 1-19). This project aimed to modernise fluorescent
MOR ligands with more practically useful fluorophores and longer linker
moieties to reduce the impact of fluorophore attachment on binding. Of the
compounds synthesised, the sulfo-Cy5 (51) and BODIPY 630/650-X (50)
compounds were particularly favoured: 50 for its high binding affinity, receptor
subtype selectivity and bright fluorescence, and 51 for its rapid, reversible
specific binding to MOR, making it well suited for confocal imaging.57 Despite
its favourable properties, 50 was found to exhibit more non-specific binding
than 51, making it less useful for confocal imaging.57
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Figure 1-19: Fluorescent oripavine-derived OR ligands synthesised by Schembri et al.57
Finally, in an attempt to broaden the range of available fluorescent OR ligands,
Lam et al.71 synthesised fluorescent OR agonists using morphine (1) and a sulfo-
Cy5 fluorophore (Figure 1-20). The fluorescent compound 52 was found to
possess similar properties to the parent compound morphine (1) and was able
to induce internalisation.71
Figure 1-20: A fluorescent OR agonist composed of morphine and sulfo-Cy5, synthesised by
Lam et al.71
For further information regarding fluorescent OR ligands, particularly those of
the KOR and DOR, a thorough review of selective and non-selective fluorescent
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opioid ligands synthesised to date has recently been published by Drakopoulos
et al.72
1.5 Research aims
Despite the progress which has been made in the development of diverse
fluorescent MOR ligands, scope remains for novel compounds with previously
unobtained properties. Perhaps most notably absent from the literature, are
red-emitting BODIPY-labelled fluorescent MOR ligands which are suitable for
confocal imaging studies. The BODIPY 630/650-X fluorescent MOR ligand 50
demonstrates the potential to produce a high affinity fluorescent ligand with
highly desirable fluorescent properties, but further development is required to
improve the specific binding profile of either this or similar fluorescent
compounds.57
A potential solution to this disadvantage of BODIPY 630/650 use can be found
in the peptide-linked fluorescent A3AR and H1R ligands described by Vernall et
al.50 and Stoddart et al.52 respectively. In both instances, lipophilic BODIPY
630/650-X-containing fluorescent ligands with hydrocarbon linkers - which
were considered unsuitable for confocal imaging - were modified with peptidic
linker moieties.50, 52 Unlike the corresponding non-peptidic ligands, peptide-
linked fluorescent ligands identified in these studies displayed displaceable
membrane binding, making them far better suited for confocal imaging and
broader pharmacological applications.50, 52 This same rationale, applied to MOR
ligands, could result in BODIPY 630/650-containing fluorescent MOR ligands
which retain the benefits of this fluorophore, while making it sufficiently
hydrophilic for broader use in pharmacological assays.
Aside from altering the physicochemical properties of the fluorescent ligands,
the incorporation of peptides into the linker of fluorescent ligands can improve
receptor binding affinity and subtype specificity.50 By progressively altering the
amino acid side chains of the peptide linker, Vernall et al.50 were able to
improve A3AR binding affinity and selectivity. It may also be possible to uncover
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beneficial interactions for MOR binding through similar modifications of amino
acids bound to a MOR ligand orthostere. Perhaps the closest example to this in
OR ligands is the study by Lipkowski et al.,73 which attempted to incorporate
peptide sections from leu-enkephalin (58) and dynorphin A (59) into the 6-
position of oxymorphone (53) and naltrexone (7) (Figure 1-21). These
modifications did not result in improvement of MOR binding or receptor
subtype selectivity, but the ligand design was based on several assumptions
around how these synthetic morphinans and endogenous ligands bind to the
MOR, and presumed overlap in the resulting ligands (54-57) which may not be
accurate.73
Figure 1-21: Oxymorphone- and naltrexone-bound derivatives of leu-enkephalin and
dynorphin A, synthesised by Lipkowski et al.73
Peptides bound to the 6-position of either oxymorphone (53) or naltrexone (7) were chosen to
match those contained in the structures of leu-enkephalin (58) and dynorphin A (59) (shown in
bold).73
This project aimed to design, synthesise and pharmacologically evaluate novel
fluorescent antagonist ligands for the MOR with several key features. To
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enhance MOR binding through interactions between the linker and receptor,
and to decrease non-specific interaction through increased hydrophilicity,
fluorescent ligands were designed to include linkers containing an optimal
number and composition of amino acids. With these modifications it was
hoped that lipophilic fluorophores such as BODIPY 630/650 could be
incorporated into the fluorescent ligand structure, while maintaining desirable
properties for confocal imaging and broader pharmacological applications. It
was decided that the compounds produced in this study should be MOR
antagonists, as they are better suited for studying receptor-ligand interactions.
Fluorescent agonist ligands, such as those synthesised by Lam et al.,71 are
useful for studying aspects of receptor signalling but induce cellular changes
through receptor activation which can make studying receptor-ligand
interaction more difficult. The evaluation, synthesis and determination of MOR
binding affinity of morphinan-based fluorescent ligands of this design are
described in Chapter 2.
As described in this chapter, the receptor binding components (orthosteres) of
fluorescent OR ligands can be divided into endogenous peptides (and their
derivatives) and small molecule morphinan-based compounds. To truly expand
the fluorescent tools available to pharmacologists studying ORs, it is important
to consider designs outside of these existing paradigms. Therefore, a further
aim of this project was to synthesise fluorescent small molecule MOR
antagonist ligands using a non-morphinan orthostere, in addition to the
inclusion of an amino acid-based linker. The evaluation, synthesis and
determination of MOR binding affinity of such fluorescent ligands is described
in Chapter 3.
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2. Design, synthesis and pharmacological evaluation
of β-naltrexamine-based fluorescent ligands 
This chapter will describe an approach to fluorescent ligand design that was
more similar to previously described fluorescent opioid ligands, as it utilised a
morphinan-containing orthostere from which a linker to a fluorophore was
attached. In contrast to previously reported fluorescent ligands based on the
morphinan scaffold, this approach incorporated amino acids in the linker
between the pharmacophore and fluorophore. As described in the previous
chapter, this aimed to improve the physicochemical properties of the
compound, as well as providing an opportunity for the residues in the linker to
form interactions with the receptor binding site.
This chapter will discuss the design process undertaken for these fluorescent
ligands, beginning with an evaluation of the SARs for ligands of this type and
how this rationalises the choice of orthostere and point of linker attachment,
before moving on to describe in silico modelling of the newly designed
compounds. This is followed by a description of the synthesis and
pharmacological evaluation of a series of non-fluorescent congeners, before
finishing with the synthesis and pharmacology of the final fluorescent ligands.
2.1 Structure-activity relationships (SARs) of morphinan opioids
There is an extensive range of diverse scaffolds for opioid receptor ligands
reported in the literature. The SAR of opioid ligands containing the morphinan
structure will be discussed here, such as the agonists morphine (1) and
buprenorphine (12), the antagonists naloxone (6) and naltrexone (7), and novel
structures from SAR studies which are not used clinically. Other non-morphinan
opioid ligand structures, such as that of the antagonist alvimopan (9), will be
discussed in Chapter 3.
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2.1.1 The morphinan core structure
Many frequently used opioids share a common morphinan (17-
azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-triene) structure. This consists of
four connected rings (Figure 2-1): an aromatic ring (ring-A) and two further
saturated carbon rings chained below (ring-B and ring-C) with a fourth ring
(ring-D) containing a nitrogen protruding from carbons 9 and 13. As is often the
case with structures bearing multiple chiral centres, the morphinan scaffold
appears in a number of naturally occurring alkaloids such as morphine (1),
codeine (2) and thebaine, all isolated from the opium plant. From these natural
products, a great number of semi-synthetic derivatives have been reported.
Figure 2-1: The morphinan structure.
The morphinan structure consists of an aromatic ring (A) with two saturated rings (B and C)
linked below. A fourth ring (D) containing a secondary amine links carbons 9 and 13. Chiral
centres are present at positions 9R, 13R and 14R.
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Figure 2-2: Common positions for modification of the morphinan structure found in opioid
receptor ligands.
A 4,5α-epoxy bridge (which forms ring-E) is commonly found in morphinan-based opioid
receptor ligands. R1 is almost always a hydroxyl group in active compounds (such as in
morphine 1) but is a common site for prodrug modifications such as ethers (codeine 2) and
esters (diamorphine 68). R2 is a highly variable site. Most opioid medicines of this type have a
ketone (naloxone 6) or chiral hydroxyl (morphine 1) or methoxyl group (buprenorphine 12) at
the 6-position, but it is frequently used by medicinal chemists as a site to introduce variability
or to alter pharmacokinetic properties (naloxegol 8). R3 is methylated in most opioid agonists
(morphine 1, oxymorphone 53), but N-allyl (naloxone 6) or N-cyclopropylmethyl (naltrexone 7)
substitution generates antagonists. In clinically used opioids, R4 is exclusively protonated or a
hydroxyl, but further modification has produced some interesting irreversible ligands
(clocinnamox 91). A 6,14-bridge allows for a broad range of modifications to R5 in the literature
but usually features a tertiary alcohol in clinical examples (buprenorphine 12, etorphine 86).
2.1.2 The 4,5α-epoxy bridge 
This large family of morphinan-containing opioid receptor ligands share many
common features, notably, the 4,5α-epoxy bridge which forms a fifth ring (ring-
E) on the morphinan scaffold (Figure 2-2). This ring-E is found in the structures
of naturally occurring alkaloids and their semi-synthetic derivatives. Crystal
structure evidence suggests that this oxygen atom acts as a hydrogen bond
acceptor for Y1483.33 of the MOR.33 However, it is not essential for binding, as
evidenced by the existence of morphinan opioid ligands which lack the 4,5α-
epoxy bridge (Figure 2-3).
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Compound R1 R2 R3
Levorphanol (60) H H CH3
Levomethorphan (61) CH3 H CH3
Butorphanol (62) H OH cBuCH2
Cyclorphan (63) H H cPrCH2
Levallorphan (64) H H Allyl
Figure 2-3: Structures of several opioid receptor ligands which lack a 4,5α-epoxy bridge. 
2.1.3 The 3-hydroxyl group
Another frequent structural feature of this family is the 3-OH found on the
aromatic ring-A. This phenolic group is a requirement for producing an active
ligand, as attempts to install alternative groups at this position have resulted in
loss of activity.74, 75 It is possible to replace the phenolic hydroxyl group with a
carboxamide and maintain activity at the opioid receptors, albeit with
significantly reduced binding affinity (Figure 2-4).75 Extension from the amide
results in further loss of binding affinity.75 It is suggested that this phenol is able
to form hydrogen bond interactions with H2976.52 of the MOR, through a chain
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Figure 2-4: The effect of 3-position substitution on the MOR binding affinity of morphine.75
Binding affinities (pKi) at MOR were determined by inhibition of [3H]-DAMGO in guinea pig
brain membranes.75
Figure 2-5: Hydrogen bonding in the crystal structure of MOR between the 3-hydroxyl group
of β-FNA (74) and H2976.52 via two water molecules.
Adapted from Manglik et al. 2012.33
The crystal structure of β-FNA bound to MOR (PDB: 4DKL) shows two water molecules (shown 
here as red stars) which could form a hydrogen bonding network (dotted red line) between the
3-hydroxyl of β-FNA and H2976.52.33
Derivatives of the phenolic hydroxyl group are common in many medicines,
including the natural product codeine (2), the 3-methyl ether of morphine (1).
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However, codeine itself has relatively weak affinity for the MOR (Ki = 0.35 µM
versus [3H]-DAMGO in guinea pig brain membranes), displaying a 200-fold
reduction in binding affinity relative to morphine (Ki = 1.8 nM).76 Instead, it acts
as a prodrug of morphine, requiring demethylation in the liver by cytochrome
P450 2D6 (CYP2D6). The reduced analgesic effect of codeine, compared to that
experienced by patients administered morphine, is a result of this necessary
metabolism, which slows release of morphine into the body. Patients who carry
allelic variants of CYP2D6, which reduce the enzyme’s rate of metabolism,
experience reduced efficacy from codeine owing to decreased morphine
concentration.77 Likewise, an allelic variant which increases CYP2D6
metabolism results in increased efficacy and morphine concentration.77
Compound R1 R2
Morphine (1) H H
Codeine (2) CH3 H
Diamorphine (68) Ac Ac
Figure 2-6: Structures of morphine and its metabolic precursors.
Both codeine (2) and diamorphine (68) are prodrugs of morphine. Codeine (2) requires liver
metabolism by CYP2D6 to yield morphine, resulting in a slower release and lower morphine
concentration in the blood.77 The 3- and 6-acetyl groups of diamorphine (68) can be hydrolysed
by plasma esterase enzymes to produce morphine.78
The other common alteration to the 3-hydroxyl group is esterification, with the
best-known example of this being diamorphine (diacetylmorphine, heroin, 68)
- the 3,6-diacetoxy analogue of morphine (1). Unlike etherified analogues, such
as codeine (2), esters do not require liver metabolism to be converted to the
active morphine, as they can be hydrolysed by plasma esterases. When
administered intravenously, the increased lipophilicity of these esters allows
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swift passage across the blood-brain barrier, resulting in its rapid effect after
administration.78 Esterification of the phenolic hydroxyl has been used to
develop opioids with differing rates of action and for alternative delivery
methods.79, 80
2.1.4 Modification of the 6-position
The 6-position on ring-C is the most varied site for modification amongst both
clinical and non-clinical compounds. In some examples, such as oxymorphone
(53), naloxone (6) and naltrexone (7), the 6-position is sp2 hybridised and
occupied by a ketone. In morphine (1), buprenorphine (12) and numerous
other examples, the 6-position is saturated, resulting in an additional chiral
centre (Figure 2-7).
As with the 3-hydroxyl group, the 6-position can be functionalised with simple
ethers and esters to alter the pharmacokinetic properties of the compound.
Larger functional groups have been substituted onto this site in numerous SAR
studies and in some drugs, to introduce greater pharmacokinetic and
pharmacodynamic changes to the ligand. The MOR antagonist naloxegol (8)
contains a methoxylated PEGyl heptamer attached to the 6-position via an
ether. The resulting increased hydrophilicity prevents it from penetrating the
blood-brain barrier.81 In addition, the PEGylation makes 8 a substrate for P-
glycoprotein (P-gp), further limiting its BBB permeability.81 Naloxegol (8)
therefore acts as a peripheral opioid antagonist and is used in the treatment of
opioid-induced constipation, having no interaction with central opioid
reeptors.81
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Figure 2-7: The structures of naloxone and naltrexone and their chiral derivatives.
The chiral configuration of the 6-position influences several ligand properties.
In the case of morphine (1), binding affinity and function at MOR are not greatly
affected by altering the chiral configuration at position-6.82 In contrast, the
epimeric products resulting from the reduction of the 6-keto moiety of
naloxone (6) and naltrexone (7) display diverse properties; the corresponding
β-alcohols (69b and 71b) share similar antagonist properties to the parent
ketones, however the α-alcohols (69a and 71a) exhibit mixed agonist-
antagonist activity for different opioid receptors.83 The 6-amino analogues of
naloxone and naltrexone are all MOR antagonists with reduced antagonist
binding affinity, relative to the parent compounds, although this difference was




6 Naloxone Allyl C=O N/A
69a α-Naloxanol Allyl CHOH 6S
69b β-Naloxanol Allyl CHOH 6R
70a α-Naloxamine Allyl CHNH2 6S
70b β-Naloxamine Allyl CHNH2 6R
7 Naltrexone cPrCH2 C=O N/A
71a α-Naltrexanol cPrCH2 CHOH 6S
71b β-Naltrexanol cPrCH2 CHOH 6R
72a α-Naltrexamine cPrCH2 CHNH2 6S
72b β-Naltrexamine cPrCH2 CHNH2 6R
8 Naloxegol Allyl CHO(CH2CH2O)7CH3 6S
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also play a role.84 Jiang et al.84 found that the binding affinity for MOR
(inhibition of [3H]-naloxone in rat brain membrane) between the α- and β-
naloxamines (70a and 70b) and naltrexamines (72a and 72b) differs; β-
naloxamine (70b, pIC50 = 7.3) and β-naltrexamine (72b, pIC50 = 9.2) both display
a higher affinity than their α-counterparts (pIC50 = 7.0 and 8.0 respectively).84
This difference remains consistent in numerous N-acyl derivatives expanding
from this position, where the β-epimers display slightly higher MOR-affinity 
than the corresponding α-epimers.85, 86
Larger modifications to the 6-position have been shown to influence subtype
selectivity. The “message-address” concept is often used to describe
modifications to the 6-position, where the main morphinan body conveys the
“message” (binding affinity and function) and modifications to ring-C, such a 6-
postion functionalisation, describe the “address” (selectivity between opioid
receptor subtypes).34 The amino acids closer to the extracellular side of the
receptor binding pocket are poorly conserved between opioid receptor
subtypes, compared to the highly-conserved amino acids found deeper in the
pocket (Figure 2-9).34 These differences allow ring-C substituents to influence
subtype specificity.
Figure 2-8: Chemical structures of opioid ligands based on the structure of β-naltrexamine. 
β-funaltrexamine (β-FNA - 74) is an irreversible antagonist of MOR which covalently binds to
K2335.39 in the MOR binding pocket.33 It differs from the δ-selective antagonist naltrindole (73)
only in ring-C substituent.34 Nalfurafine (75) and the cinnamoyl compound series (76a-d) all
possess KOR agonist activity, with 75 displaying high selectivity for KOR.87
39
This is demonstrated in the example of naltrindole (73), a δ-selective antagonist 
whose indole is proposed to prevent MOR binding, due to a steric clash with
W3187.35.33 A leucine residue (L3007.35) occupies the same position in the crystal
structure of the DOR, which does not result in a clash and allows binding and
therefore selectivity (Figure 2-9).33, 34
Figure 2-9: Overlays of naltrindole and β-FNA in the crystal structures of the mu and delta 
opioid receptor.33, 34
Source: (left) Grenier et al. 2012,34 (right) Manglik et al. 2012.33
Left: The crystal structures of DOR (PDB: 4EJ4, orange) and MOR (PDB: 4DKL, blue) are overlaid
displaying the high conservation of amino acids deeper in the binding pocket, but greater
variation in the extracellular regions of the helices. Particularly of note is L3007.35 in DOR which
is replaced by W3187.35 in MOR. The structure of naltrindole (73, yellow) is overlaid on the
crystal structure of β-FNA (74, green) covalently bound to MOR.34 Right: Naltrindole (73) is
predicted to clash with W3187.35 in the MOR, preventing its binding and conferring selectivity
for DOR.33
While modification of the 6-position of β-naltrexamine-based structures may 
confer changes to MOR, DOR, and KOR selectivity, ligand function at KOR has
also been manipulated by 6-position substitution. One such example is
nalfurafine (75), the 6-N-methyl-trans-3-(3-furyl)acrylamido analogue of β-
naltrexamine (72b).88 Despite featuring an N-cyclopropylmethyl group in the β-
naltrexamine structure, which is typically antagonism-inducing (see 2.1.6),
nalfurafine (75) is a KOR agonist with weak partial agonist activity at MOR.88
While the high KOR-selectivity of 75 seems to be dependent on the 6-N-methyl
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group,87 KOR agonism is often found in other β-naltrexamine-based 
compounds. For example, KOR agonist activity was found in the series of 6-
cinnamoyl derivatives (76a-d) described by Derrick et al.89, 90 and low level KOR
agonism is displayed by the irreversible MOR antagonist β-FNA (74).87, 91, 92 β-
naltrexamine-based ligands should therefore be tested for KOR binding affinity,
as the SAR of how KOR agonism is induced is not well understood.
2.1.5 Modification of the 7-position via a 6-14 bridge
The introduction of an ethylene bridge between carbons 6 and 14 on ring-C has
been utilised in ligands such as buprenorphine (12) and etorphine (86), to
introduce additional structural modifications and improve binding affinity.19
The bridge is installed via Diels-Alder chemistry between a diene-containing
morphinan (e.g. oripavine (78)), and methylvinyl ketone (Figure 2-10, route A).
This is typically followed by a Grignard reaction to introduce additional
functional groups (tert-butyl in the case of buprenorphine (12), n-propyl for
etorphine (86)).93 The ring-C olefin is often reduced as this can lead to higher
MOR binding affinity, perhaps due to the resulting increase in flexibility in this
region.57, 93
The high affinity of 6-14 bridged opioid ligands is well known, as is their often
poor subtype selectivity.94 For example, diprenorphine (87) is a non-selective,
weak partial agonist at all three ORs, that is used to displace other high affinity
ligands, such as the powerful tranquilizer etorphine (86), which cannot be
displaced by more frequently used antagonists like naloxone (6). These 6-14
bridged opioid ligands typically possess a mixture of partial agonism and
antagonism at different opioid receptors.94 Numerous compounds of this type
have been synthesised and characterised, displaying only minor changes in
binding affinity at the three ORs.95-98 However, manipulation of N/OFQ
receptor affinity is possible through modifications to this region.95, 98
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Compound Scaffold R1 R2
12 Buprenorphine 81 cPrCH2 t-Bu
86 Etorphine 80 Me n-Pr
87 Diprenorphine 81 cPrCH2 Me
Figure 2-10: Three approaches to the synthesis of 6-14 bridged opioid ligands.57, 93, 97, 99, 100
Using oripavine (78) or another diene-containing morphinan as the starting material, Diels-
Alder chemistry can be carried out with either methylvinyl ketone, methylacrylate or a
substituted maleimide. 57, 93, 97, 99, 100 79 can be further reacted with a Grignard reagent to
introduce an additional functional group (80).93 Ester hydrolysis of 82 and subsequent amide
coupling can also be used to functionalise the position (83).57, 97 The ring-C olefin in 80 and 83
can be reduced to give the more flexible 81 and 84 respectively.57, 93 In the synthesis of 81, the
reduction step is sometimes carried out prior to the Grignard reaction.93 This reduction has
been found not to work in imide compounds (85), possibly due to hinderance of the palladium
from accessing the site by the bulky maleimide.57
The structures of several common 6-14 bridged opioid receptor ligands are shown in the table,
referencing the R-groups and structure of the general scaffold that they are derived from.
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Figure 2-11: The structures of fluorescent opioid receptor ligands containing 6-14 bridged
morphinan orthosteres.57, 69
Left: Schembri et al.57 utilised a 7-position amide to couple an oripavine-derived orthostere to
several fluorophores (48-51). Right: One of the fluorescent ligands synthesised by Archer et
al.69 is a thebaine-derived structure similar to etorphine (86), where the fluorescent 7-
nitrobenzo-2-oxa-1,3-diazole (NBD) moiety is connected to the 7-position (47).
An alternative method for introducing variation to this region is by using an
alkyl acrylate, rather than methylvinyl ketone (Figure 2-10, route B).97 This
approach has been used extensively to introduce new chemical groups through
hydrolysis of the installed ester, followed by amidation.57, 97, 99 These
approaches have previously been used to link to a fluorophore, producing
various fluorescent ligands for the opioid receptors (Figure 2-11).57, 69 A third
method of expansion from ring-C uses a substituted maleimide in place of
methylvinyl ketone as the dienophile (Figure 2-10, route C).57, 99, 100
2.1.6 N-Alkylation
The 17-position amine of the morphinan structure is known to be highly
influential over opioid receptor ligand properties in multiple ways. Whilst a
simple N-methyl group is present in morphine and many other well-known
opioids, different alkyl groups at this position generate a notable array of
functional and pharmacodynamic properties in ligands.
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Figure 2-12: The effect of the N-substituent of different compounds in the oxymorphone
family on function.101, 102
The oxymorphone family of opioid ligands exemplifies this variety of function
with changes in N-substituent (Figure 2-12). Two of the better known opioid
antagonists, naloxone (6) and naltrexone (7), bear N-allyl and N-
cyclopropylmethyl substituents respectively to confer MOR antagonist activity,
unlike the N-methyl parent compound oxymorphone (53), which is an
agonist.101 However, the N-benzyl (89) and N-phenethyl (90) analogues are
both potent agonists and N-dimethylallyl substitution produces the partial
agonist nalmexone (88).101, 102
This demonstrates the complex role of N-substituents in the SAR of morphinan
opioid ligands. The 2012 crystal structure of the MOR (PDB: 4DKL)33 suggests
potential interactions between the N-cyclopropylmethyl group of the
covalently bound β-FNA (74) and neighbouring aromatic amino acids (Figure 2-
13). However, given the differences between the N-substituents described
above, it is challenging to predict what effect N-substitution with untested
functional groups would have on ligand binding and function. The precise SAR
of this N-substituted region still requires further investigation.
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Figure 2-13: A potential π-π stacking interaction between the N-cyclopropylmethyl group of
β-FNA, and aromatic amino acids in the binding pocket of MOR.33
Adapted from Manglik et al. 2012.33
The proximity and orientation of the N-cyclopropylmethyl group of β-FNA (74) between
Y3267.43 and W2936.48 in the crystal structure of MOR (PDB: 4DKL) suggest a π-π stacking 
interaction.
Another way in which the 17-position amine has been exploited is through
quaternisation. Alkylation (typically methylation) of the tertiary amine
produces a permanently charged quaternary species, giving it unique
properties compared to its tertiary counterparts. This charge does not interfere
greatly with binding as it is the protonated (and therefore charged) amine
which forms an ionic interaction with D1473.32 in the MOR binding pocket.33
One such example is methylnaltrexone (MNTX, 11), a peripherally-acting opioid
antagonist whose permanent charge prevents absorption across the blood
brain barrier.103
2.1.7 Modification of the 14-position
Variation at this position is fairly limited amongst most common opioid ligands






specific interaction for the 14-hydroxyl group in their crystal structure of the
MOR (PDB: 4DKL) based on its proximity to amino acids within receptor binding
pocket. It has been suggested that the presence of the hydroxyl group in the
oxymorphone-derived antagonists naloxone (6) and naltrexone (7) may restrict
the freedom of rotation of the N-substituent, and subsequently eliminates low






Compound MOR pKi R1 R2 Function
Oxymorphone (53) 9.0105 Me OH Agonist
53a 10.0105 Me OMe Agonist
53b 9.9105 Me OBn Agonist
Naloxone (6) 7.3-9.0a cPrCH2 OH Antagonist
6a 9.7106 cPrCH2 O(CH2)3Ph Agonist
Naltrexone (7) 8.1-9.7b allyl OH Antagonist
7a 9.5106 allyl O(CH2)3Ph Agonist
Clocinnamox (91) 8.0107 cPrCH2 pCCA
Antagonist
(irreversible)
pCCA – p-chlorocinnamoylamino. a – refs57, 108-112 b – refs57, 99, 108-110, 113, 114
Figure 2-14: Modifications to the 14-position and their effect on MOR binding and ligand
function.
The structures of 14-substituted opioid receptor ligands are shown, with binding data (pKi) at
MOR. Binding affinities at MOR were determined by inhibition of [3H]-DAMGO in rat brain
membranes.105-107
Several recent studies have investigated 14-alkoxymorphinans to better
establish SAR in this region (Figure 2-14). 14-O-Methylation of oxymorphone
(53) was found to produce a compound (53a) with improved binding affinity at
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all 3 opioid receptors.105 The 14-O-benzyl analogue (53b) produced similar
MOR affinity, but with reduced receptor subtype selectivity.105 The 14-O-
phenylpropyl analogues of both naloxone (6) and naltrexone (7) are full
agonists (6a and 7a respectively), in contrast to the antagonist activity of their
14-hydroxyl parent compounds.106 Even the removal of the 3-hydroxyl group
from 7a yielded a ligand with sub-nanomolar MOR affinity.115 It is unclear
whether new interactions formed by the phenylpropyl group simply overcome
the loss of the 3-hydroxyl group, or if it adopts an entirely different binding
position. A 14-amino group can also be used to functionalise this position,
usually to form the corresponding amide analogues, such as those of the
irreversible antagonist clocinnomox (91) and its derivatives.116-118
2.2 Selection of a lead molecule and fluorescent ligand design
There were several key criteria chosen to select a lead molecule. The lead
molecule needed to be an antagonist, increasing the likelihood that any
analogues synthesised would also be antagonists. A high binding affinity at
MOR was desirable, as it would be more likely to produce high affinity
fluorescent ligands. The lead molecule was also desired to be able to
accommodate a linker in a position which is not critical for binding or function
– linker attachment should not replace an important functional group.
Therefore, a lead molecule with a well-understood structure-activity
relationship (SAR) profile was sought, to minimise the disruption of key
interactions and give the most predictable outcome in terms of binding and
function.
2.2.1 Lead molecule selection
Known opioid receptor ligands were assessed using these criteria, with two
molecules identified as candidates. Both naloxone (6) and naltrexone (7) are
opioid receptor antagonists, with similarly well-established SAR profiles. Both
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are high affinity ligands which have been utilised in numerous SAR studies,
displaying tolerance for a broad range of modifications.
The well-established SAR profiles of naloxone (6) and naltrexone (7) guided the
attachment point of the linker moiety. As described above, the 3-postion and
N-substituent of morphinan-based opioid ligands are important for binding and
ligand function. The 14-position is capable of supporting larger substituents,
but can also affect ligand function and receptor binding, making these
unsuitable sites for ligand attachment.
Subsequently, the 6-position was selected as the most suitable site for linker
attachment. Introduction of an amine to the 6-position was ideal for
attachment of the amino acid-based linker by direct amide coupling.
Procedures for the reductive amination of the 6-keto moiety of both naloxone
and naltrexone are well established.84, 119 However, the vast majority of
literature examples employ β-naltrexamine (72b) as the orthostere, with few
examples of either epimer of naloxamine (70a and 70b) used. It is likely that
this is due to the higher binding affinity of 72b, providing the best starting point
to produce high affinity ligands. For these reasons, β-naltrexamine (72b) was
selected as the lead molecule for fluorescent ligand design.
Structures discounted from consideration include agonists and compounds
containing prodrug modifications, such as ethers or esters at the 3-position.
Buprenorphine (12) and other 6-14 bridged orthosteres were considered, as
these structures have been previously used in fluorescent ligands. The
fluorescent ligands described by Schembri et al.57 (Figure 2-11) were
antagonists, despite buprenorphine (12) itself being a partial agonist.
Structurally, what drives this switch from partial agonism to antagonism is
unclear. The oripavine starting material required to synthesise these
compounds is an agonist, and therefore a controlled substance with greater
legal barriers to use in synthesis. Due to these concerns, these 6-14 bridged
compounds were deemed to be unsuitable orthosteres.
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2.2.2 Fluorescent ligand design
The final fluorescent ligands were planned to consist of the β-naltrexamine 
orthostere connected to a fluorophore via a 6-position linker consisting of one
or more amino acids. The number of amino acids and their composition would
be determined through the synthesis and pharmacological evaluation of non-
fluorescent congeners, as shown in the design scheme in Scheme 2-1.
An initial set of congeners were tested, consisting of the β-naltrexamine (72b)
orthostere coupled to a single α-acetamido acid. The results from competition 
binding studies, alongside in silico modelling data, were used to inform further
linker alterations. Once the optimal linker composition was established, a
number of different fluorophores were coupled to the linker, with the resulting
fluorescent compounds evaluated for MOR binding affinity in saturation
binding experiments.
Scheme 2-1: Design scheme for the synthesis of β-naltrexamine-based fluorescent ligands. 
The approach taken to design, synthesize and pharmacologically evaluate β-naltrexamine-
based fluorescent ligands is shown: (a) reductive amination of naltrexone to naltrexamine and
purification of epimers; (b) peptide coupling to a selection of different α-acetamido acids; (c) 
competition binding assay against a fluorescent ligand; (d) if the results suggested that a longer
linker would be beneficial, coupling of a selection of different amino acids at the second
position; (e) competition binding assay against a fluorescent ligand; (f) if the results suggested
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that linker length is optimal, coupling of a selection of fluorophores to the linker; (g) saturation
binding assay against an unlabelled ligand.
2.3 Non-fluorescent β-naltrexamine congeners 
The first generation of congeners (92) were composed of variants of a single α-
acetamido acid coupled to the 6-position of β-naltrexamine. The N-acetyl
group was included to represent the further expansion of the linker, either to
another amino acid or to a fluorophore. This acetamide would be expected to
possess properties more similar to the final fluorescent ligands, than to the
corresponding free primary amine. A selection of eight amino acids were
chosen to reflect all types of amino acid (polar, non-polar, acidic, basic) as












Figure 2-15: Structures of the single amino acid non-fluorescent congeners.
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2.3.1 In silico modelling
In silico modelling of the proposed ligands was undertaken to better
understand the potential interactions of these β-naltrexamine congeners with 
the MOR, and as a tool to predict the optimal length and chemical composure
of the linker region. The modelling was carried out using the online modelling
software DockingServer (http://www.dockingserver.com/web). The crystal
structure of the MOR (PDB: 4DKL) produced by Manglik et al.33 was uploaded
to the online software and the proposed ligand structures (those shown in
Figure 2-15) were drawn and docked into the binding site of the receptor.
It was immediately clear that the predicted numerical values for binding affinity
(pKi) were inaccurate. Compounds with well-established literature pKi values,
such as naloxone (6) and naltrexone (7), were several log units lower than
typical reported values. Instead, the positions of the docked β-naltrexamine 
orthostere were analysed and the relative differences in predicted pKi were
noted.
Figure 2-16: Positional criteria for the β-naltrexamine congeners within the MOR binding site. 
Three key interactions that were easy to identify quickly were used to confirm the binding
position of the β-naltrexamine orthostere. These are highlighted for the Phe congener 92d in
the right-hand image: A - the alignment of the 3-hydroxy to H2976.52; B - the 4,5-epoxy in close
proximity to Y1483.33; C - the cyclopropylmethyl group positioned between Y3267.43 and
W2936.48.
The examples which predicted the highest relative binding affinity typically
adopted a similar position to that of the covalently bound β-FNA. Building on 
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this observation, each congener was repeatedly docked, looking for several key
positional criteria: the positioning of the cyclopropylmethyl group between
Y3267.43 and W2936.48, 4,5-epoxy in close proximity to Y1483.33 and the
alignment of the 3-hydroxyl group to H2976.52 (as shown in Figure 2-16).
Twenty examples of each ligand were collected in which the bound ligand fitted
this positional criteria. Further analysis of these examples showed that
predicted interactions of the linker moieties were highly varied for each docked
congener. Often the linker did not display any interactions or come into close
proximity with any part of the receptor. Instead, the 6-position moiety
projected into the extracellular space. However, there were several
noteworthy interactions specific to individual congeners which appeared
across multiple docking predictions.
Figure 2-17: Docked ligands with highlighted linker side chain interactions.
Left: In some predictions, the aspartate congener (92f) was shown to form an ionic interaction
with K2335.39. Right: The Lys congener (92h) was sometimes predicted to interact ionically with
E2295.35 but this resulted in disruption of some of the desirable interactions between the
pharmacophore and receptor described in Figure 2-13.
In some iterations, the Asp congener (92g) was predicted to form an ionic
interaction with K2335.39 (Figure 2-17) - the same lysine to which β-FNA is 
covalently bound in the crystal structure (PDB: 4DKL).33 When docked, a
glutamate congener was not able to form an interaction with K2335.39,
suggesting that the shorter side chain present on Asp was more ideally placed
to do so.
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An ionic interaction was also predicted between the Lys congener (92h) and
E2295.35, but this interaction distorted the docking pose of the rest of the ligand
(Figure 2-17). An interaction of this kind could be more favourable without
distortion if ornithine, or another basic amino acid with a shorter sidechain,
replaced lysine.
The non-polar Ala (92b), Val (92c) and Phe (92d) congeners were predicted to
form a non-polar interaction with Leu219. However, this residue appears in the
extracellular loop region of the receptor so it may not be available for binding
due to the flexibility of this region. Similarly, the Asn congener (92f) was, in
some instances, predicted to hydrogen bond with the backbone of this
intracellular region.
The frequency of interactions with the extracellular loop region, as well as the
trend of 6-position moieties showing no interaction with the receptor, are likely
due to two key features of the MOR ligand binding site: the binding pocket is
both shallow and polar. Manglik et al.33 noted that the binding pocket of the
MOR is particularly exposed and shallow, observing the difference between
MOR and the M3 muscarinic receptor (M3R) which is deeper and narrower
(Figure 2-18). The openness of the MOR ligand binding site means it is exposed
to the extracellular fluid, and therefore contains a high concentration of polar
amino acids. β-naltrexamine congeners containing non-polar amino acids 
might therefore be unable to find sites to make hydrophobic interactions.
The relatively short 6-position substituent of the bound β-FNA in the crystal 
structure can be seen protruding from the receptor, indicating its shallowness
within the helical bundle (Figure 2-19). The proximity of the congeners to the
surface may be why the modelling predicted interactions with the extracellular
loop regions of the receptor.
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Figure 2-18: Comparison of the ligand binding pockets of MOR and M3R.
Source: Manglik et al. 2012.33
The MOR (a) binding pocket is both wide and exposed in comparison to the M3 muscarinic
receptor (b) which has a narrow opening for ligand entry.
Figure 2-19: The MOR with bound β-FNA. 
Crystal structure taken from Manglik et al. 2012.33 Displayed in PyMOL.
A high density of polar amino acid side chains is present in the exposed binding pocket of the
MOR. The oxygen (red), nitrogen (blue) and sulfur (yellow) atoms are coloured to indicate polar
regions. The 6-position substituent is clearly visible extending to the surface of the binding
pocket (right).
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These observations were supported by the docking of two further sets of
congeners, each containing two amino acids in their linker (Figure 2-20). One
set contained Asp at the first position adjacent to the orthostere, as 92g had
the most consistent predicted interactions. The second position was varied,
with the same eight amino acids used in the single amino acid congeners
(Figure 2-15). The second set contained Ala at the first position with the same
variation at the second position. This was intended to allow the amino acid at
the second position to form interactions with reduced conformational
restriction from any interactions made by the amino acid at the first position.
Figure 2-20: General formula for docked congeners containing 6-position dipeptides.
The 16 docked compounds were composed of either Ala or Asp at the first position and one of
eight amino acids shown in Figure 2-15 at the second position.
Gathering sufficient data to reach a firm conclusion was challenging, as the
predicted binding positions of the dipeptide congeners were highly variable. In
instances where the positioning of the orthostere met the criteria described
above, the 6-position substituent was still varied in its positioning and
proposed interactions. The only common theme observed amongst most
examples was that the linker would coil back into the receptor rather than
extending toward the extracellular regions of the receptor (Figure 2-21),
possibly indicating that the linker was unable to find points of interaction
further from the binding site.
The predicted docking positions of the tested congeners indicated that the first
amino acid coupled to the 6-position of naltrexamine may be able to interact
with the ligand binding pocket. Specifically, a polar amino acid at the first
position could form the strongest interactions with the polar residues of the
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binding pocket - particularly acidic or basic side chains. However, any further
elaboration of the linker may exceed the limits of the binding pocket and was
predicted to not form beneficial interactions.
Figure 2-21: Predicted binding poses for congeners with linkers containing two amino acids.
Left: The congener containing Ala (position 1) and Phe (position 2) is docked showing the linker
coiling within the binding pocket rather than extending towards the extracellular regions of the
receptor. Right: The congener with Ala (position 1) and Ser (position 2) extends across the
entrance of the bind site rather than out of it.
The modal outcome of the docking was for the 6-position moiety to not form
any interactions or, less plausibly, interact with an extracellular loop region.
This suggests that there are few possible interactions for functional groups at
the 6-position, or perhaps that this model may not be a good predictor of in
vitro outcomes.
2.3.2 Synthesis of β-naltrexamine single amino acid congeners 
The synthesis of β-naltrexamine from naltrexone has been described previously 
in the literature.84, 119 The synthetic route used in this project (Scheme 2-2) was
a modified version of the route described by Filer et al.,119 with the tritiated
naltrexone used in the procedure substituted for the 1H isotope. This was
followed by peptide coupling to the array of α-acetamido acids shown in Figure
2-15. Congeners containing a side chain protective group were deprotected
prior to pharmacological testing.
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Sodium triacetoxyborohydride (STAB) is typically preferred as a mild reducing
agent, particularly in reductive amination reactions, due to its safety profile.120
Sodium cyanoborohydride is often avoided as it can produce the toxic
byproducts HCN and NaCN.120 However, a literature search yields no examples
of STAB use in the reductive amination of naltrexone (7) to β-naltrexamine 
(72b), with NaBH3CN preferred in every case. An unpublished synthesis by a lab
group member attempted a reductive amination of the chemically similar
naloxone (6) using STAB as the reducing agent, but this almost exclusively
yielded the α-epimer (70a). This may due to the larger acetoxy groups of STAB,
which may sterically hinder and prevent it from accessing the imine from the
face that would produce the β-epimer (70b). Alternatively, it may result from
differences in the strengths of these reducing agents, due to the electron-
withdrawing effects of their respective cyano and acetoxy groups. However,
the frequency with which STAB and NaBH3CN are interchangeable in other
reactions suggest that this is not the case.
Scheme 2-2: Synthesis of single amino acid congeners of β-naltrexamine (92). 
Reagents and conditions: (a) i. NH4OAc, MeOH, rt; ii. NaBH3CN, MeOH, rt, 25%; (b) α-acetamido 
acid, PyBOP, DIPEA, DMF, rt, 73-90%; (c) TFA, TIPS, water, CH2Cl2, rt, 90%; (d) 4M HCl in 1,4-
dioxane, rt, 99%.
Even when NaBH3CN is used, the α-epimer (72a) remains the major product.84
Use of substituted amines, such as dibenzyl amine, can direct the reduction
towards greater β-epimer (72b) yield.85 However, this approach introduces an
additional hydrogenation step which would also decrease the final yield.
A pilot reaction using NH4OAc with NaBH3CN yielded four products. The β-
epimer (72b) composed 25% of the total products, alongside the α-epimer 
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(72a) (50%) and a racemate of naltrexols (71a and 71b) (25% combined). Given
the relatively small amount of β-naltrexamine (72b) necessary for this project,
it was decided to continue with this method, to react the remaining naltrexone
(7) without further optimisation. The yield observed in this small-scale reaction
was replicated in larger scale reactions. To minimise the chance of HCN
production, the workup for this reaction was carried out at pH 9, without
adjusting to pH 1 with HCl as described in the Filer et al. protocol.119 The
products were separable by column chromatography, having replicated the
respective literature Rf values through thin layer chromatography (TLC).84
Figure 2-22: Structures of the product and by-products from β-naltrexamine (72b) coupling 
to α-acetamido acids. 
When the coupling reaction was carried out with HCTU as the coupling reagent and with an
excess of α-acetamido acid and coupling reagent, a mixture of 92, 96 and 97 were produced.
When the reaction was carried out with PyBOP as the coupling reagent and with a 1:1:1
stoichiometric ratio between the reagents, the desired product (92) was the primary product.
The purified β-naltrexamine (72b) was coupled to eight α-acetamido acids: Ac-
Gly-OH, Ac-Ala-OH, Ac-Val-OH, Ac-Phe-OH, Ac-Ser-OH, Ac-Asn-OH, Ac-Asp(4-O-
tBu)-OH and N2-Ac-N6-Boc-Lys-OH. This was carried out using benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as the coupling
reagent with diisopropylethylamine (DIPEA) in a 1:1:1:1 stoichiometric ratio (β-
naltrexamine (72b)/PyBOP/DIPEA/acetamido acid). Initial attempts to use the
uronium-based reagent O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) produced a mixture of
products (Figure 2-22). In addition to the desired product (92), the 6-
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guanidinylated by-product (97) and 3-esterified, 6-guanidinylated by-product
(96) were also present in large quantities.
To confirm that 6-position guanidinylation was occurring, two small scale
investigative reactions were carried out; β-naltrexamine (72b) and naltrexone
(7) were both separately mixed with HCTU and DIPEA in dimethylformamide
(DMF). Unaltered naltrexone (7) was identified by liquid chromatography-mass
spectrometry (LCMS), whereas the β-naltrexamine (72b) was entirely
consumed and the 6-guanidinylated product (97) was identified by LCMS. At
this time, a similar issue of guanidinylation had been encountered with the
alvimopan-based compounds (Chapter 3), so the non-uronium-based PyBOP
was chosen as an alternative coupling reagent. The stoichiometry was also
altered from a 1:3:3 ratio (β-naltrexamine/coupling reagent/α-acetamido acid) 
to 1:1:1 to discourage esterification of the 3-OH. These conditions generated
the desired products in acceptable yields (39-74%) with neither by-product 96
nor 97 detectable in the reaction mixture.
1H-NMR analysis of the products of the peptide couplings revealed varying
levels of epimerisation at the amino acid chiral centres. Racemisation of α-
acetamido acids during peptide coupling is known to occur via a 5(4H)-
oxazolone intermediate as shown in Scheme 2-3. The degree to which the
chiral centre is racemised depends on the acidity of the α-proton, which varies 
for different amino acids. For example, the chiral centres of the Asn (92f) and
Asp(tBu) (95g) β-naltrexamine congeners were highly racemised (Figure 2-23).
The electron withdrawing side chains of these amino acids can stabilise the α-
carbocation, making the α-proton more acidic.121 The electron donating alkyl
chain in the Lys(Boc) congener (95h) is less stabilising over the α-carbocation, 
and so produced very little racemisation (Figure 2-23).121
After separation by HPLC, three of the eight congeners produced sufficient
chirally pure material that both L- and D-epimers could be pharmacologically
tested. The chirality of the diastereomeric pair was assigned to each compound
based on the relative size of identifiable peaks in the 1H NMR of the mixture
(Figure 2-23). The compound associated with the larger peak in the mixed 1H
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NMR was designated as the L-epimer, and the smaller peak was assigned to the
D-epimer. In most cases this was a clear distinction, however, the 1H NMR
peaks for both epimers of the Asp(tBu) congener were very similar, suggesting
almost complete epimerisation of the chiral centre.
CR – coupling reagent
Scheme 2-3: The mechanism of α-acetamido acid racemisation via a 5(4H)-oxazolone
intermediate.
(a) The acetyl carbonyl oxygen acts as a nucleophile in conjunction with deprotonation of the
amide nitrogen, forming a lactone (5(4H)-oxazolone) and eliminating the coupling reagent (CR);
(b) Deprotonation of the 5(4H)-oxazolone α-carbon causes it to become sp2 hybridised; (c) The
negative charge from deprotonation is stabilised across several positions in the oxazolone ring;
(d) Protonation returns the α-carbon to the sp3 hybridised state, generating an equal
distribution of the two oxazolone enantiomers; (e) Nucleophilic attack of the oxazolone ester
by a primary amine reopens the ring giving the same product as a non-cyclised peptide
coupling, but with racemisation of the stereo centre.
Finally, the tert-butyl ester protecting group of both Asp congeners, and the
Boc protecting group of the Lys congener were removed. tert-Butyl ester
deprotection was carried out using an 18:1:1 mixture of trifluoroacetic acid
(TFA)/triisopropylsilane (TIPS)/H2O in CH2Cl2. Boc deprotection was achieved
using a 4M HCl/1,4-dioxane.
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Figure 2-23: 1H-NMR spectra for two β-naltrexamine congeners showing differing amounts 
of racemisation for each amino acid.
The proportion of product which has been converted to the D-epimer can be seen in the
respective peaks of several functional groups of each β-naltrexamine congener. The clearest 
view of the level of epimerisation can be seen by looking at the acetyl CH3 singlet peak (typically
around 2.0 ppm). (above) The Asp(tBu) congener (95g) was highly racemised, as seen in the
acetyl CH3 peaks (inset) where there are two peaks of similar height. (below) There was very
little racemisation of the Lys(Boc) congener (95h), as shown at the acetyl CH3 peaks (inset)
where one peak is much larger than the other.
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2.3.3 MOR binding affinity of the non-fluorescent β-naltrexamine congeners 
Before evaluating the β-naltrexamine congeners, the KD of the BODIPY
630/650-labelled oripavine derivative 50 (synthesised and characterised by
Schembri et al.57) was determined using TR-FRET in a saturation binding assay.
50 showed saturable high affinity binding to the SNAP-MOR in HEK293 cell
membranes with a pKD measured as 8.88 ± 0.36 (mean ± SEM, n = 3) (Figure 2-
24).
Figure 2-24: Structure and saturation binding of the fluorescent ligand 50 to the SNAP-MOR
in HEK293 membranes.
Membranes from Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cells were incubated with
varying concentrations of the fluorescent ligand 50 (synthesised by Schembri et al.57). Non-
specific binding (blue) was determined in the presence of 10 µM naloxone. Total binding (red)
was determined in the absence of naloxone. Data points are the mean of a single experiment
(mean ± SEM) carried out in triplicate which are representative of three separate experiments,
from each of which a value for KD was determined.
The MOR binding affinities of the non-fluorescent congeners were then
assessed by TR-FRET in a competition binding assay against 50. The results were
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plotted as competition binding curves (Figure 2-25) from which pKi values were
determined (Table 2-1).
Figure 2-25: Competition binding assay using the non-fluorescent β-naltrexamine congeners. 
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 50 (synthesised by Schembri et al.57) and increasing concentrations
of each of the β-naltrexamine congeners described in Figure 2-15. Where sufficient material of
the respective D-isomer of a congener was isolated it was also tested. Data points are the mean
of 3 or 4 separate experiments (mean ± SEM), each carried out in duplicate.
All congeners reduced binding to non-specific binding levels. Competition
binding experiments indicated that, although changes to linker composition
produced a range of affinities (one-way ANOVA, P = 0.01), none of the linkers
resulted in a significant change in MOR binding affinity compared to the
unsubstituted β-naltrexamine (72b).
Similarly, no significant increase in binding affinity was seen with any congener
compared to the glycine congener (92a), although congeners 92e and 92g (L-
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isomers) showed a significant reduction in binding affinity from 92a (P < 0.05,
post-hoc Dunnett’s multiple comparisons test). However, there was no
significant difference between 92a and the D-isomers 98e and 98g.
Compound Config. R MOR pKi ± SEM n
Naloxone (6) 7.69 ± 0.11 4
β-Naltrexamine (72b) 7.30 ± 0.08 4
92a R H 7.56 ± 0.16 3
92b R CH3 7.19 ± 0.28 3
92c R CH(CH3)2 7.50 ± 0.11 4
92d R CH2Ph 7.76 ± 0.11 4
92e R CH2OH 6.93 ± 0.12 3
98e S CH2OH 7.61 ± 0.17 3
92f R CH2CONH2 7.57 ± 0.12 3
98f S CH2CONH3 7.05 ± 0.13 3
92g R CH2COOH 6.98 ± 0.11 3
92g S CH2COOH 7.44 ± 0.19 3
92h R (CH2)4NH2 7.37 ± 0.08 3
Table 2-1: MOR binding affinities of α-acetamido acid β-naltrexamine congeners. 
pKi values at MOR were calculated from experimental IC50 values using the Cheng-Prusoff
equation.122 Experimental IC50 values were determined by competitive displacement of the
fluorescent ligand 50 (synthesised by Schembri et al.57) in Lumi4-Tb-labelled SNAP-MOR-
expressing HEK293 cell membranes. Values are the mean of 3 or 4 separate experiments (mean
± SEM), each carried out in duplicate.
In light of these findings, along with the in silico modelling results, it was
decided that there was no basis for further elaboration of the linker.
Importantly, attachment of the linker at the 6-position did not diminish the
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binding affinity of the unsubstituted β-naltrexamine (72b), indicating that the
amino acid linker was well tolerated, regardless of side chain group. Synthesis
of the final fluorescent ligands was carried out without further investigation of
non-fluorescent congeners.
2.4 Synthesis and pharmacological evaluation of fluorescent ligands
The synthesised fluorescent ligands were composed of the β-naltrexamide 
bound to one of three fluorophore moieties via either an α-acetamidolysyl or 
β-alanyl linker (Figure 2-26). The fluorophores used were BODIPY 630/650-X,
BODIPY 630/650 (without the hexanoyl spacer) and sulfo-Cy5.
Figure 2-26: Structures of β-naltrexamine fluorescent compounds. 
Two β-naltrexamine scaffolds bound to different linker moieties were combined with three 
fluorophores to give six novel fluorescent ligands. The two scaffolds utilise α-acetamidolysyl or 
β-alanyl linkers, which are bound to either BODIPY 630/650-X, BODIPY 630/650 or sulfo-Cy5. 
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The inclusion of an amino acid-based linker in these fluorescent ligands aimed
to increase hydrophilicity and reduce non-specific binding, potentially making
these fluorescent ligands more suitable for different imaging applications. The
sulfo-Cy5 fluorescent ligand (51) synthesised by Schembri et al.57 was preferred
due to improved confocal imaging properties compared to the BODIPY
630/650-X compound (50), which displayed incomplete displacement of
binding in the presence of an excess of unlabelled competitor, suggesting a
higher level of non-specific binding. Fluorescent ligands composed of two
different BODIPY 630/650 variants, with differing distances between
orthostere and fluorophore, were synthesised to test the effect of this spacer
on MOR binding affinity and potentially non-specific binding. However,
fluorescent ligands containing sulfo-Cy5 (101 and 104) were also synthesised
as they potentially possessed properties that were better suited to different
pharmacological applications.
2.4.1 Synthesis of fluorescent β-naltrexamine compounds 
Amino acid coupling of β-naltrexamine to the two amino acids was carried out 
using PyBOP and DIPEA in a 1:1:1:1 stoichiometric ratio (β-naltrexamine 
(72b)/PyBOP/DIPEA/acetamido acid), followed by Boc-deprotection of both
compounds in 4M HCl/1,4-dioxane. BODIPY 630/650-X and sulfo-Cy5 were
both pre-formed N-hydroxysuccinimide (NHS) esters, which were reacted with
the β-naltrexamine congeners in the presence of DIPEA to produce the final 
fluorescent BODIPY 630/650-X (99 and 102) and sulfo-Cy5 (101 and 104)
compounds. Coupling to the shorter BODIPY 630/650 compound differed, as it
was a free acid rather than an NHS ester, requiring the use of PyBOP with DIPEA
in a 1:1:1 ratio (PyBOP/BODIPY/β-naltrexamine congener) to discourage 3-
position ester formation.
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Scheme 2-4: Synthesis of fluorescent β-naltrexamine-based compounds. 
Reagents and conditions: (a) N2-acetyl-N6-Boc-lysine or N-Boc-β-alanine, PyBOP, DIPEA, DMF, 
rt, 73-90%; (b) 4M HCl in dioxane, rt, 99%; (c) BODIPY 630/650-X-OSu or sulfo-Cy5-OSu, DIPEA,
DMF, rt, 35-83%; (d) BODIPY 630/650-OH, PyBOP, DIPEA, DMF, rt, 42-47%.
2.4.2 MOR binding affinity of fluorescent β-naltrexamine compounds 
MOR binding affinities (pKD) of the fluorescent compounds 99-104 were
determined in saturation binding experiments (Figure 2-27, Figure 2-27a and
Table 2-2). The four BODIPY 630/650-containing ligands (99, 100, 102 and 103)
all exhibited sub-nanomolar binding affinities for MOR. Differences in linker
composition or length were found to not significantly change MOR binding
affinity (One-way ANOVA, P = 0.32). However, the sulfo-Cy5-containing 101
displayed a near-100-fold loss in pKD compared to the BODIPY 630/650-
containing (99 and 100) lysine-linked compounds.
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The total binding curve for compound 104 at this concentration did not appear
to reach saturation, meaning that a reliable pKD value could not be determined.
This suggests a significantly lower MOR binding affinity for 104 than the other
measurable compounds.
Figure 2-27: Saturation binding assay results for the lysine-linked fluorescent β-naltrexamine 
compounds.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with
increasing concentrations of the fluorescent compounds 99-101. Non-specific binding (blue)
was determined in the presence of 10 µM naloxone. Total binding (red) was determined in the
absence of naloxone. Specific binding (black) was calculated from total binding minus non-
specific binding. Data points are the mean of a single experiment (mean ± range) carried out in
duplicate which are representative of four separate experiments from which a value for KD was
determined.
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Figure 2-27a: Saturation binding assay results for the β-alanine-linked fluorescent β-
naltrexamine compounds.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with varying
concentrations of the fluorescent compounds 102-104. Non-specific binding (blue) was
determined in the presence of 10 µM naloxone. Total binding (red) was determined in the
absence of naloxone. Specific binding (black) was calculated from total binding minus non-
specific binding. Data points are the mean of a single experiment (mean ± range) carried out in
duplicate which are representative of three separate experiments from which a value for KD
was determined.
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Compound MOR pKD ± SEM n
99 9.22 ± 0.16 4
100 9.20 ± 0.15 4
101 7.43 ± 0.12 4
102 9.58 ± 0.10 3
103 9.22 ± 0.16 3
104 N/Aa 3
a – could not determine KD within the tested concentration range
Table 2-2: MOR binding affinities of β-naltrexamine-based fluorescent ligands. 
pKD values were determined for the specific binding of each fluorescent ligand from the total
binding and non-specific binding (+ 10 µM naloxone) curves generated in Lumi4-Tb-labelled
SNAP-MOR-expressing HEK293 cell membranes. pKD values are the mean of a 3-4 experiments
(± SEM), each carried out in duplicate.
Following this, compound 102 was selected for further competition binding
assays against naloxone (6) and naltrexone (7) to confirm it was specifically
labelling the MOR (Figure 2-28).
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Compound Obs. pKi ± SEM Lit. pKi range
Naloxone (6) 7.68 ± 0.26 7.3-9.0a
Naltrexone (7) 7.86 ± 0.37 8.1-9.7b
a – refs57, 108-112 b – refs57, 99, 108-110, 113, 114
Figure 2-28: Competition binding assay results for naloxone and naltrexone against the
fluorescent ligand 102.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 102 and varying concentrations of naloxone (6) and naltrexone (7).
Data points and the observed pKi values are the means of 4 separate experiments (mean ±
SEM), each carried out in triplicate. Values for pKi were determined from the experimental IC50
and the fluorescent ligand KD and concentration using the Cheng-Prusoff equation.122 Ranges
of reported pKi values for these compounds at MOR are included.
2.5 Discussion
Six fluorescent ligands with amino acid-based linkers joining the β-
naltrexamine (72b) orthostere to a fluorophore were successfully synthesised
and pharmacologically evaluated for binding affinity at MOR.
The 6-position of the morphinan scaffold of β-naltrexamine (72b) was
identified as a suitable site for linker attachment, and subsequent substitution
of this position with N-acetylated amino acids resulted in no significant loss of
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MOR binding affinity from 72b, indicating that substitution at this position is
well tolerated.
It was hoped that interactions made between the amino acid substituent side
chain groups and the receptor might improve MOR binding affinity. In silico
modelling suggested that some beneficial interactions may be possible with
certain amino acid side chains, but most docking predictions indicated a lack of
interactions at this position. Competition binding experiments showed few
significant differences in MOR binding affinity between amino acid congeners,
mostly in agreement with the in silico predictions. These findings may be an
example of the “message-address” concept described for morphinan opioid
ligands, which suggests that ring-C substituents can affect receptor subtype
selectivity but are not beneficial for binding affinity.34
The only amino acid side chains which resulted in significant differences in MOR
binding affinity from the Gly-congener 92a were the L-Ser (92e) and L-Asp (92g)
congeners, which had significantly lower MOR binding. However, the
respective D-isomers 98e and 98g showed similar MOR binding affinities to
92a, suggesting that particular conformations of these polar side chains are
detrimental to MOR binding. In accordance with the “message-address”
concept of OR binding, it may be that these side chain groups are able to confer
some degree of receptor subtype selectivity against MOR binding. This could
be illuminated by KOR and DOR competition binding experiments for these
compounds.
In order to calculate the pKi values for these non-fluorescent congeners, it was
necessary to determine the KD of the fluorescent competitor ligand 50. The pKD
of 50 was measured as 8.88, slightly higher than the reported pA2 value (8.37 -
determined from antagonist concentration response curves fitted to a
Gaddum-Schild equation in an ERK1/2 phosphorylation assay against the MOR
agonist DAMGO and carried out in CHO cells expressing MOR).57 Given the
practical differences in determining these receptor binding values, it is
unsurprising that the values differ. However, these values are similar enough
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to give confidence to the measured values obtained from the saturation
binding experiments.
The inclusion of amino acids in the linker aimed to increase the hydrophilicity
of the compounds, to reduced non-specific binding. This had previously been
proposed as a drawback of the BODIPY-based fluorescent MOR ligand 50,
which had displayed incomplete loss of fluorescence in the presence of an
excess of unlabelled competitor, suggesting a higher level of non-specific
binding.57 Prior to carrying out the assays, there was some indication of success
in meeting this aim. When preparing for the competition binding studies of
non-fluorescent congeners, the 10 mM stock solution of 50 in dimethyl
sulfoxide (DMSO) was found to be insoluble in HEPES-buffered saline solution
(HBSS). The 10mM solution of 50 had to be further diluted in DMSO to 1 mM
before it could be solubilised in HBSS. By comparison, the BODIPY 630/650-
containing compounds from this study were soluble in HBSS buffer solution
from a 10mM stock solution in DMSO. This suggests an improved hydrophilicity
profile in these BODIPY 630/650-containing ligands compared to 50, which may
lead to fewer non-specific interactions away from the orthosteric binding site.
Further testing will be required in order to confirm to what degree the
compounds synthesised in this study participate in non-specific binding.
The four BODIPY 630/650-containing compounds (99, 100, 102 and 103) all
exhibited sub-nanomolar binding affinities for MOR (Table 2-2), which was
unchanged by variation in linker design (N-acetyl lysine or β-alanine) and length 
(the inclusion or absence of a hexanoyl spacer moiety). The lysine-linked sulfo-
Cy5 compound (101) displayed a binding affinity for MOR comparable to the
sulfo-Cy5 fluorescent MOR ligand (51) synthesised by Schembri et al.,57 but the
total binding curve for 104 did not reach saturation in the tested range so a
reliable pKD value could not be determined.
To confirm it was specifically labelling the MOR, 102 was selected for further
competition binding assays against naloxone (6) and naltrexone (7). There was
a high degree of variation in the results of these experiments (Figure 2-28),
which could be attributed to the concentration of fluorescent ligand used. It is
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common for the fluorescent ligand (or radioligand) concentration used in a
competition binding assay to be equal to its KD. However, due to the high MOR
binding affinity of compound 102, this concentration is very low. More
consistent results would likely be achieved if a higher concentration of
fluorescent ligand 102 was used.
The observed pKi value for naltrexone (7) is slightly lower than previously
reported, and the pKi value for naloxone (6) is only comparable to some of the
lower reported values. This also may have resulted from the inconsistency of
the results. However, the pKi value obtained for naloxone (6) in the competition
binding experiments, which used the fluorescent ligand 50 (Table 2-1), was
comparable to the value obtained with 102. To ensure that receptor occupancy
was at equilibrium, the experiment using 50 was repeated with a longer
incubation period, but this produced a similar outcome. This suggests that this
difference in obtained pKi values is a result of methodological differences from
the literature values.
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3 Design, synthesis and pharmacological evaluation
of 3,4-dimethyl-4-(3-hydroxyphenyl) piperidine-
based fluorescent ligands
Existing fluorescent opioid receptor ligands are typically composed of a
fluorophore bound to either an endogenous opioid peptide, or a morphinan-
based opioid ligand, such as the fluorescent compounds synthesised in Chapter
2. The biological applications of fluorescent ligands continue to grow, as does
the need for fluorescent ligands of different structures and properties. In order
to escape the existing paradigm of fluorescent opioid ligand design, non-
morphinan structures were considered to form the basis of a new class of
fluorescent opioid ligands.
A problem associated with morphinan-based fluorescent ligand design is the
legal barriers associated with the acquisition and synthetic use of narcotic
starting materials. Even antagonist starting materials, such as the naltrexone
(7) used in the synthesis of β-naltrexamine-based fluorescent ligands described 
in Chapter 2, require additional oversight during synthesis. Therefore, a
fluorescent ligand synthesised from non-biologically active, commercially
available starting materials would be desirable.
3.1 Selection of a lead molecule
The same criteria used to select a morphinan orthostere in Chapter 2 were also
used to select a non-morphinan lead molecule. The chosen characteristics of a
lead molecule were an MOR antagonist with high MOR binding affinity and a
well-established SAR profile. The range of well-described opioid ligands which
are neither morphinan-based, nor developed from an endogenous peptide, is
quite limited. The 2007 review of opioid antagonists by Goodman et al.123
includes a diverse array of novel opioid receptor ligand structures from patent
literature (Figure 3-1). Many of these structures are reported to possess sub-
nanomolar binding affinities for MOR which would be highly desirable for
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fluorescent ligand design.123 However, publications describing the SAR of these
compounds are rare and, whilst some aspects of SAR can be inferred from the
structures covered under the patent, it is unclear where might be suitable on
these structures for linker attachment with minimal impact on MOR binding
affinity.
Figure 3-1: Structures of novel MOR antagonists or inverse agonists.
105-108 are a selection of MOR antagonist structures with the reported MOR binding affinities
taken from patents.123 These structures have not been reported outside of these patents, so
their SAR profiles are not well understood. 109 is better described in the literature, but is an
inverse agonist, rather than an antagonist, and was therefore unsuitable as a lead molecule.
Many of these compounds have been targeted towards treatment of
compulsive consumption of food, alcohol and drugs.123 Similarly, GSK1521498
(109) has been the subject of numerous published studies on compulsive
reward-related behaviours.109, 124, 125 Though often described as an antagonist,
this compound has shown inverse agonism of MOR, KOR and DOR.125 In this
project, the lead molecule for fluorescent ligand design should be an
antagonist, rather than a reverse agonist, as it is desirable that the fluorescent
ligand does not elicit a response upon receptor binding. The functional profiles
of many of these novel opioid ligands is not well described, so the outcome of
using them as the orthostere in a fluorescent ligand is unpredictable. Due to
this uncertainty, these compounds were not considered appropriate for use in
this study. While it may be possible to synthesise a fluorescent opioid
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antagonist from these structures, a thorough study of their SAR would first be
required, which falls outside the scope of this project.
Alvimopan (9) was chosen as the lead molecule for this study, fulfilling the
criteria as a high affinity MOR antagonist, which has also been the subject of
numerous SAR studies. The structure of alvimopan (9) was published by
Zimmerman et al.110 in 1994 but the (3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl)
piperidine (DMHPP) orthostere it contains was first reported in 1978.126
Numerous SAR studies of DMHPP-containing ligands led to the discovery of
alvimopan (9) and have defined much of the structure’s SAR. This made it an
ideal candidate for fluorescent ligand design, as this existing SAR could be used
to select a point of attachment for the linker moiety and guide linker design.
3.2 SARs of (3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine structures
Unlike other non-morphinan opioid antagonists, alvimopan (9) has a well-
established SAR which has been explored in numerous published studies. The
antagonist function of alvimopan (9) and other related compounds is derived
from the DMHPP orthostere which is described below. SAR studies exploring
the effect of modifications to DMHPP on MOR binding affinity, receptor
subtype selectivity and function, are also described in this section.
3.2.1 Structural determinants of function
Zimmerman et al.126 first described the discovery of the DMHPP structure,
focusing on the chiral relationship between the 3- and 4-position substituents.
They describe the change in function of known agonist 110 to antagonism
when methylated at the 3-position, with antagonist activity found to be greater
in the (R)-methyl diastereomer 111 than the (S)-methyl 112. Further study of
the relationship between these methyl groups has shown a trend of slightly
lower MOR binding by the 3S,4S-enantiomer, with the 3R,4R-enantiomer (111)
preferred in most studies using this scaffold.127
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Figure 3-2: Variants of the 3,4-dimethyl-4-(3-hydroxyphenyl) piperidine structure.
The antagonist DMHPP structure 111 discovered by Zimmerman et al. is the 3R-methyl variant
of the agonist 110. The 3S-methyl variant 112 showed a weaker antagonist activity in rat and
mouse responses than 111.126 These findings led to the discovery of the opioid antagonist
alvimopan (9).110
It has been hypothesised that this change in function is not the result of
interactions made by the 3-methyl group in the receptor, but rather the effect
that this group has on the piperidine ring conformation.123 Unlike the more
rigid structures of morphinan opioids, there is some flexibility for the phenol to
adopt either an axial or equatorial position relative to the piperidine. The
proposed equatorial positioning of alvimopan (9) is supported by crystal
structure data127 as well as the antagonist activity of the equatorially locked
structure 113 (Figure 3-3).128 Even removal of the 3-methyl group of this
equatorially locked species produced an antagonist (114),129 supporting the
role of 3R-methyl as being responsible for conformational change, rather than
interacting with the receptor.
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Figure 3-3: The proposed equatorial phenol positioning in DMHPP antagonists.
The phenol of alvimopan (9) is hypothesised to adopt an equatorial position relative to the
piperidine ring as a result of 3-position methylation.123 The equatorially locked compounds 113
and 114 support this claim, as they are both antagonists.128, 129 The DMHPP-containing opioid
antagonist LY255582 (115) is shown above its crystal structure, adopting an equatorial
position.127
The opioid antagonist axelopran (116) was initially believed to adopt a similar
conformation to that of alvimopan (9),130 but separation of the precursor
isomers 117a and 117b revealed 117b to be a weakly binding partial agonist,
while 117a was a high affinity antagonist (Figure 3-4).131 To produce this
antagonism, it is possible that the piperidine ring of 117a switches to a boat
conformation for the phenol to adopt an equatorial conformation, but x-ray
crystallography of 117a shows it adopting the axial chair conformation.131 The
absence of the 3- and 4-methyl groups may cause the phenol to prefer this axial
conformation. The antagonism of axelopran (116) may result from a steric clash
between the axial phenol and the 2-6 ethylene bridge, preventing it from
adopting an agonist binding pose.
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Figure 3-4: The structures of axelopran (116) and its precursor isomers.130, 131
The opioid ligand axelopran (116) and its precursor 117a are both antagonists, despite
appearing to position their 4-aryl rings axially.130, 131 117b, the isomer of 117a possesses partial
agonist activity, though its active conformation has not been investigated.131
3.2.2 Modification of the aromatic ring
Outside of the conserved chirality of the piperidine 3- and 4-position
substituents, SAR studies have sought to evaluate the suitability of different
positions on the DMHPP structure for substitution and elaboration. The
aromatic ring has been investigated by modification of substituent position and
composition.
The phenol ring of DMHPP structures is understood to interact with the
receptor similarly to the phenol ring-A of morphinan opioid ligands, but
DMHPP-based ligands appear to have a higher tolerance for functionalisation.
While the substitution of an amide onto the aromatic ring of morphine results
in a dramatic loss in binding affinity (Figure 2-4),75 the same change in the
DMHPP compounds 118a and 115 results in a minor change in MOR binding
affinity (Figure 3-5).111, 132 This is exemplified by the MOR antagonist axelopran
(116), a ligand possessing similar properties to alvimopan (9), which is achieved
through numerous bioisosteric replacements, including a meta-amide group.
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R Scaffold 118 MOR pKi Scaffold 119 MOR pKi
3-OH 118a 8.72 LY255582 (115) 10.00
3-CONH2 118b 8.33 119b 9.7
3-CONHMe 118c 7.15
3-CON(Me)2 118d 5.92
3-CO2Me 118e 6.07 119e 7.36
3-CO2H 119f 6.84
3-CH2OH 118g 7.96
3-NH2 118h 6.82 119h 8.72




Figure 3-5: Comparison of different aryl ring substituents and their effect on MOR binding
affinity.111, 132
Small, polar functional groups such as an amide (118b, 119b) can be substituted onto DMHPP
scaffolds such as 118 and 119 with relatively small changes to MOR binding affinity compared
to the corresponding hydroxyl-containing compounds (118a and 115).111, 132 Larger groups
typically see a reduction in pKi, but not to the degree seen in morphinan ligands (as shown in
Figure 2-4). Ionisable groups are also less favoured, but removal of the hydroxyl (119j) can still
produce a high affinity ligand.132 Relocation of the hydroxyl group to either the para- or meta-
position results in a large loss of MOR binding affinity (119k and 119m).132
Other small polar groups at this position can also be tolerated, and can even be
used to improve receptor subtype selectivity, albeit with a lower affinity for
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MOR.111, 132 Removal of the hydroxyl group from 115, while resulting in a loss
of MOR binding affinity, still produced a high affinity ligand (119j) due to the
exceptional MOR binding affinity of the parent compound. MOR binding
affinity of the KOR-selective ligand JDTic (120) is actually improved by removal
of the hydroxyl, with no effect shown over KOR binding (Figure 3-6).133 A meta-
amide group on this structure produces no change in MOR affinity, but rather
a loss in binding affinity at KOR.133, 134
Compound R pKe (MOR) pKe (DOR) pKe (KOR)
JDTic (120)a OH 7.60 7.13 10.70
121a H 8.05 6.35 10.62
122b CONH2 7.68 6.32 9.92
a - ref133, b - ref134
Figure 3-6: Opioid receptor binding affinities for JDTic (120) and its meta-substituted
variants.133, 134
Removal of the aryl hydroxyl group from the KOR-selective antagonist JDTic (120) results in a
gain in MOR binding affinity with little effect on KOR binding affinity. Replacement of the
hydroxyl group with an amide does not affect MOR binding but reduces KOR binding affinity.133,
134
Relocation of the hydroxyl group of 115 can result in a more drastic loss of
binding affinity. The para-hydroxyl variant (119m) binds with similar MOR
affinity to some of the less well-tolerated meta-substituents shown in Figure 3-
5, but the ortho-hydroxyl compound 119k suffers a 4000-fold loss in MOR
binding affinity compared to 115.132
The fact that some changes to the composition and position of the aryl ring
substituent are tolerated, whilst other changes cause an extreme reduction in
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MOR binding affinity, demonstrates that this region of the orthostere is highly
influential over receptor binding. Despite the variety of tolerated substituents,
the aryl ring is clearly tightly bound within the receptor binding site, leaving
room for only subtle structural modifications, without suffering unacceptable
losses to binding affinity.
3.2.3 N-substitution
In morphinan opioid ligands, the N-substituent is crucial in determining ligand
function, with minor structural changes causing the ligand to switch its
agonist/antagonist activity (see Figure 2-12). As previously discussed, the
functionality of DMHPP ligands is determined by the stereoisomerism of the 3-
and 4-methyl groups, and N-substitution has not been found to influence ligand
function. Instead, the N-substituent can influence receptor subtype selectivity,
as demonstrated by the DMHPP-based KOR antagonist JDTic (120). In this
regard, the role of DMHPP N-substituents is similar to the 6-position
substituents of morphinan-based opioid ligands. However, the “message-
address” concept described for morphinan opioid ligands (2.1.4) cannot be
applied to DMHPP compounds, as N-substitution is also able to modulate
receptor binding affinity.
SAR studies investigating N-substitution of DMHPP determined that a phenyl
or cyclohexyl group bound to the amine via an ethylene or propylene spacer
was optimal for MOR binding;127, 135 N-substitution of a phenylpropyl group
(125) resulted in a 100-fold increase in MOR affinity compared to the N-methyl
compound (111) (Figure 3-7).135 This phenyl positioning is conserved in the
structure of alvimopan (9), alongside a 2-amide-bound glycine moiety, which
alters the compound’s physicochemical properties to restrict its absorption
from the GI tract.110
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Figure 3-7: The effect of differences in N-alkyene-phenyl substituent spacing on MOR binding
affinity.127, 135
Binding affinities were determined by displacement of [3H]-naloxone from MOR in rat brain
homogenate.127, 135
The N-substituent conformation which facilitates this increased binding affinity
has been investigated through restriction of the N-alkyl spacer. A study by Le
Bourdonnec et al.136 synthesised and tested a series of conformationally locked
congeners of the N-phenylethyl DMHPP compound 124 (Figure 3-8). Two of
these quinolizidine compounds possessed higher binding affinities than the
unrestricted 124. Functional assays revealed 131b to be an agonist, while 130b
remained an antagonist. In silico analysis of their respective lowest energy
conformations showed that 124 and 130b maintained equatorial phenols,
while an axial phenol conformation was generated for 131b. The same group
investigated further substitution of the quinolizidine ring of 130b, but this was
found to be detrimental to MOR binding.137
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Compound Scaffold Conformation MOR pKi
124 - - 8.74
130a 130 6R,9R 6.37
130b 130 6S,9S 9.21
130c 130 6R,9S 6.96
130d 130 6S,9R 6.96
131a 131 2R,9R 7.59
131b 131 2S,9S 9.05
131c 131 2R,9S 7.43
131d 131 2S,9R 7.14
Figure 3-8: MOR binding affinities of DMHPP compounds with conformationally restricted N-
substituents.136
A series of fused ring compounds were investigated to determine the active conformation of
the phenylethyl DMHPP compound 124.136 Every isomeric combination of the quinolizidines
130 and 131 were tested, with two analogues identified to possess higher binding affinities
than the unrestricted 124. 131b was found to be an agonist, likely due to distortion of the
piperidine ring. 130b displayed antagonist activity and was determined to represent the active
conformation of 124.
Another approach to conformational restriction of N-substituents introduced
functional groups into the propylene spacer of compound 125 (Figure 3-9).138
MOR binding affinity was impaired when the spacer was forced to adopt a cis-
conformation through the introduction of a double bond (133), but the trans-
isomer (132) displayed a similar MOR affinity to 125, suggesting that they share
similar binding poses. Substitution of a benzofuran (134) also resulted in a loss
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of MOR binding affinity, indicating that rotational freedom of the phenyl ring is
necessary for it to be optimally positioned for binding.138
Figure 3-9: DMHPP compounds with conformationally restricted N-substituents.138
A series of conformationally restricted variants of the phenylpropyl DMHPP compound 125
were synthesised. The MOR binding affinity of the trans-propenyl isomer 132 was unchanged
from the unrestricted 125. The cis-propenyl isomer 133 exhibited a lower MOR binding affinity,
suggesting that the trans-conformation is representative of the binding pose of 125. The loss
of MOR binding affinity displayed by the benzofuran congener (134) reveals that rotational
freedom of the phenyl ring is necessary to be optimally positioned for binding.138
Functionalisation of the amino acid side chain of alvimopan (9) has also been
explored, with several different amino acids utilised to replace glycine (Figure
3-10).139 Most of these modifications were found to reduce MOR binding
affinity, except the lysine variant (135d), which had a similar MOR binding
affinity to alvimopan but possessed far greater receptor subtype selectivity.
Removal of the benzyl group from alvimopan resulted in a larger loss of binding
affinity, but this could be partially recovered when different amino acids were
substituted for glycine.139 It is noteworthy that addition of a phenyl group to
alvimopan (135b) resulted in a loss in MOR binding affinity, but the same
modification in the des-benzyl structure improved binding affinity (136e). This
may suggest that these functional groups compete for the same binding site,
making the amino acid side chain detrimental for MOR binding when the benzyl
group is present, but favourable for binding when the benzyl group is absent.
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Compound R1 R2 MOR pKi or % inh. at 10 µM
Alvimopan (9) Bn H 9.33
135a Bn Me 9.20
135b Bn Bn 8.77
135c Bn CH2COOH 8.14
135d Bn (CH2)4NH2 9.30
136a H H 20%
136e H Bn 7.44
136f H CH2cHex 7.70
136g H (CH2)2Ph 7.24
136i H (CH2)4NH2 45%
Figure 3-10: Modifications to the structure of alvimopan (9).139
Modification of the amino acid utilised in the structure of alvimopan (9) resulted in loss of MOR
binding affinity (135a-c) except the lysine congener (135d) which showed similar binding
affinity to alvimopan (9). Removal of the benzyl group from alvimopan (9) resulted in a loss of
MOR binding affinity (136a), which was partially recovered by the inclusion of amino acids
containing a phenyl or cyclohexyl group (136e-g).
3.2.4 Modification of the piperidine ring
The crucial role that 3- and 4-position substituents play in determining ligand
function limits how the piperidine ring can be functionalised. Outside of the
fused ring structures described above, modifications to the piperidine ring have
been more limited than those seen in other regions. Most elaboration of the
piperidine ring had been through internal bridging to investigate piperidine ring
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conformation, such as 113 and 114 (Figure 3-3),128, 129 and the 2-6 ethylene
bridge seen in axelopran (116).130, 131
Substitution onto the 6-position of 124 showed that modification of this
position with even small alkyl groups was detrimental to opioid receptor
binding, with further loss of binding affinity associated with larger
substituents.140 Substitution of the piperidine ring should therefore be avoided,
except to confer specific positioning of the N-substituent (as seen in Figure 3-
8).
3.3 Fluorescent ligand and non-fluorescent congener design
The SAR studies of the DMHPP structure reveal its potential to produce high
affinity antagonist ligands for MOR. Modification of the piperidine ring is best
avoided due to the potential for function-altering conformation shifts and,
while aryl ring substitution can be tolerated, a meta-hydroxyl or amide group
should be utilised for optimal MOR binding affinity. Contrastingly, N-
substitution could provide an ideal location for linker and fluorophore
attachment.
Elaboration of the linker from the existing glycine moiety of alvimopan (9) could
achieve this project’s aim of utilising amino acids in the linker of a DMHPP-
based fluorescent ligand to improve physiochemical properties. The study by
Le Bourdonnec et al.139 into amino acid substitution of alvimopan (9) supports
the potential for incorporating different amino acids at this site, but only in the
absence of the benzyl group (Figure 3-10). While loss of this group is
detrimental to MOR binding affinity, it has been shown that certain amino acids
are able to recover some of the lost binding affinity.139 Benzyl removal also has
synthetic benefits, as the epimers generated by benzylation must be separated,
resulting in a loss of useful material.110, 141
It was decided that fluorescent compounds of the design shown in Figure 3-11
would be synthesised. The composition of the first bound amino acid (referred
to as “the first position”) would be determined using synthesised non-
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fluorescent single amino acid congeners (136) through measurement of MOR
binding affinity. These results would be used to inform any further elaboration
of the linker. It was planned that click chemistry would be used to attach the
alkynyl group of a modified fluorophore to a terminal azidoalanine moiety,
forming a 1,2,3-triazole ring (Scheme 3-1). Some non-fluorescent congeners
would incorporate a terminal phenylalanine moiety as a bioisostere of the
1,2,3-triazole amino acid (138).
Figure 3-11: General design of DMHPP-based fluorescent ligands.
The planned structure of the fluorescent ligands designed in this chapter consisted of the 3,4-
dimethyl-4-(3-hydroxyphenyl) piperidine orthostere connected to a peptidic linker region
(137). The composition of this linker region was refined by the synthesis and pharmacological
evaluation of non-fluorescent congeners (136 and 138). Click chemistry was planned to be used
to attach the alkynyl group of a modified fluorophore to an azidoalanine moiety, forming a
1,2,3-triazole ring (Scheme 3-1). This was represented in non-fluorescent congeners by
incorporating a phenylalanine bioisostere (138).
Scheme 3-1: Mechanism of the azide-alkyne cycloaddition between azidoalanine and the
alkyne of a modified fluorophore.
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3.4 Synthesis of 3,4-dimethyl-4-(3-hydroxyphenyl) piperidine
A benefit of the DMHPP structure as a lead molecule is that it can be
synthesised from commercially available, non-narcotic starting materials.
Synthesis of DMHPP 146a was first described by Mitch et al.142 (Scheme 3-2)
but suffered from low yield and included the neurotoxic intermediate 141, the
m-methoxy-variant of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
which is known to induce Parkinsonism.143 A safer, higher yielding route with
fewer synthetic steps was published by Werner et al.141 five years later
(Scheme 3-7) and has served as the standard route to 146a synthesis since, on
both laboratory and industrial scales.
Scheme 3-2: Synthetic scheme for (3R,4R) 3,4-dimethyl-4-(3-hydroxyphenyl) piperidine by
Mitch et al.142
Reported reagents and conditions: (a) (3-methoxyphenyl)lithium, THF, -70°C; (b) p-TsOH,
PhMe, reflux; (c) n-BuLi, MeI, THF, -10°C; (d) H2CO, (Me)2NH, H2SO4, H2O, 70°C; (e) H2,
Pd/Ba2SO4, EtOH, rt; (f) i) NaBH3CN, MeOH, rt; ii) dibenzoyl L-tartrate, EtOH; (g) i) vinyl
chloroformate, DCE, reflux; ii) HCl, EtOH, reflux, iii) HBr, AcOH, reflux.
Both of these racemic synthetic routes produce undesired isomers which
require chiral purification and result in significant losses in mass of useful
product. In response to this problem, an enantioselective synthetic route to
146a was developed by Furkert et al.144 which almost exclusively produced the
desirable 3R,4R-isomer (Scheme 3-3). The reported overall yields of both the
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Werner et al.141 and Furkert et al.144 routes were similar (15-16%), although the
latter involved more synthetic steps.
Unlike the commonly utilised Mitch et al. and Werner et al. syntheses, there
are no reports of the enantioselective synthetic route being repeated since the
paper was published in 2007. Therefore, it was initially decided that the route
described by Furkert et al.144 would be followed in this project, as an external
assessment of the utility of this synthetic route. The chemistry following the
Furkert et al.144 route is reported in section 3.4.1 below. Unfortunately, the
enantioselectivity described by the authors could not be replicated in this
project. Instead, the synthetic route described by Werner et al.141 was pursued,
and is reported on in section 3.4.2.
3.4.1 Enantioselective synthetic route
The reported enantioselective synthetic route by Furkert et al.144 is shown in
Scheme 3-3. Unfortunately, the described enantioselectivity could not be
replicated in this project, and thus the synthetic route was not followed to
completion. The completed chemistry from this project is shown in Scheme 3-
4.
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Scheme 3-3: Synthetic scheme for chirally-selective route to (R),(R)-3,4-dimethyl-4-(3-
hydroxyphenyl)piperidine by Furkert et al.144
Reported reagents and conditions: a) t-BuSOCl, NEt3, DCM, 2 h, 0°C; b) m-CPBA, DCM, 3 h, RT;
c) Et3SiH, BF3·OEt2, DCM, 3 h, 0°C; d) Br2, NEt3, DCM, 1 h, 0°C; e) CBS catalyst, BH3·PhNEt2, THF,
16 h, 0°C; f) (EtO)2P(O)Cl, DMAP, NEt3, DCM, 24 h, 0°C; g) MeMgBr, CuBr·SMe2, dry THF, 5 h, -
40°C; h) 3-OMe-PhB(OH)2, Pd(Ph3P)4, Na2CO3, 1:1 ethanol/toluene, 100°C, 30 min; i) TfOH,
anisole, DCM, 30 min, 0°C; j) CH2O, NaBH3CN, MeCN, 30 min, RT; k) n-BuLi, Me2SO4, THF, 30
min, -50°C; l) NaBH4, methanol, 3 h, 0°C; m) 1)NaOH, PhOCOCl, toluene, 2 h, reflux; 2) HBr,
AcOH, 18 h, reflux.
In contrast to the literature method, the coupling of tert-butylsulfonyl chloride
(tBuSOCl) to α-furfurylamine (147) was carried out using a stoichiometric
amount tBuSOCl, added dropwise as a dilute solution in dichloromethane
(DCM) to prevent di-substitution of the amine. The reaction of sulfinamide 148
with meta-chloroperbenzoic acid (mCPBA) had two effects. Upon addition of
mCPBA, oxidation of the sulfinamide to produce the sulfonamide was quickly
observed by TLC. A Prilezhaev reaction then introduced an epoxide onto the
furan ring, with a subsequent aza-Achmatowitz rearrangement to produce the
6-membered ring 149 (Scheme 3-5). Alcohol reduction using boron trifluoride
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diethyl etherate and triethylsilane resulted in a poor yield of 150 (22% over two
steps), vastly different from the reported 78% yield.144 Attempts to modify the
reaction conditions (temperature, stoichiometry, order of reagent addition)
produced only minor changes to overall yield. A key discovery was that the
reaction did not scale up well, with the best yield of 36% achieve using 100 mg
of 150. The remaining material was reacted in twelve separate reaction vessels
in parallel to optimise the yield over these steps.
Scheme 3-4: Synthesis of (R),(R)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine precursors.144
Based on the synthesis described by Furkert et al.144 shown in Scheme 3-3. Reagents and
conditions: (a) t-BuSOCl, NEt3, DCM, 2 h, 0°C, 90%; (b) m-CPBA, DCM, 3 h, RT; (c) Et3SiH,
BF3·OEt2, DCM, 3 h, 0°C, 36% (2 steps); (d) Br2, NEt3, DCM, 1 h, 0°C, 77%; (e) CBS catalyst,
BH3·PhNEt2, THF, 16 h, 0°C, 77%; (f) (EtO)2P(O)Cl, DMAP, NEt3, DCM, 24 h, 0°C, 82%; (g)
MeMgBr, CuBr·SMe2, dry THF, 5 h, -40°C, 34%; (h) 3-OMe-PhB(OH)2, Pd(Ph3P)4, Na2CO3, 1:1
ethanol/toluene, 100°C, 30 min, 73%; (i) TfOH, anisole, DCM, 30 min, 0°C, 94%; (j) CH2O,
NaBH3CN, MeCN, 30 min, RT, 89%.
Bromination of 150 by Br2 in the presence of triethylamine (TEA) produced the
4-bromo compound 151 in good yield. The ketone was then enantioselectively
reduced to the (S)-alcohol using a CBS catalyst ((3aR)-1-methyl-3,3-diphenyl-
3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole). The chiral purity of 152
was confirmed by determination of [α]D which was comparable to the literature
value.144 The alcohol of 152 was then esterified by diethyl chlorophosphate and
4-dimethylaminopyridine (DMAP) in high yield, although the reaction did not
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go to completion under the tested conditions, with a small amount of starting
material recovered each time.
Scheme 3-5: Oxidation and rearrangement of N-furfurylsulfonamide by mCPBA.
Oxidation of 148 results in epoxide formation, which occurs via a Prilezhaev reaction. An aza-
Achmatowitz rearrangement converts the 5-membered epoxide intermediate into the 6-
membered intermediate 149.
The procedure developed by Furkert et al.144 had optimised the reaction
conditions for the enantioselective methylation of 153, using different
methylating agents and copper catalysts. It was therefore disappointing to find,
when using the described methyl Grignard and copper (I) bromide dimethyl
sulphide complex, that the product 154 was a mixture of enantiomers, in
contrast to the near-complete enantioselectivity reported in the protocol.144
The authors described the reaction as occurring via an SN2’ mechanism, with
methylation occurring at the unsaturated 5-position to produce the desired (R)-
isomer (154a). They report that the (S)-isomer (154b) was produced by the SN2
mechanism through direct displacement of the phosphate (Scheme 3-6). The
conditions used were proposed to direct the methylation almost exclusively to
the SN2’ route, but the experiments carried out in this study did not replicate
the literature results, producing a mixture of 154a and 154b.
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Scheme 3-6: Reaction mechanisms to produce the two 3-methyl enantiomers of 154.
Above: The SN2 mechanism results in direct substitution at the 3-position of the piperidine ring,
producing the (R)-isomer 154b. Below: The (S)-isomer is produced by an SN2’ mechanism,
substituting onto the 5-position and eliminating the phosphate from the sp2-hybridised 3-
position.
After several attempts to direct the methylation towards the desired product
were unsuccessful, it was decided that the synthetic route should be switched
to the route developed by Werner et al.141 (Scheme 3-7). Since this method
would require separation of enantiomers, the Furkert et al.144 synthesis was
continued, using the mixed methylation products (154) to produce 157. Since
157 differs only from compound 161 in the Werner et al.141 synthesis in their
respective O-phenol substituents, testing the separability of the enantiomers
of 157 would indicate if the enantiomers of 161 were also separable.
For that purpose, a Suzuki coupling was carried out between the mixed
enantiomers of 154 and 3-methoxybenzeneboronic acid in the presence of
tetrakis(triphenylphosphine)-palladium (0) and sodium carbonate to give the
product 155. This was then treated with triflic acid and anisole to remove the
tert-butylsulfonyl (bus) protecting group to give the secondary amine 156.
Reductive amination of formaldehyde by 156, using STAB as the reducing
agent, yielded the N-methyl piperidine 157.
The 3R (157a) and 3S (157b) isomers were successfully isolated by high
performance liquid chromatography (HPLC), indicating that the iso-propyl
derivative 161 could also be purified using this method. 157a made up 61% of
the isolated product, with 157b composing the remaining 39%. It is assumed
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that this ratio is unchanged for compounds 154-157 and that this is
representative of the ratio of SN2’ to SN2 products 154a and 154b in Scheme 3-
6.
3.4.2 Non-enantioselective synthetic route
As discussed above, once it was established that chirally-pure products would
not be achievable using the method developed by Furkert et al.,144 it was
decided that the protocol described by Werner et al.141 would be a more
suitable route to synthesis of 146a (Scheme 3-7). In the absence of any benefit
over chiral selectivity, this approach was more desirable as it halved the
number of synthetic steps from fourteen to seven (shown in Figure 3-8).
Scheme 3-7: Non-chirally-selective synthesis of 3,4-dimethyl-4-(3-
hydroxyphenyl)piperidine.141
Based on the synthesis described by Werner et al.141 with shown yields achieved in this project.
Reagents and conditions: (a) i) n-BuLi, THF, -75°C, 1 h; ii) 1,3-dimethylpiperid-4-one, -75°C, 94%;
(b) EtO2CCl, EtOAc, 24 h, 79%; (c) decalin, 24 h, reflux, 99%; (d) n-BuLi, Me2SO4, THF, 1 h, -50°C,
77%; (e) NaBH4, MeOH, 0°C, 71%; (f) NaOH, PhOCOCl, toluene, 2 h, reflux, 74%; (g) HBr, AcOH,
18 h, reflux, 86%.
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Scheme 3-8: Comparison of synthetic routes to produce DMHPP 146.
The longer synthetic route developed by Furkert et al.144 describes enantiomeric selectivity in
favour of the (R)-isomer of 157. However, this result could not be replicated in this study. In
the absence of chiral selectivity, the shorter route developed by Werner et al.141 to synthesise
161 was preferred. Both methods incorporate the same final four steps to produce 146.
1-Bromo-3-iso-propoxybenzene was stirred with n-BuLi, converting it to the
more reactive aryllithium, to which dimethylpiperid-4-one was added, resulting
in addition of the phenol into the ketone. This produced a mixture of all four
stereoisomers of the tertiary alcohol 159 in high yield. Ethylchloroformate was
coupled to the alcohol to give the carbonate ester 160. Heating 160 to 195°C in
decalin resulted in thermal elimination of ethanol and carbon dioxide, leaving
the unsaturated 1,2,3,6-tetrahydropyridine 161 and trace amounts of 159.
At this stage the enantiomers of 161 were separated by HPLC using the same
method developed to purify the enantiomers of 157. As expected, 161a and
161b were easily separated using this method. Following separation, the
remaining chemistry was carried out on both enantiomers separately and in
parallel, using the same conditions.
Deprotonation of the 6-position of 161 by n-BuLi and 4-position methylation by
dimethyl sulfide yielded chirally-pure 162a and 162b in separate reactions. The
presence of the chiral 3-methyl group resulted in exclusively trans-methylation
of the 4-position. A stoichiometric amount of dimethyl sulfide was used to
avoid previously reported amine quaternisation.141 Due to initial difficulties in
sourcing dimethyl sulfide, methyl iodide was also investigated as a methylating
agent in this reaction. However, this approach produced only small quantities
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of product, with mostly unreacted starting material and a mixture of
unidentified by-product recovered. A similar result had also been reported
when using methyl iodide or methyl bromide as methylating agents.141
The unsaturated bond of the 1,2,3,4-tetrahydropyridine ring was reduced by
sodium borohydride to produce 163. Displacement of the N-methyl group by
phenylchloroformate (164) and subsequent removal of both the N- and O-
substituents by hydrogen bromide in acetic acid completed the syntheses of
146a and 146b.
3.5 First generation non-fluorescent congeners
Following the successful synthesis of the DMHPP orthostere, a series of single
amino acid congeners bound to DMHPP by a N-propanamide moiety were
synthesised, and their MOR binding affinity determined over two phases
(Figure 3-12). An initial set of glycine congeners using both the 3R,4R-isomer
146a and the 3S,4S-isomer 146b were synthesised and tested. This was carried
out to both confirm 146a as the higher MOR affinity isomer, and to substantiate
the reported loss of MOR binding affinity when the benzyl group is removed
from alvimopan (9).139 The second set of congeners were exclusively
synthesised from 146a, with various amino acids substituted onto the N-
propanamide. This set included several of the congeners synthesised and
tested by Le Bourdonnec et al.139 and some previously untested structures.
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Figure 3-12: Structures of the tested single amino acid congener sets.
The first set of tested congeners included both the 3R,4R-orthostere 146a and its 3S,4S-isomer
146b. For each orthostere structure a glycine acid, glycine methyl ester and unsubstituted N-
propionic acid congener were tested. In the second set, a series of different amino acid
congeners bound to 146a were tested as both the methyl ester and acid forms.
3.5.1 Synthesis of enantiomeric DMHPP congeners
The synthesis shown in Scheme 3-9 follows a route similar to the one proposed
by Zimmerman et al.110 in their paper describing the discovery of alvimopan (9).
A propanoate moiety was introduced to the piperidine amine by Michael
addition of 146a to ethyl acrylate. This ethyl ester (167a) was hydrolysed under
acidic conditions to produce the acid 165a. Coupling to glycine methyl ester
using the coupling reagent (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) with hydroxybenzotriazole
(HOBt) and DIPEA, produced 166a in a surprisingly low yield. The purity of the
base used in the reaction was questionable, so the reaction was repeated with
fresh DIPEA. This change did not result in an improved yield, but sufficient
material had been produced for testing and for further ester hydrolysis to give
the free acid 136a. Synthesis of the 3S,4S congeners was carried out using the
same method, as shown in Scheme 3-9.
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Scheme 3-9: Synthesis of non-fluorescent glycine DMHPP congeners.
Reagents and conditions: (a) ethyl acrylate, DMF, 20 h, 50°C, 84%; (b) 4M HCl, dioxane, 2 h,
reflux, 99%; (c) glycine-OMe.HCl, HBTU, HOBt, DIPEA, THF, 24 h, 16%.
3.5.2 MOR binding affinities of enantiomeric DMHPP congeners
Figure 3-13: The structures of the oripavine-derived fluorescent ligands used in this study,
synthesised and characterised by Schembri et al.57
These fluorescent MOR ligands were used as labelled competitor ligands in competition
binding studies to determine the MOR binding affinities of unlabelled compounds. The Sulfo-
Cy5 fluorescent ligand 51 was most appropriate to be used in the competition binding studies
measured by automated confocal imaging (described in 3.5.2), due to its low levels of non-
specific binding.57 The BODIPY 630/650-X fluorescent ligand 50 was found to be better suited
for the TR-FRET competition binding studies due to its higher MOR binding affinity (described
in 3.5.4).
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The MOR binding affinities of the first set of congeners was determined using
automated confocal microscopy in a competition binding assay against the
sulfo-Cy5-labelled oripavine derivative 51 (synthesised and characterised by
Schembri et al.57). The results were plotted as competition binding curves
(Figure 3-14) from which pKi values were determined.
Figure 3-14: Competition binding assay for enantiomeric DMHPP congeners.
MOR-expressing HEK293 cells were incubated with 50 nM of the fluorescent ligand 51
(synthesised by Schembri et al.57) and increasing concentrations of each of the enantiomeric
congeners described in Figure 3-15. Data points are the mean of 3 or 4 separate experiments
(mean ± SEM), each carried out in duplicate.
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Figure 3-15: MOR binding affinities of enantiomeric DMHPP congeners.
pKi values at MOR were calculated from experimental IC50 values using the Cheng-Prusoff
equation.122 Experimental IC50 values were determined by competitive displacement of the
fluorescent ligand 51 (synthesised by Schembri et al.57) in MOR-expressing HEK293 cells. Values
are the mean of 3 or 4 separate experiments (mean ± SEM), each carried out in duplicate.
All congeners reduced binding to non-specific binding levels. Competition
binding experiments indicated significant differences within the range of
affinities (one-way ANOVA, P = 0.004) and between the Gly-OMe congeners
166a and 166b and the remaining acidic congeners (P < 0.05, post-hoc Tukey’s
multiple comparisons test). Significant differences in MOR binding affinity were
not found between any of enantiomeric pairs, with only minor differences in
pKi exhibited.
3.5.3 Synthesis of further single amino acid congeners
In the second set of single amino acid congeners, the composition of the amino
acid coupled to the propanamide of the 3R,4R-isomer 165a was altered with a
selection of different amino acids (Scheme 3-10). A previous study by Le
Bourdonnec et al.139 had tested a limited selection of congeners sharing the
Compound MOR pKi ± SEM n
Naloxone (6) 8.70 ± 0.15 4
165a - (R,R)-OH 6.28 ± 0.20 3
165b - (S,S)-OH 6.55 ± 0.31 3
166a - (R,R)-Gly-OMe 7.40 ± 0.17 3
166b - (S,S)-Gly-OMe 7.04 ± 0.16 3
136a - (R,R)-Gly-OH 6.68 ± 0.17 3
136b - (S,S)-Gly-OH 6.48 ± 0.23 3
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structure 136 (Figure 3-10). Some of these described compounds were
synthesised, along with a selection of other amino acid congeners.
Scheme 3-10: Synthesis of single amino acid DMHPP congeners.
Reagents and conditions: (a) ethyl acrylate, DMF, 50°C, 84%; (b) 4M HCl, dioxane, reflux, 99%;
(c) amino acid alkyl ester hydrochloride, HBTU, HOBt, DIPEA, THF, 12-17%.
The method used to synthesise these congeners was unaltered from the
method described for the first set of single amino acid congeners (3.5.2) and
again resulted in low reaction yields. However, sufficient material had been
produced for testing (166a,c-i) and for further ester hydrolysis to give the free
acids (136a,c-i).
3.5.4 MOR binding affinity of single amino acid congeners
Given the large number of compounds, the higher throughput TR-FRET-based
method of competition binding assay against the BODIPY 630/650-labelled
oripavine derivative 50 (synthesised and characterised by Schembri et al.57),
was used to determine the MOR binding affinities of the second set of single
amino acid congeners. The results were plotted as competition binding curves
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(Figure 3-16 and Figure 3-17), from which pKi values were determined for
compounds which reduced binding to non-specific levels (Table 3-1).
Percentage inhibition at the highest tested concentration (10 µM) is given for
compounds which did not produce full competition binding curves.
CHA – cyclohexylalanine, HoPhe - homophenylalanine
Figure 3-16: Competition binding assay results for single amino acid DMHPP congeners.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 50 (synthesised by Schembri et al.57) and increasing concentrations
of each of the amido ester congeners described in Scheme 3-10. Data points are the mean of
3 or 4 separate experiments (mean ± SEM), each carried out in duplicate.
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CHA – cyclohexylalanine, HoPhe - homophenylalanine
Figure 3-17: Competition binding assay results for single amino acid DMHPP congeners.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 50 (synthesised by Schembri et al.57) and increasing concentrations of
each of the amido acid congeners described in Scheme 3-10. Data points are the mean of 3 or
4 separate experiments (mean ± SEM), each carried out in duplicate.
Amongst the methyl ester compounds that displayed full inhibition of
fluorescent ligand 50, a significant range of pKi values were observed (one-way
ANOVA, P = 0.001). 166e and 166h were found to possess significantly higher
MOR binding affinities than 166d and 166g (P < 0.05, post-hoc Tukey’s multiple
comparisons test). Fewer acidic congeners were able to produce full
competition binding curves, but of those that did, 136e showed significantly
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higher MOR binding affinity than 136g (P < 0.05, post-hoc Tukey’s multiple
comparisons test).
Compound
MOR pKi ± SEM or % inh.
at 10 µM (lit. valuea) n Compound
MOR pKi ± SEM or
% inh. at 10 µM n
136a Gly 28% (20%) 4 166a Gly 59% 4
136c Ala 60% 3 166c Ala 82% 3
136d Val 40% 3 166d Val 6.79 ± 0.17 3
136e Phe 7.07 ± 0.13 (7.44) 4 166e Phe 7.39 ± 0.07 4
136f CHA 6.67 ± 0.17 (7.70) 3 166f CHA 7.32 ± 0.14 3
136g HoPhe 6.34 ± 0.10 (7.24) 3 166g HoPhe 6.91 ± 0.12 3
136h Tyr 78% 3 166h Tyr 7.53 ± 0.14 3
136i Lys 60% (45%) 3 166i Lys 73% 3
CHA – cyclohexylalanine, HoPhe - homophenylalanine
Table 3-1: MOR binding affinities of single amino acid DMHPP congeners.
pKi values at MOR were calculated from experimental IC50 values using the Cheng-Prusoff
equation.122 Experimental IC50 values were determined by competitive displacement of the
fluorescent ligand 50 (synthesised by Schembri et al.57) in Lumi4-Tb-labelled SNAP-MOR-
expressing HEK293 cell membranes. Where a complete dose-response curve could not be
established, percentage inhibition of the fluorescent ligand 50 by unlabelled congener at 10
µM is given. Values are the mean of 3 or 4 separate experiments (mean ± SEM), each carried
out in duplicate.
a – Reported pKi values by Le Bourdonnec et al.139 measured by competitive displacement of
[3H]-diprenorphine from MOR-expressing CHO cells.
Based on these results, phenylalanine was identified as the optimal amino acid
to occupy the first position of a DMHPP-based fluorescent ligand linker. The
higher MOR binding affinities displayed by the methyl ester congeners,
compared to the corresponding acids, suggested that this was a suitable
position for linker elaboration.
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Figure 3-18: DMHPP-containing fluorescent ligand and non-fluorescent congener design.
Left: General formula for the planned DMHPP-containing fluorescent ligands. The peptidic
linker region would contain a phenylalanine moiety at the first position based on previous
pharmacological testing. The second position would be occupied by one of the amino acids
shown in the table. The third position was planned to be a 1,2,3-triazole with a fluorophore
attached via the 4-position. Right: To determine the optimal amino acid composition at the
second position, a series of non-fluorescent congeners were synthesised with each of the
amino acids shown in the table. In these congeners, a phenylalanine moiety was substituted
into the third position as a bioisostere of the 1,2,3-triazole.
It was decided that the composition of an amino acid at the second position
should be explored, but, unlike the single amino acid congeners (136), there
was no existing literature data for compounds of this kind with two or more
amino acids. A range of amino acids representative of all amino acid types were
selected to be used at the second position in this set of congeners (Figure 3-
18). It was planned that a fluorophore could be attached to the linker via an
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azide-alkyne cycloaddition between the alkyne of a modified fluorophore and
an azidoalanine amino acid (Scheme 3-1). Rather than using the more
expensive azidoalanine in the non-fluorescent congeners, a phenylalanine was
incorporated at the third position as a bioisostere of the 1,2,3-triazole which
results from this click reaction. Eight compounds with the final structures 170
shown in Figure 3-18 were synthesised and their MOR binding affinities
determined to identify the optimal composition of the linker.
3.6.1 Synthesis of tripeptide congeners
The longer tripeptide linkers were assembled by solid phase peptide synthesis
prior to coupling to 165a. This resulted in a much faster synthetic route to
produce the tripeptide congeners, which could be carried out in parallel
reactions. Solid phase synthesis proceeded as shown in Scheme 3-11 using a
rink amide resin. The initial (C-terminal) Fmoc-protected phenylalanine was
coupled to the resin amine using an excess of amino acid, HCTU and DIPEA in
DMF. The resin was washed with DMF, followed by Fmoc deprotection with a
20% solution of piperidine in DMF. The resin was washed again in DMF and the
coupling and deprotection steps were repeated twice more with the
appropriate amino acids in order to give the final products (176). After each
coupling step (before deprotection), a 3:2 mixture of acetic anhydride/pyridine
was added to the resin to “cap” (acetylate) any unreacted amino groups. Once
the tripeptides (176) were assembled and Fmoc-deprotected, they were
cleaved from the resin using an 18:1:1 mixture of TFA/TIPS/water. Any amino
acid side chain protective groups were also removed by the cleavage mixture.
It was planned that the purified tripeptide would then be coupled to 165a to
give the final tripeptide congeners.
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Scheme 3-11: Proposed solid phase synthesis of the linker tripeptides and coupling to the
DMHPP orthostere.
Solid phase peptide synthesis was carried out using a rink amide resin. Three cycles of Fmoc-
amino acid coupling followed by Fmoc deprotection were carried out. Cleavage from the resin
and amino acid side chain deprotection was carried out simultaneously. The final compounds
170a-h were proposed to be synthesised by coupling to 165a, but this method yielded no
identifiable products. Reagents and conditions: (a) Fmoc-phenylalanine, HCTU, DIPEA, DMF, rt;
(b) Pyridine, DMF, rt; (c) Fmoc-amino acid, HCTU, DIPEA, DMF, rt; (d) TFA, TIPS, water, rt; (e)
165a, HCTU, DIPEA, DMF.
Use of newer rink amide resin was found to improve the yield of solid-phase
tripeptide synthesis, suggesting degradation in some of the older samples used.
The cleavage products (177a-h) were typically mixed with large quantities of
unidentified by-products, which may have been a mixture of resin fragments
and acetyl-capped incomplete peptides. The desired products were easily
separable from this mixture by column chromatography. Despite having
isolated 10-20 mg of each tripeptide, a coupling reaction with 165a produced
no identifiable products (170). A small amount of uncoupled tripeptide was
recovered but the starting 165a could not be identified in the reaction mixture.
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It was proposed that 165a could be forming esters with the phenolic hydroxyl
group (Figure 3-19), so several protecting groups for the phenol were
investigated to avoid this potential esterification. Initially a tert-
butyldimethylsilyl (TBS) group was coupled to the phenol using TBS chloride
with an imidazole catalyst (Scheme 3-12). TBS is known to be stable under basic
conditions and easily cleaved by acid, so ester hydrolysis of 179 was carried out
using 1M NaOH. However, the phenol is a better leaving group than an aliphatic
alcohol, making the TBS-phenol-ether more susceptible to basic cleavage and,
as a result, this reaction yielded only 165a, without any remaining TBS-
protected product.
Figure 3-19: The proposed structure of a di-DMHPP ester.
The low yields observed in the peptide coupling reactions described in 3.5.1, 3.5.3 and 3.6.1
between the N-propionic acid DMHPP 165a and an amino ester or tripeptide were proposed
to have resulted from esterification between the N-substituent and the phenolic hydroxyl
group, giving the structure shown (178). Further coupling between 178 and additional units of

















Scheme 3-12: TBS-protection of the phenol of 167a followed by an unsuccessful ester
hydrolysis.
The phenolic hydroxyl group of 167a was successfully protected with a tert-butyldimethylsilyl
(TBS) group, but basic hydrolysis of the ethyl ester of 179 also removed the TBS group. Reagents
and conditions: (a) TBS chloride, imidazole, DMF, rt; (b) 1M NaOH, EtOH, H2O, rt.
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The phenol was instead benzyl-protected using benzyl bromide with potassium
carbonate (Scheme 3-13). It was found that equal amounts of benzyl bromide
and 167a were necessary in order to avoid benzylation of the tertiary amine
(181). This stoichiometry resulted in a 70% yield with incomplete consumption
of both reagents, but heating the reaction promoted quaternisation of the
amine (181). Instead, the reaction was stopped after stirring overnight at room
temperature and the product (180) and unreacted starting material (167a)
were recovered. Ester hydrolysis of 180 was successfully carried out under
acidic conditions.
Scheme 3-13: Benzyl-protection of the phenol of 167a followed by ester hydrolysis.
The phenolic hydroxyl group of 167a was successfully benzyl-protected with a stoichiometric
amount of benzyl bromide at room temperature to avoid producing the dibenzyl quaternised
species 181. Acidic hydrolysis of the ethyl ester of 180 produced the acid 182. Reagents and
conditions: (a) BnBr, K2CO3, DMF, rt; (b) 2M HCl, dioxane, H2O, rt.
Coupling of 182 to the tripeptide was again unsuccessful, with disappearance
of 182 and limited recovery of unreacted tripeptide. Alternative reaction
conditions were trialled for this coupling reaction, replacing HCTU with
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) to generate an
in-situ acid fluoride to couple to the tripeptide. Once again, this reaction was
unsuccessful, but a noteworthy outcome was the identification by LCMS of a
common by-product of both the HCTU and TFFH reactions. The by-product had
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a molecular weight of 394, a number which could not be fitted to any LCMS
adduct of the starting materials or desired product. 1H NMR analysis of the
purified by-product revealed a profile typical of a DMHPP-based compound and
it was determined that the structure was likely to be the guanidinylated
DMHPP 183 (Figure 3-20).
Uronium-based coupling reagents are known to “cap” peptide amines, forming
a guanidinum and preventing further amide formation. It is therefore plausible
that this could occur on the secondary amine of this piperidine ring. Formation
of 183 is surprising though, as it would have to result from a reverse Michael
reaction, followed by attack by the piperidine on the HCTU uronium. However,
the matching molecular weight by LCMS and 1H NMR evidence (Figure 3-20)
strongly suggest that this was the case.
Since both HCTU and TFFH contain the uronium group, it was decided that
substitution of these coupling reagents for the phosphonium-based PyBOP
would illuminate the issue. The coupling reaction between 165a and the
asparagine-containing tripeptide (177e) with PyBOP successfully produced the
product 170e, albeit in a low yield (15%). 146a was identified in the reaction
mixture, confirming that a reverse Michael reaction had occurred under these
basic coupling conditions. It seems that the α-proton of the N-propanoate was
more acidic than anticipated and was removed by the DIPEA under these
conditions, resulting in the reverse Michael reaction.
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Figure 3-20: 1H NMR of the guanidinylated DMHPP 183.
Above: The structure is clearly identifiable as containing the DMHPP structure from features
such as the 3-CH3 3H doublet at 0.63 ppm, the 4-CH3 3H singlet at 1.23 ppm, the characteristic
piperidine peaks between 1.90 and 2.35 ppm, the benzyl CH2 peak at 5.08 ppm, and the
arrangement of aromatic peaks. The noteworthy additions to this spectra are the two large
singlet peaks at 2.79 and 2.97 ppm. The 1H NMR predictions generated by the MestReNova and
ChemDraw software both -predicted two large singlet peaks for the guanidinium methyl
groups, but differed dramatically in their predicted locations, likely due to interpretation of the
permanent charge in this region. Below: The 1H NMR of HCTU also showed two large singlet
peaks in a similar region (3.03 and 3.39 ppm, the latter overlaps with a water peak) which adds

































The PyBOP-coupled reaction could have been further optimised to improve the
yield, however an alternative solution was pursued in which acrylic acid was
coupled to the resin-bound peptide. Michael addition of 146a to the cleaved
acrylamide 185 yielded the products 170a-h (Scheme 3-14), without the need
for phenol hydroxyl protection.
Scheme 3-14: Alternative route to synthesis of DMHPP tripeptide congeners.
Reagents and conditions: (a) Acrylic acid, HCTU, DIPEA, DMF, rt; (b) TFA, TIPS, water, rt; (c)
146a, NMP, 85°C.
3.6.2 MOR binding affinity of tripeptide congeners
The MOR binding affinities of the non-fluorescent congeners were then
assessed by TR-FRET in a competition binding assay against the fluorescent
compound 50. The results were plotted as competition binding curves (Figure
3-21), from which pKi values were determined (Table 3-2). All congeners
reduced binding to non-specific levels.
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Figure 3-21: Competition binding assay results for tripeptide DMHPP congeners.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 50 (synthesised by Schembri et al.57) and increasing concentrations
of each of the tripeptide congeners described in Figure 3-18. Data points are the mean of 3 or
4 separate experiments (mean ± SEM), each carried out in duplicate.
The competition binding assay results for the tripeptide congeners produced a
significant range of pKi values (one-way ANOVA, P = 0.009), although only 170b
exhibited a significantly higher pKi value than 170d, 170e and 170f (P < 0.05,
post-hoc Tukey’s multiple comparisons test), with no other significant
differences found. Comparison of these results with the Phe-OH congener 136e
showed no significant change in binding affinity from 136e (P > 0.05, post-hoc
Dunnett’s multiple comparisons test). However, all of these congeners
produced significantly lower binding affinities than the Phe-OMe congener
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166e (P < 0.05, post-hoc Dunnett’s multiple comparisons test) except for 170a
and 170b.
Compound MOR pKi ± SEM n
Naloxone (6) 7.69 ± 0.11 4
170a Phe-Gly-Phe 7.03 ± 0.09 3
170b Phe-Ala-Phe 7.11 ± 0.14 3
170c Phe-Val-Phe 6.86 ± 0.12 3
170d Phe-Ser-Phe 6.68 ± 0.12 3
170e Phe-Asn-Phe 6.74 ± 0.16 3
170f Phe-Asp-Phe 6.72 ± 0.13 3
170g Phe-Lys-Phe 6.78 ± 0.17 3
170h Phe-Arg-Phe 6.82 ± 0.11 3
Table 3-2: MOR binding affinities of tripeptide DMHPP congeners.
pKi values at MOR were calculated from experimental IC50 values using the Cheng-Prusoff
equation.122 Experimental IC50 values were determined by competitive displacement of the
fluorescent ligand 50 (synthesised by Schembri et al.57) in Lumi4-Tb-labelled SNAP-MOR-
expressing HEK293 cell membranes. Values are the mean of 3 or 4 separate experiments (mean
± SEM), each carried out in duplicate.
The absence of improvement in MOR binding affinity shown by these tripeptide
congeners indicated that the introduction of further amino acids to the linker
was unlikely to improve binding affinity. Therefore, the decision was made for
the project to proceed to synthesis of the fluorescent ligands.
3.7 Fluorescent 3,4-dimethyl-4-(3-hydroxyphenyl) piperidine-based
compounds
Since amino acid composition at the second position was shown not to
significantly influence MOR binding affinity, it was decided that a glycine
moiety would be used at this position, giving a fluorescent ligand of the design
189 shown in Scheme 3-15. It was planned that an azidoalanine would occupy
the third position of the tripeptide linker, and once bound to the DMHPP
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orthostere, would undergo a click reaction with an alkyne-bound BODIPY
630/650 (190) to produce the 1,2,3-triazole-linked fluorescent product 189.
Scheme 3-15: Synthesis of the click-BODIPY 630/650 DMHPP fluorescent ligand.
The proposed synthetic scheme for synthesis of the fluorescent compound 189. Reagents and
conditions: (a) TFA, TIPS, H2O, rt; (b) 146a, NMP, 85°C; (c) 190, H2O, rt.
3.7.1 Synthesis of fluorescent β-naltrexamine compounds 
Solid-phase synthesis of the azido-containing tripeptide (186) was unchanged
from the method described in Scheme 3-11. Following TFA cleavage of the
peptide from the resin, the purified peptide 187 was reacted with 146a in NMP
at 85°C. Formation of a new product was observed by TLC, however, LCMS
analysis revealed that it was not the desired product (188). The limited amount
of material recovered made it difficult to definitively determine what occurred
in the reaction, but 1H NMR and LCMS evidence suggested that the dipeptide
191 had been produced, with loss of the azidoalanine.
A proposed mechanism for the formation of this product is shown in Scheme
3-16. The excess of 146a in this highly concentrated reaction would create a
basic environment which could have resulted in deprotonation of the α-carbon 
of azidoalanine. Literature examples describe β-elimination of azidoalanine 
under basic, high temperature conditions to produce dehydroalanine.145, 146
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Tautomerism of the dehydroalanine from the alkene to the imine would then
provide a site for nucleophilic attack by water molecules present in the
hygroscopic solvent.147, 148 Further research is required in order to confirm the
presence of both the dipeptide congener with a terminal amide (191) and 2-
oxopropanamide following this reaction.
Scheme 3-16: The proposed reaction and mechanism for the β-elimination of azidoalanine 
and subsequent imine hydrolysis.
(a) The piperidine amine of 146a deprotonates the α-carbon of azidoalanine, resulting in 
elimination of an azide ion and forming dehydroalanine; (b) Tautomerization of dehydroalanine
converts it to the imine; (c) Hydrolysis of the imine results in a new primary amide and the loss
of 2-oxopropanamide.
This reaction may have been possible at a lower temperature and reduced
concentration of 146a without loss of the azidoalanine, but this would require
the reaction to be left for several weeks. Even at 85°C and in a highly
concentrated solution, these Michael reactions typically took 2-3 days to reach
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completion. At this stage of the project there was insufficient time remaining
to experiment with different conditions to form the azido product 188, so a
different approach was decided upon.
Scheme 3-17: Synthesis of fluorescent DMHPP compounds from 170g.
Reagents and conditions: (a) BODIPY 630/650-X-OSu or sulfo-Cy5-OSu, DIPEA, DMF, rt, 40-53%;
(b) BODIPY 630/650-OH, PyBOP, DIPEA, DMF, rt, 35%.
The Phe-Lys-Phe congener 170g had been produced in sufficient quantity that
it could be used to produce fluorescent ligands by coupling a fluorophore
carboxylic acid to the lysine amine (Scheme 3-17). This approach benefitted
from both speed of synthesis and that a greater variety of fluorophores could
now be attached, as an alkynyl group on the fluorophore was no longer
necessary for attachment. Similar to the fluorescent compounds described in
Chapter 2, three fluorophores were coupled to 170g: BODIPY 630/650-X,
BODIPY 630/650 and sulfo-Cy5.
Due to the apparent acidity of the propanamide α-proton, the use of base in 
these fluorophore couplings was problematic. BODIPY 630/650-X and sulfo-Cy5
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were both pre-formed NHS esters, which theoretically did not require base to
react. However, the 1H NMR of 170g showed that it was a di-formic acid salt,
due to formic acid used during HPLC purification. It was decided that these
reactions would be carried out in the absence of base, and, should the reaction
not proceed, dilute base could be added slowly until the reaction was
complete. This caution was unnecessary in practice, as the reaction proceeded
without base to produce the products 192 and 194. Coupling to the shorter
BODIPY 630/650 compound differed, as it was a free acid rather than an NHS
ester. In this reaction, the coupling reagent PyBOP and BODIPY 630/650 were
mixed in DMF with one equivalent of DIPEA to form the active ester before the
addition of 170g. It was hoped that the base would be consumed during this
first step, with none remaining to deprotonate the propanamide. These
conditions successfully produced the fluorescent compound 193.
3.7.2 MOR binding affinity of fluorescent β-naltrexamine compounds 
MOR binding affinities (pKD) of the fluorescent compounds 192-194 were
determined in saturation binding experiments (Figure 3-22 and Table 3-3). The
specific binding curves of the BODIPY 630/650-containing ligands (192 and 193)
were both saturated, displaying similar pKD values. However, the specific
binding curve for compound 194 at this concentration did not appear to reach
saturation, meaning that a reliable pKD value could not be determined. This
suggests a significantly lower MOR binding affinity for 194 than 192 and 193.
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Figure 3-22: Saturation binding assay results for fluorescent DMHPP compounds.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with
increasing concentrations of the fluorescent compounds 192-194. Non-specific binding (blue)
was determined in the presence of 10 µM naloxone. Total binding (red) was determined in the
absence of naloxone. Specific binding (black) was calculated from total binding minus non-
specific binding. Data points are the mean of a single experiment (mean ± range) carried out in
duplicate which are representative of four separate experiments from which a value for KD was
determined.
Following this, compound 192 was selected for further competition binding
assays against naloxone (6) and naltrexone (7) to confirm it was specifically
labelling the MOR (Figure 3-23).
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Compound pKD ± SEM n
192 - BODIPY 630/650-X 8.47 ± 0.04 3
193 - BODIPY 630/650 8.18 ± 0.09 3
194 - sulfo-Cy5 N/Aa 3
a – could not determine KD within the tested concentration range
Table 3-3: MOR binding affinities of fluorescent DMHPP ligands.
pKD values were determined for the specific binding of each fluorescent ligand from the total
binding and non-specific binding (+ 10 µM naloxone) curves generated in Lumi4-Tb-labelled
SNAP-MOR-expressing HEK293 cell membranes. pKD values are the mean of a 3-4 experiments
(mean ± SEM), each carried out in duplicate.
Compound Obs. MOR pKi ± SEM Lit. MOR pKi range
Naloxone (6) 8.20 ± 0.15 7.3-9.0a
Naltrexone (7) 8.18 ± 0.14 8.1-9.7b
a – refs57, 108-112 b – refs57, 99, 108-110, 113, 114
Figure 3-23: Competition binding assay results for naloxone and naltrexone against the
fluorescent ligand 192.
Lumi4-Tb-labelled SNAP-MOR-expressing HEK293 cell membranes were incubated with 2 nM
of the fluorescent ligand 192 and varying concentrations of naloxone (6) and naltrexone (7).
Data points and the observed pKi values are the mean of 4 separate experiments (mean ± SEM),
each carried out in triplicate. Values for pKi were determined from the experimental IC50 and
the fluorescent ligand KD and concentration using the Cheng-Prusoff equation.122 Ranges of
reported pKi values for these compounds at MOR are included.
122
3.8 Discussion
Three fluorescent peptide-linked MOR ligands were successfully synthesised
and pharmacologically evaluated for binding affinity at MOR using the DMHPP
orthostere.
The synthesis of the DMHPP structure itself and its N-substituted congeners
encountered several challenges. The initial synthetic route pursued to
synthesise 146a was carried out in accordance with the method described by
Furkert et al.,144 but did not result in the described enantioselectivity of
products. The observed ratio of enantiomers 157a and 157b, which were
quantified following chiral purification, suggests a synthetic bias in favour of
the desired 3R enantiomer 154a during methylation, but not the near-
complete enantioselectivity previously reported. Without the benefit of
enantioselectivity, the non-selective synthetic route described by Werner et
al.141 was preferred, and was completed without complication to produce 146a
and 146b.
The discovery that the N-propanoic acid congener 165a undergoes both a
reverse Michael reaction, and subsequent guanidinylation of the piperidine
amine, was unexpected. This is only the second reported instance of amide
couplings to 165a, the first being Le Bourdonnec et al.139 in 2008, in which 165a
was coupled to a Wang resin-bound amino acid with no reported synthetic
issues (Scheme 3-18). However, the absence of reported yields for these
reactions make them difficult to compare.139 In the same study, it was reported
that N-substituted amino acids (195) could not be coupled to 165a using, “a
wide range of coupling reagents and reaction conditions”, but a similar
approach to the one described in Scheme 3-14 to form acrylamides (185)
before carrying out a Michael addition to 146a was successful (Scheme 3-
18).139 Without further development of the findings of Le Bourdonnec et al.,139
it is not possible to determine if similar issues were encountered or resolved.
123
Scheme 3-18: Synthetic routes used by Le Bourdonnec et al.139 to synthesis single amino acid
DMHPP congeners.
Above: Synthesis of congeners of the formula 136 were reported by Le Bourdonnec et al.139 to
have been successfully synthesised by coupling 165a to Wang resin-bound amino acids. Below:
Le Bourdonnec et al.139 reported that N-substituted resin-bound amino acids (195) could not
be coupled to 165a by the same method. Instead the N-substituted resin-bound amino acids
(195) were coupled to acryloyl chloride and the subsequent acrylamides (196) were reacted
with 146a to give 197 after resin cleavage.
Only minor differences in binding affinity were observed between the tested
3R,4R and 3S,4S enantiomers of 136a-b, 165a-b and 166a-b, but differences of
this magnitude can be found in other DMHPP-based compounds, with 3R,4R
enantiomers typically displaying a slightly higher MOR binding affinity than the
respective 3S,4S enantiomer.127 The enantiomers of both of the acidic
compounds 136 and 165 displayed similar MOR binding affinities, suggesting
that the glycine moiety does not play a crucial role in MOR binding. These acidic
congeners displayed lower MOR binding affinities than the corresponding
methyl esters, indicating that the free acid, while beneficial for imparting
important pharmacokinetic properties on alvimopan (9) as a clinical drug, may
not be beneficial for MOR binding.
A loss in MOR binding affinity was observed for all methyl ester congeners (166)
when hydrolysed to their respective acids (136), but the magnitude of MOR
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affinity attenuation differed between congeners. Congeners containing an
aromatic or cyclohexyl amino acid side chain displayed the highest MOR
binding affinities, although some of the calculated pKi values were lower than
previously reported, but these difference may be due to the different methods
used to measure MOR binding affinity (see Table 3-1).139 Phe was identified as
the optimal amino acid to occupy the first position of the linker due to the high
pKi values of both the methyl ester 166e and acid 136e, the similarity between
the observed and literature pKi values of 136e, and the high receptor subtype
selectivity reported for 136e, which is desirable, despite not being an explicit
aim of the project.139
No significant differences in MOR binding affinity were found between the
tripeptide congeners 170a-h, suggesting that no further benefit would be
gained from linker elaboration. Much like the β-naltrexamine congeners 
described in Chapter 2, it is likely that the functional groups of the second
position amino acid are too far from the shallow binding pocket of MOR to
positively influence binding affinity. These tripeptide congeners produced a
similar MOR binding affinity to the phenylalanine congener 136e, showing that
elaboration of the linker through a longer peptide chain was well tolerated,
providing a suitable site for linker and fluorophore attachment.
The BODIPY 630/650-containing compounds (192 and 193) exhibited similar
MOR binding affinities to the BODIPY 630/650 compound 50 described by
Schembri et al.57 The total binding curve for the sulfo-Cy5-containing
compound 194 did not reach saturation in the tested range, so a reliable pKD
value could not be determined. To confirm it was specifically labelling the MOR,
192 was selected for further competition binding assays against naloxone (6)
and naltrexone (7). The observed pKi values for naloxone (6) and naltrexone (7)
were within the range reported in the literature (see Figure 3-23).
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4 General discussion and conclusion
A series of fluorescent ligands based on the MOR antagonists naltrexone (7)
and alvimopan (9) were successfully synthesised and evaluated for their MOR
binding affinity. Common outcomes were observed in the MOR binding
affinities of both β-naltrexamine- and DMHPP-based fluorescent ligands, and 
the corresponding non-fluorescent congeners, which are discussed below, as
well as identification of further pharmacological experimentation necessary to
better characterise these ligands. Additionally, opportunities for future
projects based on the results of this study are proposed.
4.1 General discussion
Across all tested orthostere and linker combinations, the BODIPY 630/650-
containing compounds possessed higher MOR binding affinities than the
corresponding sulfo-Cy5 compounds. Of the sulfo-Cy5-containing compounds,
only 101 exhibited saturated specific MOR binding at 500 nM, so pKD values for
104 and 194 could not be determined. The MOR binding affinity of 104 (pKD =
7.43) is similar to the single amino acid congeners (92a-h, 98g-h) (pKi = 6.93-
7.76) and the unsubstituted β-naltrexamine (72b) (pKi = 7.30). A similar trend
was found for the sulfo-Cy5 compound 51 synthesised by Schembri et al.,57
which also had a similar MOR binding affinity to its non-fluorescent congener.
The pA2 value of 51 (pA2 = 7.31 by displacement of DAMGO in MOR-expressing
CHO cells) was similar to the pKi value of the unsubstituted precursor (pKi =
6.97 by displacement of [3H]-diprenorphine in MOR-expressing CHO cell
membranes).
In contrast, BODIPY 630/650 attachment to these congeners was beneficial for
MOR binding, resulting in significant increases in MOR binding compared to
their non-fluorescent congeners. In silico modelling of other BODIPY 630/650-
containing fluorescent ligands has predicted that the BODIPY 630/650
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fluorophore can become embedded in the cellular membrane, benefitting
ligand binding through hydrophobic interactions.50 This could explain the
difference in MOR binding affinity observed between BODIPY 630/650- and
sulfo-Cy5-containing compounds in this study, as the hydrophilic sulfo-Cy5
fluorophore would not gain the same benefit from these hydrophobic
interactions.
4.2 Further in vitro characterisation
Due to significant interruption to laboratory access during the 2020/21 COVID-
19 pandemic, there were aspects of this project which could not be completed
in full. Further pharmacological investigation of the fluorescent ligands
synthesised in this project is required to better understand their properties and
applications. Given the promising results displayed by these ligands in the
assays undertaken so far, it is anticipated that these subsequent assays will
soon be completed.
The non-specific binding profiles of these compounds should be established,
particularly for the BODIPY 630/650-containing ligands. The high binding
affinities of these compound must be contextualised by establishing to what
degree non-specific binding contributes to these values. The non-specific
binding values determined in the TR-FRET saturation binding assays, whilst
insightful, do not fully express the non-specific binding of the tested
compounds. The non-specific binding measured in these assays were based on
proximity and alignment with the Lumi4-Tb-tagged receptor, and non-specific
binding which occurred further away from a tagged receptor was not reflected
in the saturation binding assay results. The non-specific binding profiles of
these compounds could be determined through live cell confocal imaging, both
with and without an excess of an unlabelled orthosteric competitor.
Colocalization of the fluorescent ligands with the fluorescently labelled
receptors, and the degree of displacement of the fluorescent ligand by the
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competitor, would clarify whether non-specific binding is influential over the
obtained binding affinities.
It would also be valuable to establish the receptor subtype selectivity of the
fluorescent ligands, which could be achieved by conducting similar saturation
binding experiments to those carried out in this study. Fluorescently labelled
DOR- and KOR-expressing cell lines would be used, and the non-specific binding
curve would be established through coincubation with known DOR and KOR
antagonists in place of naloxone (6). While high receptor subtype selectivity is
not a requirement for these fluorescent ligands to be pharmacologically useful,
understanding the selectivity would give clearer guidance for how these
fluorescent ligands could be used.
This project specifically aimed to produce fluorescent antagonists for MOR.
Given the literature precedent of 6-sustituted β-naltrexamine compounds 
which have retained antagonist activity, and the conserved antagonist profile
of the DMHPP orthostere, it is likely that these synthesised fluorescent ligands
will remain antagonists of MOR. However, a functional assay will be necessary
to confirm this. Antagonism of the fluorescent compounds could be
determined by measuring the inhibition of a functional response, such as ERK
phosphorylation or cAMP production, when the fluorescent ligand is in
competition with a MOR agonist such as DAMGO. Furthermore, it could be
useful to carry out similar experiments at DOR and KOR, as some opioid ligands
are known to possess mixed functional activities at different ORs.
4.3 Future works
In addition to the characterisation of these synthesised fluorescent
compounds, this study could form the foundation for future investigations into
fluorescent opioid ligands with optimised physicochemical and receptor
binding properties. Further improvements to MOR binding affinity of the β-
naltrexamine-based compounds could be developed through modifications to
other regions of the morphinan scaffold. In particular, 14-position
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modifications provide intriguing possibilities for improvements to binding
affinity, while balancing these improvements against changes to ligand
function (Figure 2-14). As further research is carried out to better establish the
SAR of this region, the results could be used to inform better fluorescent ligand
design.
While modifications to the 6-position of β-naltrexamine (72b) did not yield
benefits to MOR binding affinity, the “message-address” concept suggests that
the 6-linker region could be investigated for receptor subtype selectivity. The
N-acetylated single amino acid β-naltrexamine congeners synthesised in this 
study could form the starting point of such an investigation, from which larger
functional groups could be introduced to refine any existing subtype selectivity.
The DMHPP-based fluorescent ligands described in this study display that this
orthostere can be fluorescently labelled to produce high affinity fluorescent
MOR ligands, but further refinement of these structures may be possible.
Fluorescent ligands of the design 189 could not be synthesised due to
decomposition of the azidoalanine precursor 187, possibly via the proposed
mechanism described in Scheme 3-16. Further investigation is required to
confirm the by-products of this reaction and to determine appropriate reaction
conditions to synthesise 189, but it would likely require a significant decrease
in reaction concentration and temperature, resulting in a far longer reaction
time. Instead, optimisation of the existing fluorescent ligands might be
preferable. It is unclear whether the terminal phenylalanine moiety, which had
been used as a bioisostere of 1,2,3-triazole, is beneficial for binding. The lack
of significant differences in MOR binding affinity between the congeners 170a-
h suggest that that modification of amino acids in the linker beyond the first
position are not influential over MOR binding affinity. Therefore, removal or
replacement of the phenylalanine, as shown in the designs 198 and 199 (Figure
4-1), may result in increased hydrophilicity and better confocal imaging
properties, without reducing MOR binding affinity.
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Figure 4-1: The planned DMHPP based ligand design of this project and proposed alternative
fluorescent ligand designs.
Fluorescent ligands of the design 189 could not be synthesised due to decomposition of the
precursor 187 under reaction conditions. 198 and 199 are proposed as alternative fluorescent
ligand designs which could maintain the binding profile of 192, while potentially increasing
hydrophilicity and improving photophysical properties.
Removal of the benzyl group from alvimopan results in a large drop in MOR
binding affinity,139 but the fluorescent ligands synthesised in this project show
that high affinity fluorescent ligands can be produced in the absence of this
benzyl group. Reintroduction of the benzyl group could lead to further gains in
binding affinity, although the study by Le Bourdonnec et al.139 demonstrates
that substitution of glycine from the structure of alvimopan with other amino
acids does not improve MOR binding affinity. However, the lysine congener
(200) possessed a similar MOR binding affinity to alvimopan (7) with greater
receptor subtype selectivity (Figure 4-2). Incorporation of 7 or 200 into
fluorescent ligands of the design 201 could produce fluorescent ligands that
possess high binding affinity and selectivity for MOR.
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Compound MOR pKi KOR pKi DOR pKi
Alvimopan (7) 9.33 7.00 7.92
200 9.30 6.24 5.82
Figure 4-2: Design for alvimopan-based fluorescent ligands containing a peptidic linker.
Le Bourdonnec et al.139 identified that replacement of the glycine moiety of alvimopan (7) with lysine
resulted in a compound (200) possessing similar MOR binding affinity to 7 but with greatly improved
receptor subtype selectivity. Investigation of fluorescent ligands of the structure 201 could produce
fluorescent compounds with high binding affinity and selectivity for MOR, where R2 = H or (CH2)4NH2.
4.4 General conclusions
This project succeeded in synthesising high affinity fluorescent ligands for the
MOR containing amino acid-based linkers. Fluorescent ligands composed of a
β-naltrexamine (72b) orthostere fluorescently labelled with a BODIPY 630/650
fluorophore via an amino acid linker, displayed sub-nanomolar binding affinity
for MOR. Additionally, the first fluorescent ligands based on the MOR
antagonist alvimopan (7) are reported, with two BODIPY 630/650-containing
fluorescent ligands displaying high MOR binding affinities.
Although improvement in MOR binding affinity through the introduction of
amino acid-based linkers was limited, these fluorescent ligands may possess
improved confocal imaging properties from increased hydrophilicity, compared
to previously reported high affinity fluorescent MOR ligands. Further
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pharmacological evaluation is required to fully assess the receptor subtype




Chemicals and solvents were purchased from standard commercial suppliers
without further purification. Deuterated solvents were purchased from Fisher
Scientific UK Ltd and VWR International LLC. Flash column chromatography was
performed using Fluorochem silica gel 60A 40-63u. Thin-layer chromatography
(TLC) was performed using Merck silica gel 60F 254 plates and examination was
carried out under UV light (254 nm).
Reactions were monitored by liquid chromatography-mass spectrometry
(LCMS) or TLC. Staining was carried out using potassium permanganate,
vanillin, ninhydrin and 2,4-dinitrophenylhydrazine (2,4-DNP). Unless otherwise
stated, reactions were carried out at room temperature. Organic extracts
following aqueous work up procedures were dried using MgSO4 or Na2SO4
before gravity filtration and evaporation. Evaporation of organic solvents was
done in vacuo at 40°C in a water bath.
LCMS results were collected on a Shimadzu UFLCXR HPLC system with an
Applied Biosystems MDS SCIEX API2000 electrospray ionisation mass
spectrometer. The coupled column was a Phenomenex Gemini-NX 3 µm-110 Å
C18, 50x2mm column thermostated at 40°C. The flow rate was 0.5 mL/min and
the UV detection was at 220 nm and 254 nm. The eluent used was a MeCN/H2O
mix containing 0.1% formic acid at a gradient of 1:19 to 19:1 (v/v) over 5
minutes.
High resolution mass spectrometry (HRMS) time of flight, electrospray (TOF ES
+/-) were recorded on a Waters 2795 separation module/micromass LCT
platform.
Specific rotation was measured using a Bellingham + Stanley Ltd ADP220
Polarimeter with a 1 ml sample tube with a 0.5 dm pathway length. [α]TD was





Where α = measured rotation in degrees. l = length of the pathway in
decimetres. c = concentration in g/ml. T = temperature at which the
measurement was taken (Celsius).
1H-NMR spectra were recorded on a Bruker-AV 400 at 400.13 MHz and 13C-
NMR was recorded at 101.62 MHz. Chemical shifts (δ) were recorded in ppm 
with reference to the chemical shift from the deuterated solvent. Coupling
constants (J) were recorded in Hz.
Analytical HPLC was performed using either system 1 or 2 to confirm purity.
System 1: Phenomenex Gemini reverse phase 5 µm C18 column (250 x 4.6 mm),
a flow rate of 1.00 mL/min and UV detection at 214 and 254 nm. Linear gradient
5% - 95% solvent B over 30 minutes. Solvent A: 0.1% formic acid (FA) in water;
Solvent B: 0.1% FA in MeCN.
System 2: Phenomenex Gemini reverse phase 5 µm C18 column (250 x 4.6 mm),
a flow rate of 1.00 mL/min and UV detection at 214 and 254 nm. Linear gradient
5% - 95% solvent B over 30 minutes. Solvent A: water; Solvent B: MeOH.
Semi-preparative HPLC was performed using either system 3 or 4.
System 3: Phenomenex Genimi reverse phase 5 µm C18 column (250 x 10 mm),
a flow rate of 5.00 mL/min and UV detection at 214 and 254 nm. Linear gradient
5% - 95% solvent B over 30 minutes. Solvent A: 0.1% formic acid (FA) in water;
Solvent B: 0.1% FA in MeCN.
System 4: Phenomenex Gemini reverse phase 5 µm C18 column (250 x 10 mm),
a flow rate of 5.00 mL/min and UV detection at 214 and 254 nm. Linear gradient
5% - 95% solvent B over 30 minutes. Solvent A: water; Solvent B: MeOH.
Chirally-selective HPLC (analytical and semi-preparative) was performed using
either system 5 (analytical) or 6 (semi-preparative).
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System 5: Phenomenex Lux 3 µm Cellulose-1 column (250 x 4.6 mm), a flow
rate of 1.00 mL/min and UV detection at 214 and 254 nm. Isocratic 1% solvent
B over 10 minutes. Solvent A: n-Hexane; Solvent B: EtOH.
System 6: Phenomenex Lux 5 µm Cellulose-1 column (250 x 10 mm), a flow rate
of 5.00 mL/min and UV detection at 214 and 254 nm. Isocratic 1% solvent B
over 10 minutes. Solvent A: n-Hexane; Solvent B: EtOH.
(4R,4aS,7R,7aR,12bS)-7-amino-3-(cyclopropylmethyl)-1,2,3,4,5,6,7,7a-
octahydro-4aH-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol (72b)
Naltrexone (7) (100 mg, 0.29 mmol, 1.0 eq) and ammonium acetate (224 mg,
2.90 mmol, 10.0 eq) were dissolved in dry MeOH (5 ml) under N2 and stirred at
room temperature for 30 min. A solution of sodium cyanoborohydride (20 mg,
0.32 mmol, 1.2 eq) in MeOH (2 ml) was added dropwise to the reaction mixture
and stirred at room temperature for 2 hr. The reaction mixture was then
diluted with water (50 ml) and the pH adjusted to 9 using 1M NaOH. It was then
extracted with chloroform (3 x 20 ml) and the combined organic extracts were
dried over MgSO4. The solvent was evaporated in vacuo and column
chromatography (1-5% 1M NH4OH in MeOH/CH2Cl2) afforded 72b as a yellow
oil (25 mg, 25%).
[α]19D: -131.9 (H2O, c 1.00)
1H NMR (MeOD): δ 0.09 – 0.22 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.47 –
0.60 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.82 – 0.95 (m, 1h, cyclopropyl 1-
CH), 1.34 – 1.45 (m, 2H, 8-CH2, 15-CH2), 1.49 – 1.60 (m, 2H, 7-CH2, 8-CH2), 1.79
(td, J = 12.9, 10.3 Hz, 1H, 7-CH2), 2.14 (td, J = 10.0, 3.2 Hz, 1H, 16-CH2), 2.22 (td,
J = 12.0, 4.3 Hz, 1H, 15-CH2), 2.38 (dd, J = 12.1, 5.9 Hz, 1H, N-CH2-C3H5), 2.42
(dd, J = 12.1, 6.0 Hz, 1H, N-CH2-C3H5), 2.51 (ddd, J = 12.1, 7.3, 4.4 Hz, 1H, 6-CH),
2.63 (td, J = 12.4, 6.0 Hz, 1H, 16-CH2), 263 – 2.69 (m, 1H, 10-CH2), 3.06 (d, J =
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18.4 Hz, 1H, 10-CH2), 3.10 (d, J = 5.7 Hz, 1H, 9-CH), 4.22 (d, J = 7.3 Hz, 1H, 5-CH),
6.54 (d, J = 8.1 Hz, 1H, 1-CH), 6.61 (d, J = 8.0 Hz, 1H, 2-CH)
13C NMR (MeOD): δ 3.9, 4.1, 9.6, 18.6, 22.7, 25.7, 30.7, 31.0, 44.1, 47.5, 53.5, 
59.3, 62.4, 70.5, 97.4, 118.6, 119.6, 123.1, 131.2, 141.0, 141.7.
General procedure 1 – amide coupling of β-naltrexamine and N-acetylated
amino acid
Amino acid (0.06 mmol) and HBTU (22 mg, 0.06 mmol, 1.0 eq) were dissolved
in DMF (2.5 mL). DIPEA (10.5 µL, 0.06 mmol, 1.0 eq) was added and the reaction
mixture was stirred for 20 minutes. β-naltrexamine (20 mg, 0.06 mmol, 1.0 eq) 
was separately dissolved in DMF (2.5 mL) and added dropwise to the main
reaction mixture. The reaction mixture was stirred for two hours. The solvent
was removed under high vacuum and the residue was purified by column
chromatography (1:19 MeOH: CH2Cl2). Where necessary, further purification




The title compound was synthesised as described in general procedure 1, using
N-acetyl-glycine (7 mg, 0.06 mmol) to give 92a, a white solid (19 mg, 73%).
1H NMR (MeOD): δ 0.25 (d, J = 4.9 Hz, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.60
(p, J = 9.3 Hz, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.93 (h, J = 8.7, 7.9 Hz, 1H,
cyclopropyl 1-CH), 1.42-1.53 (m, 2H, 8-CH2 and 15-CH2), 1.55-1.64 (m, 2H, 7-
CH2 and 8-CH2), 1.86 (qd, J = 13.5, 12.5, 3.9 Hz, 1H, 7-CH2), 2.23-2.39 (m, 2H,
15-CH2 and 16-CH2), 2.46-2.56 (m, 1H, N-CH2-C3H5), 2.60-2.84 (m, 3H, 10-CH2
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and 16-CH2 and N-CH2-C3H5), 3.15 (d, J = 18.5 Hz, 1H, 10-CH2), f3.69 (ddd, J =
12.4, 7.7, 4.5 Hz, 1H, 6-CH), 3.85 (d, J = 1.5 Hz, 2H, glycine-CH2), 4.48 (d, J = 7.7
Hz, 1H, 5-CH), 6.60 (d, J = 8.2 Hz, 1H, 2-CH), 6.65 (d, J = 8.1 Hz, 1H, 1-CH).
13C NMR (MeOD): δ 2.6, 3.5, 13.1, 19.5, 21.1, 22.4, 23.8, 29.7, 42.3, 48.5, 51.3, 
58.5, 60.1, 62.5, 70.2, 91.4, 117.4, 118.9, 140.7, 142.3, 170.0, 172.5.




The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-alanine (8 mg, 0.06 mmol) to give 92b, a white solid (20 mg, 74%).
1H NMR (DMSO-d6): δ 0.05-0.07 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.29-
0.45 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.67-0.82 (m, H, cyclopropyl 1-CH),
1.07 (d, J = 7.1 Hz, 3H, alanine CH3), 1.10 – 1.21 (m, 2H, 8-CH2 and 15-CH2), 1.28
– 1.40 (m, 2H, 7-CH2 and 8-CH2), 1.55 (qd, J = 12.7, 2.5 Hz, 1H, 7-CH2), 1.75 (s,
3H, acetyl CH3), 1.87 (td, J = 12.0, 3.8 Hz, 1H, 16-CH2), 2.03 (td, J = 12.3, 5.0 Hz,
1H, 15-CH2), 2.17 – 2.29 (m, 2H, N-CH2-C3H5), 2.51 – 2.59 (m, 1H, 10-CH2), 2.55
– 2.62 (m, 1H, 16-CH2), 2.86 (d, J = 18.4 Hz, 1H, 10-CH2), 2.90 (d, J = 5.6 Hz, 1H,
9-CH), 4.19 (p, J = 7.2 Hz, 1H, alanine α-CH), 4.37 (d, J = 7.7 Hz, 1H, 5-CH), 6.42
(d, J = 8.1 Hz, 1H, 1-CH), 6.48 (d, J = 8.0 Hz, 1H, 2-CH), 7.91 (d, J = 8.2 Hz, 1H,
acetamide NH), 8.04 (d, J = 7.9 Hz, 1H, 6-NH), 8.27 (s, 1H, 3-OH).
13C NMR (DMSO-d6): δ 3.5, 3.7, 9.3, 19.0, 22.2, 22.7, 24.3, 29.8, 30.4, 43.7, 47.0, 
47.8, 51.1, 58.4, 61.7, 69.6, 90.5, 117.0, 118.4, 123.5, 131.3, 140.4, 142.1,
168.8, 172.0.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-valine (10 mg, 0.06 mmol) to give 92c, a white solid (16 mg, 55%).
1H NMR (DMSO-d6): δ 0.07 – 0.17 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.40 –
0.54 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.82 (dd, J = 8.4, 6.8 Hz, 6H, valine
CH(CH3)2), 0.78 – 0.91 (m, 1H, cyclopropyl 1-CH), 1.24 (dd, J = 11.6, 2.8 Hz, 1H,
15-CH2), 1.26 (td, J = 13.8, 3.0 Hz, 1H, 8-CH2), 1.42 (dt, J = 13.5, 3.3 Hz, 1H, 8-
CH2), 1.48 - 1.57 (m, 1H, 7-CH2), 1.64 (qd, J = 13.0, 2.8 Hz, 1H, 7-CH2), 1.82 –
1.93 (m, 1H, valine CH(CH3)2), 1.88 (s, 3H, acetyl CH3), 1.98 (td, J = 11.9, 3.7 Hz,
1H, 16-CH2), 2.13 (td, J = 12.4, 5.0 Hz, 1H, 15-CH2), 2.28 – 2.42 (m, 2H, N-CH2-
C3H5), 2.51 – 2.59 (m, 1H, 10-CH2), 2.60 (dd, J = 7.2, 4.1 Hz, 1H, 16-CH2), 2.97 (d,
J = 18.4 Hz, 1H, 10-CH2), 3.02 (d, J = 5.5 Hz, 1H, 9-CH2), 3.35 – 3.48 (m, 1H, 6-
CH), 4.18 (dd, J = 9.3, 6.9 Hz, 1H, valine α-CH), 4.46 (d, J = 7.8 Hz, 1H, 5-CH),
6.52 (d, J = 8.1 Hz, 1H, 1-CH), 6.58 (d, J = 8.1 Hz, 1H, 2-CH), 7.86 (d, J = 9.3 Hz,
1H, acetamide NH), 8.22 (s, 1H, 3-OH), 8.26 (d, J = 7.8 Hz, 1H, 6-NH).
13C NMR (DMSO-d6): δ 4.0, 4.2, 9.6, 18.7, 19.5, 22.6, 23.0, 24.8, 30.3, 30.7, 31.6, 
44.3, 47.4, 1.6, 57.6, 58.8, 62.2, 70.0, 90.9, 117.5, 118.9, 123.8, 131.7, 140.9,
142.5, 169.6, 171.0.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-phenylalanine (12 mg, 0.06 mmol) to give 92d, a white solid (20 mg,
63%).
1H NMR (DMSO-d6): δ 0.13 (d, J = 4.9 Hz, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.35
– 0.63 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.74 – 0.97 (m, 1H, cyclopropyl 1-
CH), 1.18 – 1.30 (m, 2H, 8-CH2 and 15-CH2), 1.33 – 1.44 (m, 2H, , 7-CH2 and 8-
CH2), 1.49 (td, J = 12.6, 2.7 Hz, 1H, 7-CH2), 1.79 (s, 3H, acetyl CH3), 2.00 (td, J =
12.2, 3.9 Hz, 1H, 16-CH2), 2.14 (td, J = 12.5, 5.1 Hz, 1H, 15-CH2), 2.29 – 2.46 (m,
2H, N-CH2-C3H5), 2.53 – 2.67 (m, 1H, 16-CH2), 2.73 (dd, J = 13.5, 8.9 Hz, 1H,
phenylalanine CH2), 2.92 (dd, J = 13.5, 5.6 Hz, 1H, phenylalanine CH2), 2.98 (d,
J = 18.4 Hz, 1H, 10-CH2), 3.05 (d, J = 5.5 Hz, 1H, 9-CH), 3.38 – 3.45 (m, 1H, 6-CH),
4.45 (d, J = 7.7 Hz, 1H, 5-CH), 4.51 (td, J = 8.8, 5.7 Hz, 1H, phenylalanine α-CH), 
6.53 (d, J = 8.1 Hz, 1H, 1-CH), 6.59 (d, J = 8.0 Hz, 1H, 2-CH), 7.15 – 7.31 (m, 5H,
phenylalanine aromatic protons), 8.10 (d, J = 8.7 Hz, 1H, acetamide NH), 8.17
(s, 1H, 3-OH), 8.26 (d, J = 8.0 Hz, 1H, 6-NH).
13C NMR (DMSO-d6): δ 3.5, 3.8, 9.0, 22.2, 22.6, 24.1, 29.7, 30.2, 38.6, 43.9, 46.9, 
51.1, 53.8, 58.3, 61.7, 69.6, 90.4, 117.1, 118.5, 123.3, 126.2, 128.0, 129.2,
131.2, 137.8, 140.4, 142.0, 168.9, 170.6.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-serine (9 mg, 0.06 mmol) to give 92e, a white solid (12 mg, 43%).
1H NMR (DMSO-d6): δ 0.04 – 0.21 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.41 –
0.51 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.75 – 0.92 (m, 1H, cyclopropyl 1-
CH), 1.17 – 1.30 (m, 2H, 8-CH2 and 15-CH2), 1.41 (dt, J = 13.2, 3.3 Hz, 1H, 8-CH2),
1.49 (dq, J = 12.5, 3.6 Hz, 1H, 7-CH2), 1.66 (qd, J = 12.9, 2.9 Hz, 1H, 7-CH2), 1.88
(s, 3H, acetyl CH3), 1.98 (td, J = 12.0, 3.7 Hz, 1H, 16-CH2), 2.14 (td, J = 12.4, 5.1
Hz, 1H, 15-CH2), 2.33 (h, J = 6.1 Hz, 2H, N-CH2-C3H5), 2.59 (td, J = 11.5, 5.2 Hz,
1H, 16-CH2), 2.96 (d, J = 18.3 Hz, 1H, 10-CH2), 3.01 (d, J = 5.6 Hz, 1H, 9-CH), 3.38
– 3.58 (m, 1H, 6-CH), 3.51 (dd, J = 5.9, 2.2 Hz, 2H, serine CH2), 4.30 (dt, J = 8.5,
5.9 Hz, 1H, serine α-CH), 4.52 (d, J = 7.6 Hz, 1H, 5-CH), 6.52 (d, J = 8.1 Hz, 1H, 1-
CH), 6.58 (d, J = 8.0 Hz, 1H, 2-CH), 7.86 (d, J = 8.4 Hz, 1H, acetamide NH), 8.15
(d, J = 8.1 Hz, 1H, 6-NH), 8.26 (s, 1H, 3-OH).
13C NMR (DMSO-d6): δ 3.5, 3.7, 9.2, 22.1, 22.7, 24.4, 29.8, 30.4, 43.7, 47.0, 51.2, 
54.8, 58.4, 61.7, 62.1, 69.6, 90.5, 117.0, 118.4, 123.4, 131.3, 140.4, 142.1,
169.2, 169.7.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-serine (9 mg, 0.06 mmol) to give 98e (a white solid) as a biproduct
of 92e (7 mg, 25%).
1H NMR (DMSO-d6): δ 0.06 – 0.17 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.42 –
0.53 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.79 – 0.91 (m, 1H, cyclopropyl 1-
CH), 1.18 – 1.33 (m, 2H, 8-CH2 and 15-CH2), 1.38 – 1.49 (m, 2H, 7-CH2 and 8-
CH2), 1.72 (qd, J = 13.1, 3.3 Hz, 1H, 7-CH2), 1.90 (s, 3H, acetyl CH3), 1.97 (td, J =
12.0, 3.7 Hz, 1H, 16-CH2), 2.13 (td, J = 12.5, 5.1 Hz, 1H, 15-CH2), 2.32 (h, J = 6.1
Hz, 2H, N-CH2-C3H5), 2.58 (td, J = 12.3, 5.5 Hz, 1H, 16-CH2), 2.96 (d, J = 18.3 Hz,
1H, 10-CH2), 3.01 (d, J = 5.6 Hz, 1H, 9-CH), 3.39 – 3.59 (m, 1H, 6-CH), 3.56 (d, J
= 5.4 Hz, 2H, serine CH2), 4.23 (dt, J = 8.4, 5.4 Hz, 1H, serine α-CH), 4.53 (d, J =
7.6 Hz, 1H, 5-CH), 6.51 (d, J = 8.1 Hz, 1H, 1-CH), 6.57 (d, J = 8.0 Hz, 1H, 2-CH),
7.87 (d, J = 8.4 Hz, 1H, acetamide NH), 8.08 (d, J = 8.4 Hz, 1H, 6-NH), 8.37 (s, 1H,
3-OH).
13C NMR (DMSO-d6): δ 3.5, 3.7, 9.2, 22.1, 22.8, 24.5, 29.9, 30.4, 43.7, 47.0, 51.2, 
55.4, 58.4, 61.7, 61.8, 69.6, 90.6, 117.0, 118.3, 123.4, 131.3, 140.4, 142.1,
169.4, 169.9.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-asparagine (10 mg, 0.06 mmol) to give 92f, a white solid (13 mg,
44%).
1H NMR (DMSO-d6): δ 0.05 – 0.20 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.40 –
0.58 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.74 – 0.94 (m, 1H, cyclopropyl 1-
CH), 1.17 – 1.32 (m, 2H, 8-CH2 and 15-CH2), 1.37 – 1.48 (m, 2H, 7-CH2 and 8-
CH2), 1.71 (td, J = 13.1, 12.6, 10.0 Hz, 1H, 7-CH2), 1.87 (s, 3H, acetyl CH3), 1.97
(td, J = 12.0, 3.7 Hz, 1H, 16-CH2), 2.13 (td, J = 12.4, 5.1 Hz, 1H, 15-CH2), 2.32 (dd,
J = 12.7, 6.5 Hz, 1H, N-CH2-C3H5), 2.36 (dd, J = 12.7, 6.5 Hz, 1H, N-CH2-C3H5),
2.39 (dd, J = 15.4, 8.1 Hz, 1H, asparagine CH2), 2.46 (dd, J = 15.4, 4.8 Hz, 1H,
asparagine CH2), 2.59 (td, J = 12.6, 12.0, 5.0 Hz, 1H, 16-CH2), 2.96 (d, J = 18.4
Hz, 1H, 10-CH2), 3.01 (d, J = 5.6 Hz, 1H, 9-CH), 3.35 – 3.46 (m, 1H, 6-CH), 4.50
(td, J = 8.2, 4.8 Hz, 1H, asparagine α-CH), 4.55 (d, J = 7.7 Hz, 1H, 5-CH), 6.51 (d,
J = 8.0 Hz, 1H, 1-CH), 6.57 (d, J = 8.1 Hz, 1H, 2-CH), 6.85 (s, 1H, asparagine
CONH2), 7.27 (s, 1H, asparagine CONH2), 7.94 (d, J = 8.4 Hz, 1H, acetamide NH),
8.03 (d, J = 8.4 Hz, 1H, 6-NH), 8.31 (s, 1H, 3-OH).
13C NMR (DMSO-d6): δ 3.5, 3.7, 9.2, 22.1, 22.9, 24.4, 29.9, 30.4, 37.5, 43.7, 47.0, 
49.8, 51.3, 58.4, 61.7, 69.6, 90.5, 117.0, 118.3, 123.4, 131.3, 140.4, 142.1,
169.1, 170.9, 171.6.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-asparagine (10 mg, 0.06 mmol) to give 98f (a white solid) as a
biproduct of 92f (8 mg, 27%).
1H NMR (DMSO-d6): δ 0.08 – 0.19 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.42 –
0.54 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.75 – 0.92 (m, 1H, cyclopropyl 1-
CH), 1.20 – 1.30 (m, 2H, 8-CH2 and 15-CH2), 1.37 – 1.50 (m, 2H, 7-CH2 and 8-
CH2), 1.67 (qd, J = 14.0, 13.5, 3.4 Hz, 1H, 7-CH2), 1.85 (s, 3H, acetyl CH3), 1.99
(td, J = 12.1, 3.8 Hz, 1H, 16-CH2), 2.14 (td, J = 12.4, 5.0 Hz, 1H, 15-CH2), 2.31 (dd,
J = 15.1, 8.2 Hz, 1H, N-CH2-C3H5), 2.31 – 2.43 (m, 2H, N-CH2-C3H5 and asparagine
CH2), 2.46 (dd, J = 15.1, 5.8 Hz, 1H, asparagine CH2), 2.59 (td, 18.4, 5.7 Hz, 1H,
16-CH2), 2.98 (d, J = 18.4 Hz, 1H, 10-CH2), 3.04 (d, J = 5.6 Hz, 1H, 9-CH), 3.37 –
3.45 (m, 1H, 6-CH), 4.54 (d, J = 7.6 Hz, 1H, 5-CH), 4.57 (td, J = 8.3, 5.8 Hz, 1H,
asparagine α-CH), 6.52 (d, J = 8.1 Hz, 1H, 1-CH), 6.59 (d, J = 8.0 Hz, 1H, 2-CH),
6.85 (s, 1H, asparagine CONH2), 7.24 (s, 1H, asparagine CONH2), 7.99 (d, J = 8.4
Hz, 1H, acetamide NH), 8.09 (d, J = 8.1 Hz, 1H, 6-NH), 8.20 (s, 1H, 3-OH).
13C NMR (DMSO-d6): δ 3.5, 3.8, 9.1, 22.2, 22.8, 24.1, 29.8, 30.3, 38.1, 43.9, 46.9, 
49.7, 51.3, 58.3, 61.7, 69.6, 90.4, 117.1, 118.4, 123.4, 131.2, 140.4, 142.1,
169.1, 170.8, 171.3.





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-aspartic acid 4-tert-butyl ester (14 mg, 0.06 mmol) to give 95g, a
white solid (13 mg, 39%).
1H NMR (MeOD): δ 0.42 – 0.57 (m, 2H,  cyclopropyl 2-CH2 and 3-CH2), 0.68 –
0.87 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 1.02 – 1.16 (m, 1H, cyclopropyl 1-
CH), 1.46 (s, 9H, t-Bu CH3), 1.51 – 1.68 (m, 3H, 7-CH2, 8-CH2, 15-CH2), 1.71 (dt, J
= 13.8, 3.1 Hz, 1H, 8-CH2), 1.94 (qd, J = 12.9, 2.8 Hz, 1H, 7-CH2), 1.99 (s, 3H,
acetyl CH3), 2.48 – 2.66 (m, 1H, 16-CH2), 2.60 (dd, J = 16.3, 8.5 Hz, 1H, aspartate
CH2), 2.69 (td, J = 12.6, 3.7 Hz, 1H, 15-CH2), 2.78 (dd, J = 16.3, 5.3 Hz, 1H,
aspartate CH2), 2.86 (dd, J = 13.5, 7.5 Hz, 1H, N-CH2-C3H5), 3.08 (dd, J = 12.5, 4.3
Hz, 1H, 16-CH2), 3.14 (dd, J = 19.5, 6.0 Hz, 1H, 10-CH2), 3.30 – 3.40 (m, 2H, 10-
CH2, N-CH2-C3H5), 3.60 (ddd, J = 12.7, 7.8, 5.0 Hz, 1H, 6-CH), 3.89 (d, J = 5.7 Hz,
1H, 9-CH), 4.62 (d, J = 7.9 Hz, 1H, 5-CH), 4.70 (dd, J = 8.4, 5.4 Hz, 1H, aspartate





The title compound was synthesised as described in general procedure 1, using
N-acetyl-L-aspartic acid 4-tert-butyl ester (14 mg, 0.06 mmol) to give 95d (a
white solid) as a biproduct of 95g (10 mg, 30%).
1H NMR (MeOD): δ 0.40 – 0.57 (m, 2H,  cyclopropyl 2-CH2 and 3-CH2), 0.63 –
0.91 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 1.02 – 1.15 (m, 1H, cyclopropyl 1-
CH), 1.44 (s, 9H, t-Bu CH3), 1.51 – 1.67 (m, 3H, 7-CH2, 8-CH2, 15-CH2), 1.70 (dt, J
= 13.8, 3.1 Hz, 1H, 8-CH2), 1.92 (qd, J = 12.9, 2.8 Hz, 1H, 7-CH2), 2.01 (s, 3H,
acetyl CH3), 2.48 – 2.66 (m, 1H, 16-CH2), 2.55 (dd, J = 16.0, 7.7 Hz, 1H, aspartate
CH2), 2.68 (td, J = 12.5, 3.5 Hz, 1H, 15-CH2), 2.77 (dd, J = 16.1, 6.4 Hz, 1H,
aspartate CH2), 2.85 (dd, J = 13.5, 7.5 Hz, 1H, N-CH2-C3H5), 3.01 – 3.18 (m, 2H,
10-CH2, 16-CH2), 3.34 – 3.39 (m, 2H, 10-CH2, N-CH2-C3H5), 3.61 (ddd, J = 12.7,
7.8, 4.8 Hz, 1H, 6-CH), 3.87 (d, J = 5.7 Hz, 1H, 9-CH), 4.62 (d, J = 7.8 Hz, 1H, 5-
CH), 4.72 (dd, J = 7.7, 6.4 Hz, 1H, aspartate α-CH), 6.71 (d, J = 8.3 Hz, 1H, 1-CH),







e]isoquinolin-7-yl)amino)-4-oxobutanoate (95g) (1 mg, 0.002 mmol) in DMF (1
ml) was added an 18:1:1 mixture of TFA (0.9 ml), TIPS (0.05 ml) and water (0.05
ml). The reaction mixture was stirred at room temperature until complete by
TLC. Solvent was removed under high vacuum and purification by reverse
phase HPLC (system 4) yielded 92g, a white solid (1 mg, 99%).
1H NMR (DMSO-d6): δ 0.26 – 0.51 (m, 2H,  cyclopropyl 2-CH2 and 3-CH2), 0.51 –
0.74 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.92 – 1.09 (m, 1H, cyclopropyl 1-
CH), 1.86 (s, 3H, acetyl CH3), 2.42 (dd, J = 16.1, 8.0 Hz, 1H, aspartic acid CH2),
2.62 (dd, J = 16.1, 5.8 Hz, 1H, aspartic acid CH2), 3.35 – 3.44 (m, 1H, 6-CH), 4.59
(td, J = 8.1, 5.9 Hz, 1H, aspartic acid α-CH), 4.65 (d, J = 7.5 Hz, 1H, 5-CH), 6.62
(d, J = 8.0 Hz, 1H, 1-CH), 6.68 (d, J = 8.2 Hz, 1H, 2-CH), 8.12 (s, 1H, acetamide
NH), 8.14 (s, 1H, 6-NH).






e]isoquinolin-7-yl)amino)-4-oxobutanoate (95e) (1 mg, 0.002 mmol) in DMF (1
ml) was added an 18:1:1 mixture of TFA (0.9 ml), TIPS (0.05 ml) and water (0.05
ml). The reaction mixture was stirred at room temperature until complete by
TLC. Solvent was removed under high vacuum and purification by reverse
phase HPLC (system 4) yielded 98g, a white solid (1 mg, 99%).
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1H NMR (DMSO-d6): δ 0.27 – 0.51 (m, 2H,  cyclopropyl 2-CH2 and 3-CH2), 0.50 –
0.75 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.93 – 1.10 (m, 1H, cyclopropyl 1-
CH), 1.86 (s, 3H, acetyl CH3), 2.63 (dd, J = 16.4, 4.9 Hz, 1H, aspartic acid CH2),
3.34 – 3.44 (m, 1H, 6-CH), 4.54 (td, J = 8.3, 5.1 Hz, 1H, aspartic acid α-CH), 4.66 
(d, J = 7.5 Hz, 1H, 5-CH), 6.61 (d, J = 8.2 Hz, 1H, 1-CH), 6.67 (d, J = 8.2 Hz, 1H, 2-
CH).




The title compound was synthesised as described in general procedure 1, using
N2-acetyl-N6-Boc-L-lysine (17 mg, 0.06 mmol) to give 95h, a white solid (27 mg,
73%).
1H NMR (MeOD): δ 0.08 – 0.26 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.47 –
0.62 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.82 – 0.95 (m, 1H, cyclopropyl 1-
CH), 1.24 – 1.70 (m, 8H, 7-CH2, 8-CH2, 15-CH2, lysine β-CH2, lysine γ-CH2, lysine
δ-CH2), 1.43 (s, 9H, Boc CH3), 1.69 – 1.92 (m, 2H, 8-CH2, lysine β-CH2), 2.01 (s,
3H, acetyl CH3), 2.15 (td, J = 12.1, 11.6, 3.2 Hz, 1H, 16-CH2), 2.24 (td, J = 12.1,
4.5 Hz, 1H, 15-CH2), 2.40 (h, J = 6.4 Hz, 2H, N-CH2-C3H5), 2.63 - 2.68 (m, 1H, 10-
CH2), 2.65 (td, J = 18.8, 6.0 Hz, 1H, 16-CH2), 2.96 – 3.19 (m, 4H, 9-CH2, 10-CH2,
lysine ε-CH2), 3.67 (ddd, J = 12.3, 7.4, 4.6 Hz, 1H, 6-CH), 4.31 (dd, J = 8.4, 5.6 Hz,
1H, lysine α-CH), 4.46 (d, J = 7.5 Hz, 1H, 5-CH), 6.56 (d, J = 8.1 Hz, 1H, 1-CH),
6.62 (d, J = 8.1 Hz, 1H, 2-CH).
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13C NMR (MeOD): δ 4.2, 4.5, 10.2, 22.6, 23.5, 24.1, 25.4, 28.8, 30.6, 31.1, 32.0, 
33.2, 41.1, 45.3, 52.8, 54.9, 60.2, 63.7, 71.7, 79.7, 93.0, 118.6, 120.0, 125.4,







(25mg, 0.041 mmol) in dioxane (1 ml) under N2 was added 4M HCl in dioxane
(1 ml). The reaction mixture was stirred at room temperature until complete
by TLC. Solvent was removed under high vacuum and purification by reverse
phase HPLC (system 4) yielded 92h, a white solid (24 mg, 100%).
1H NMR (MeOD): δ 0.46 – 0.59 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.69 –
0.87 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 1.05 – 1.18 (m, 1H, cyclopropyl 1-
CH), 1.35 – 2.02 (m, 10H, 7-CH2, 8-CH2, 15-CH2, lysine β-CH2, lysine γ-CH2, lysine
δ-CH2), 2.04 (s, 3H, acetyl CH3), 2.62 (td, J = 13.1, 6.2 Hz, 1H, 16-CH2), 2.70 (td,
J = 10.0, 3.2 Hz, 1H, 15-CH2), 2.87 – 2.99 (m, 3H, N-CH2-C3H5, lysine ε-CH2), 3.08
– 3.23 (m, 2H, 10-CH2, 16-CH2), 3.30 – 3.42 (m, 2H, 10-CH2, N-CH2-C3H5), 3.60 –
3.71 (m, 1H, 6-CH), 3.95 (d, J = 5.4 Hz, 1H, 9-CH), 4.33 (dd, J = 8.5, 5.3 Hz, 1H,
lysine α-CH), 4.69 (d, J = 7.8 Hz, 1H, 5-CH), 6.71 – 6.77 (m, 2H, 1-CH, 2-CH).
13C NMR (MeOD): δ 3.4, 6.2, 6.9, 22.6, 23.7, 24.5, 24.6, 28.1, 28.9, 31.1, 32.7, 
40.5, 43.8, 47.6, 52.7, 54.8, 58.7, 62.2, 68.1, 91.9, 119.6, 120.9, 121.9, 130.7,
143.0, 143.7, 173.5, 174.1.
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The title compound was synthesised as described in general procedure 1, using
N-Boc-β-alanine (11 mg, 0.06 mmol) to give 95i, a white solid (28 mg, 90%).
1H NMR (MeOD): δ 0.09 – 0.22 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.45 –
0.59 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.81 – 0.92 (m, 1H, cyclopropyl 1-
CH), 1.34 – 1.48 (m, 2H, 8-CH2, 15-CH2), 1.40 (s, 9H, Boc CH3), 1.49 – 1.61 (m,
2H, 7-CH2, 8-CH2), 1.78 (qd, J = 13.8, 12.6, 3.4 Hz, 1H, 8-CH2), 2.16 (td, J = 9.2,
3.6 Hz, 1H, 16-CH2), 2.23 (td, J = 11.9, 4.1 Hz, 1H, 15-CH2), 2.34 (t, J = 6.8 Hz, 2H,
β-alanine NH-CH2-CH2-CO), 2.34 – 2.54 (m, 1H, N-CH2-C3H5), 2.58 – 2.73 (m, 2H,
10-CH2, 16-CH2), 3.06 (d, J = 18.5 Hz, 1H, 10-CH2), 3.15 (d, J = 5.5 Hz, 1H, 9-CH),
3.24 – 3.30 (m, 2H, β-alanine NH-CH2-CH2-CO), 3.62 (ddd, J = 12.7, 7.8, 4.8 Hz,
1H, 6-CH), 4.37 (d, J = 7.7 Hz, 1H, 5-CH), 6.54 (d, J = 8.2 Hz, 1H, 1-CH), 6.60 (d, J
= 8.1 Hz, 1H, 2-CH).
13C NMR (MeOD): δ 4.1, 4.6, 9.9, 23.6, 25.5, 28.8, 31.2, 31.6, 37.5, 37.9, 45.6, 








yl)amino)-3-oxopropyl)carbamate (95i) (26mg, 0.050 mmol) in dioxane (1 ml)
under N2 was added 4M HCl in dioxane (1 ml). The reaction mixture was stirred
at room temperature until complete by TLC. Solvent was removed under high
vacuum and purification by reverse phase HPLC (system 4) yielded 92i, a white
solid (25 mg, 100%).
1H NMR (MeOD): δ 0.45 – 0.60 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 0.66 –
0.88 (m, 2H, cyclopropyl 2-CH2 and 3-CH2), 1.04 – 1.19 (m, 1H, cyclopropyl 1-
CH), 1.51 – 1.67 (m, 2H, 8-CH2, 16-CH2), 1.67 – 1.81 (m, 2H, 7-CH2, 8-CH2), 1.88
(qd, J = 12.8, 2.0 Hz, 1H, 7-CH2), 2.61 (td, J = 13.2, 4.8 Hz, 1H, 16-CH2),2.59 –
2.72 (m, 2H, NH-CH2-CH2-CO), 2.70 (td, J = 12.8, 3.6 Hz, 1H, 15-CH2), 2.91 (dd, J
= 13.6, 7.6 Hz, 1H, N-CH2-C3H5), 3.08 – 3.25 (m, 4H, 10-CH2, 16-CH2, NH-CH2-
CH2-CO), 3.33 – 3.43 (m, 2H, 10-CH2, N-CH2-C3H5), 3.62 – 3.72 (m, 1H, 6-CH),
3.95 (d, J = 5.8 Hz, 1H, 9-CH), 4.58 (d, J = 7.9 Hz, 1H, 5-CH), 6.73 (d, J = 8.2 Hz,
1H, 1-CH), 6.76 (d, J = 8.3 Hz, 1H, 2-CH).
13C NMR (MeOD): δ 3.4, 6.2, 6.8, 24.4, 24.7, 28.8, 31.1, 33.0, 37.0, 43.7, 47.6, 









e]isoquinolin-7-yl)hexanamide (92h) (0.88 mg, 1.5 µmol, 1.0 eq) in DMF (0.5
ml) was added DIPEA (0.78 µl, 4.5 µmol, 3.0 eq) followed by BODIPY 630/650-
X NHS ester (1.0 mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml). The reaction mixture
was stirred at room temperature for 90 min. Solvent was removed under high
vacuum and purification by reverse phase HPLC (system 3) yielded 99, a blue
solid (1.2 mg, 75%).






To BODIPY 630/650 (0.68 mg, 1.5 µmol) in DMF (0.5 ml) was added PyBOP (0.78
mg, 1.5 µmol, 1.0 eq) and DIPEA (1.30 µl, 7.5 µmol, 5.0 eq). The reaction
mixture was stirred at room temperature for 15 min after which (S)-2-
acetamido-6-amino-N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-
dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-
e]isoquinolin-7-yl)hexanamide (92h) (0.88 mg, 1.5 µmol, 1.0 eq) in DMF (0.5
ml) was added. The reaction mixture was then stirred at room temperature for
90 min. Solvent was removed under high vacuum and purification by reverse
phase HPLC (system 3) yielded 100, a blue solid (0.6 mg, 42%).









e]isoquinolin-7-yl)hexanamide (92h) (0.88 mg, 1.5 µmol, 1.0 eq) in DMF (0.5
ml) was added DIPEA (0.78 µl, 4.5 µmol, 3.0 eq) followed by sulfo-Cy5 NHS ester
(1.17 mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml). The reaction mixture was stirred at
room temperature for 90 min. Solvent was removed under high vacuum and
purification by reverse phase HPLC (system 3) yielded 101, a blue solid (0.6 mg,
35%).









yl)propanamide (92i) (0.73 mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml) was added
DIPEA (0.78 µl, 4.5 µmol, 3.0 eq) followed by BODIPY 630/650-X NHS ester (1.0
mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml). The reaction mixture was stirred at room
temperature for 90 min. Solvent was removed under high vacuum and
purification by reverse phase HPLC (system 3) yielded 102, a blue solid (1.2 mg,
83%).







To BODIPY 630/650 (0.68 mg, 1.5 µmol) in DMF (0.5 ml) was added PyBOP (0.78
mg, 1.5 µmol, 1.0 eq) and DIPEA (1.30 µl, 7.5 µmol, 5.0 eq). The reaction
mixture was stirred at room temperature for 15 min after which 3-amino-N-
((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-
yl)propanamide (92i) (0.73 mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml) was added.
The reaction mixture was then stirred at room temperature for 90 min. Solvent
was removed under high vacuum and purification by reverse phase HPLC
(system 3) yielded 103, a blue solid (0.6 mg, 47%).








yl)propanamide (92i) (0.73 mg, 1.5 µmol, 1.0 eq) in DMF (0.5 ml) was added
DIPEA (0.78 µl, 4.5 µmol, 3.0 eq) followed by sulfo-Cy5 NHS ester (1.17 mg, 1.5
µmol, 1.0 eq) in DMF (0.5 ml). The reaction mixture was stirred at room
temperature for 90 min. Solvent was removed under high vacuum and
purification by reverse phase HPLC (system 3) yielded 104, a blue solid (0.7 mg,
45%).
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m/z: HRMS C55H66N5O11S2- [M]- calcd 1036.4211; found 1036.4231
N-(Furfuryl)-tert-butylsulfinamide (148)
To a solution of furfurylamine (3.5 g, 3.18 mL, 36.00 mmol) and triethylamine
(10.9 g, 15.00 mL, 107.7 mmol, 3 eq) in dichloromethane (20 mL) at 0°C was
added tert-butylsulfinyl chloride (5.0 g, 4.41 mL, 35.6 mmol, 1 eq) in
dichloromethane (40 ml) dropwise over a period of 30 minutes. The mixture
was stirred for a further 1 hour at 0°C and reaction completion was confirmed
by thin layer chromatography (TLC) (50% EtOAc in petroleum ethers (PE)). The
solution was diluted with further dichloromethane and washed with water (20
mL) and brine (20 mL). The organic phase was dried over magnesium sulfate
and the solvent evaporated off under vacuum. Column chromatography (50%
EtOAc in PE) afforded 148 as a yellow oil (6.5 g, 90%).
1H NMR (CDCl3): δ 1.21 (s, 9H, t-Bu CH3), 3.46 (br t, J = 6.26 Hz, 1H, NH), 4.23
(dd, J = 14.82/7.01, 1H, CH2), 4.33 (dd, J = 14.82/5.22, 1H, CH2), 6.26 (dd, J =
3.25/0.81 Hz, 1H, furan 3-CH), 6.32 (dd, J = 3.21/1.84 Hz, 1H, furan 4-CH), 7.37
(dd, J = 1.85/0.86 Hz, 1H, furan 5-CH).
13C NMR (CDCl3): δ 22.5, 42.2, 56.0, 107.8, 110.3, 142.4, 151.9.  
m/z: LCMS C9H15NO2S [MH]+ calcd 202.3, found 202.1 with tR of 2.44 min.
N-(tert-Butylsulfonyl)-1,2-dihydropyridin-3-one (150)
To a solution of N-(furfuryl)-tert-butylsulfinamide (148) (100 mg, 0.50 mmol, 1
eq) in dichloromethane (5 mL) at room temperature was added 3-
chloroperbenzoic acid (m-CPBA) (86 mg, 0.50 mmol, 1 eq). After 20 minutes a
further 1 molar equivalent of m-CPBA was added (86 mg, 0.50 mmol) and again
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at 40 minutes and 60 minutes (total m-CPBA used was 344 mg, 2.00 mmol, 4
eq). The reaction was monitored throughout by TLC (50% EtOAc in PE) which
showed that after 2 hours the reaction was complete. The mixture was diluted
in dichloromethane (15 mL) and washed with saturated sodium bicarbonate
solution (10 mL x2), water (10 mL) and brine (10 mL). The organic phase was
dried over magnesium sulfate and the solvent evaporated until approximately
5 mL of solvent remained (note: this solution should not be evaporated to
dryness as the product has been observed to decompose explosively1). The
solution was cooled to 0°C and triethylsilane (58 mg, 0.08 mL, 0.50 mmol, 1 eq)
added with stirring. BF3·OEt2 (71 mg, 0.06 mL, 0.50 mmol, 1 eq) was then added
dropwise and the reaction was stirred at 0°C for 3 hours. The mixture was
diluted in dichloromethane (15 mL) and washed with saturated sodium
bicarbonate solution/10% w/v sodium sulfite (1:1) (10 mL), saturated sodium
bicarbonate solution (10 mL), water (10 mL) and brine (10 mL). The organic
phase was dried over magnesium sulfate and the solvent evaporated off under
vacuum. Column chromatography (20-50% EtOAc in PE) afforded 150 as an off-
white solid (39 mg, 36%).
mp: 113-114°C
1H NMR (CDCl3): δ 1.39 (s, 9H, t-Bu CH3), 4.06 (s, 2H, pyridinone 2-CH2), 4.23 (s,
2H, pyridinone 6-CH2), 6.25 (dt, J = 10.28/2.17 Hz, 1H, pyridinone 4-CH), 7.08
(dt, J = 10.30/3.62 Hz, 1H, pyridinone 5-CH).
13C NMR (CDCl3): δ 24.4, 46.1, 54.4, 62.1, 128.3, 146.4, 192.2. 
m/z: LCMS C9H15NO3S [MH+MeCN]+ calc 259.3, found 259.2 with tR of 2.30 min.
4-Bromo-N-(tert-butylsulfonyl)-1,2-dihydropyridin-3-one (151)
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To a solution of N-(tert-butylsulfonyl)-1,2-dihydropyridin-3-one (150) (665 mg,
3.06 mmol) in dichloromethane (30 mL) at 0°C was added bromine (489 mg,
0.16 mL, 3.06 mmol, 1 eq) in dichloromethane (13.7 mL) dropwise. After 30
minutes the reaction was complete by TLC (50% EtOAc in PE). Triethylamine
(310 mg, 0.43 mL, 3.06 mmol, 1 eq) was then added with further stirring at 0°C
for 30 minutes. The mixture was diluted in dichloromethane (50 mL) and
washed with water (30 mL x2), saturated sodium bicarbonate solution (30 mL)
and brine (30 mL). The organic phase was dried over magnesium sulfate and
the solvent evaporated off under vacuum. Recrystallization in methanol
afforded 151 as colourless crystals (696 mg, 77%).
mp: 128-130°C.
1H NMR (CDCl3): δ 1.40 (s, 9H, t-Bu CH3), 4.23 (s, 2H, pyridinone 2-CH2), 4.27 (d,
J = 3.9 Hz, 2H, pyridinone 6-CH2), 7.47 (t, J = 3.9 Hz, 1H, pyridinone 5-CH).
13C NMR (CDCl3): δ 24.3, 48.2, 54.7, 62.2, 122.2, 146.8, 185.0 
m/z: LCMS C9H14NO3BrS [MH]+ calc 295.0, found 295.1 with tR of 2.59 min.
(S)-4-Bromo-N-(tert-butylsulfonyl)-1,2,3,6-tetrahydropyridin-3-ol (152)
To a solution of (R)-(+)-2-methyl-CBS-oxazaborolidine (263 mg, 0.95 mmol, 0.3
eq) in tetrahydrofuran (15 ml) at 0°C was added borane-N,N-diethylaniline
(1.034 g, 1.13 mL, 6.34 mmol, 2 eq). 4-Bromo-N-(tert-butylsulfonyl)-1,2-
dihydropyridin-3-one (151) (940 mg, 3.17 mmol) in tetrahydrofuran (30 mL)
was then added dropwise over 15 minutes. The reaction was allowed to warm
slowly to room temperature and was stirred for 16 hours. Excess borane was
quenched with methanol (2.1 mL) and the solvents removed by evaporation.
The resulting residue was re-dissolved in dichloromethane (50 mL) and washed
with 1M HCl (20 mL x2), water (20 mL) and brine (20 mL). The organic phase
157
was dried over magnesium sulfate and the solvent evaporated off under
vacuum. Column chromatography (30% EtOAc in PE) afforded 152 as an off-
white solid (886 mg, 94%).
[α]19D: -46.0 (MeOH, c 1.00).
mp: 120-122°C.
1H NMR (CDCl3) δ 1.42 (s, 9H, t-Bu CH3), 2.75 (br s. 1H, OH), 3.68 (d, J = 4.2 Hz,
2H, pyridinol 6-CH2), 3.86 (d, J = 17.6, 1H, pyridinol 2-CH2), 4.04 (d, J = 17.8, 1H,
pyridinol 2-CH2), 4.23 (br s, 1H, pyridinol 3-CH), 6.25 (t, J = 3.5 Hz, 1H, pyridinol
5-CH).
13C NMR (CDCl3) δ 24.5, 47.8, 51.5, 62.0, 68.6, 124.1, 128.8 
m/z: LCMS C9H16NO3BrS [MH]+ calc 297.0, found 297.0 with tR of 2.41 min.
(S)-4-Bromo-N-(tert-butylsulfonyl)-1,2,3,6-tetrahydropyridin-3-yl diethyl
phosphate (153)
To a solution of (S)-4-bromo-N-(tert-butylsulfonyl)-1,2,3,6-tetrahydropyridin-
3-ol (152) (1.265 g, 4.24 mmol) in dichloromethane (28 mL) at 0°C was added
triethylamine (3.432 g, 4.73 mL, 33.92 mmol, 8 eq) and a catalytic amount of
dimethylaminopyridine (26 mg, 5%). Chlorodiethylphosphate (2.195 g, 1.84
mL, 12.72 mmol, 3 eq) was added gradually over 2.5 hours. It was then allowed
to warm to room temperature and left to stir overnight. It was then washed
with brine (20 mL) and the aqueous layer extracted with dichloromethane (10
mL x3). The combined organic extracts had their solvent evaporated under
vacuum before column chromatography (75% EtOAc in PE) afforded 153 as an
orange oil (1.511 g, 82%).
[α]19D: -19.0 (MeOH, c 1.00).
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1H NMR (CDCl3): δ 1.37 (two overlapping quartets, J = 7.0 Hz, 6H, Et CH3), 1.42
(s, 9H, t-Bu CH3), 3.63 (dd, J = 14.1/3.6 Hz, 1H, pyridinol 2-CH2), 3.85 (d, J = 17.8
Hz, 1H, pyridinol 6-CH2), 3.95 (dd, J = 14.5/3.6 Hz, 1H, pyridinol 2-CH2), 4.04 (d,
J = 17.7, 1H, pyridinol 6-CH2) 4.22 (two overlapping quintets, J = 7.0 Hz, 4H in
total, Et CH2), 4.88-4.92 (m, 1H, pyridinol 3-CH), 6.36 (t, J = 3.5 Hz, 1H, pyridinol
5-CH).
13C NMR (CDCl3): δ 16.0, 16.1, 24.5, 47.9, 50.4, 62.1, 64.4, 64.5, 73.3, 118.6, 
131.4.
m/z: LCMS C13H25NO6BrPS [MH]+ calc 433.0, found 433.1 with tR of 2.76 min.
4-Bromo-N-(tert-butylsulfonyl)-3-methyl-1,2,3,6-tetrahydropyridine (154)
To a slurry of Copper (I) bromide dimethyl sulfide complex (103 mg, 0.50 mmol,
2 eq) in tetrahydrofuran (1 mL) at 0°C was added methyl magnesium bromide
(0.17 mL of a 3.0 M solution in diethyl ether, 0.50 mmol, 2 eq). The mixture was
stirred for 30 minutes before reducing the temperature to -40°C using a bath
of dry ice and acetonitrile. (S)-4-Bromo-N-(tert-butylsulfonyl)-1,2,3,6-
tetrahydropyridin-3-yl diethyl phosphate (153) (108 mg, 0.25 mmol) in
tetrahydrofuran (1.5 mL) was then added dropwise over 15 minutes. The
reaction conditions were maintained at -40°C until the reaction was complete
by TLC (100% EtOAc). The reaction was quenched with saturated ammonium
chloride solution (5 mL) and extracted with diethyl ether (5 mL x3) and the
combined layers were washed with brine (5 mL). The organic phase was dried
over magnesium sulfate and then filtered through Celite. Evaporation of the
solvent under vacuum afforded 154 as an off-white solid (25 mg, 34%).
mp: 96-97°C.
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1H NMR (CDCl3): δ 1.20 (d, J = 7.0 Hz, 3H, pyridine 3-CH3), 1.37 (s, 9H, tBu CH3),
2.60 (d, J = 7.2 Hz, 1H, pyridine 3-CH), 3.29 (d, J = 9.7 Hz, 1H, pyridine 2-CH2),
3.62 (dd, J = 13.4/4.6 Hz, 1H, pyridine 2-CH2), 3.90 (t, J = 19.5 Hz, 2H, pyridine
6-CH2), 6.01 (td, J = 3.6/1.5 Hz 1H, pyridine 5-CH).
13C NMR (CDCl3): δ 17.7, 24.6, 38.5, 47.9, 51.3, 61.8, 125.2, 127.0. 
m/z: LCMS C10H18NO2BrS [MH]+ calc 295.0, found 295.1 with tR of 2.90 min.
N-(tert-butylsulfonyl)-4-(3-methoxyphenyl)-3-methyl-1,2,3,6-
tetrahydropyridine (155)
To a solution of 4-Bromo-N-(tert-butylsulfonyl)-3-methyl-1,2,3,6-
tetrahydropyridine (154) (15 mg, 0.05 mmol) in 1:1 ethanol-toluene (1.2 mL)
were added 3-methoxybenzeneboronic acid (9 mg, 0.06 mmol, 1 eq) and
sodium carbonate (1 M, 0.22 mL). A catalytic amount of
tetrakis(triphenylphosphine)palladium(0) (5%) was added and the reaction
heated to 100°C in a microwave for 30 minutes. The solvent was then removed
by evaporation under vacuum and the resulting mixture partitioned between
diethyl ether (5 mL) and water (5 mL) before the organic phase was washed
with brine (5 mL). The organic phase was dried over magnesium sulfate and the
solvent evaporated off under vacuum. Column chromatography (15-30% EtOAc
in PE) afforded 155 as a pale yellow oil (12 mg, 73%).
1H NMR (CDCl3): δ 1.08 (d, J = 6.9 Hz, 3H, pyridine 3-CH3), 1.45 (s, 9H, tBu CH3),
2.91 (br s, 1H, pyridine 3-CH), 3.55 (m, 2H, pyridine 6-CH2), 3.85 (s, 3H, O-CH3),
4.04 (d, J = 17.7 Hz, 1H, pyridine 2-CH2), 4.19 (d, J = 17.8 Hz, 1H, pyridine 2-CH2),
5.86 (dd, J = 3.4/1.0 Hz, 1H, pyridine 5-CH2), 6.85 (dd, J = 10.8/2.5 Hz, 2H, phenol
2 and 6-CH), 6.92 (dt, J = 7.7/1.3 Hz, 1H, phenol 4-CH), 7.28 (t, J = 7.7 Hz, 1H,
phenol 5-CH).
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13C NMR (CDCl3): δ 18.0, 25.0, 32.4, 47.0, 51.1, 55.4, 61.9, 112.2, 112.7, 118.7, 
120.8, 129.5, 141.8, 159.8.
m/z: LCMS C17H25NO3S [MH]+ calc 324.2, found 324.4 with tR of 2.20 min.
4-(3-methoxyphenyl)-3-methyl-1,2,3,6-tetrahydropyridine (156)
To a solution of N-(tert-butylsulfonyl)-4-(3-methoxyphenyl)-3-methyl-1,2,3,6-
tetrahydropyridine (155) (323 mg, 1.00 mmol) and anisole (2.17 mL, 2.163 g,
20.00 mmol, 20 eq) in dichloromethane (30.1 mL) was added a solution of triflic
acid (0.53 mL, 900 mg, 6.00 mmol, 6 eq) in dichloromethane (30.1 mL) dropwise
at 0°C. The reaction was left to stir at 0°C until complete by TLC. The reaction
was quenched by the addition of 2M NaOH (40 mL) and the organic and
aqueous layers separated. The aqueous layer was extracted with
dichloromethane (20 mL x3) and the combined organic phases dried over
magnesium sulfate. Solvents were evaporated under vacuum. Column
chromatography (10% 1M NH3/ MeOH in dichloromethane) afforded 156 as a
colourless oil (157 mg, 77%).
1H NMR (CDCl3) δ 1.02 (d, J = 7.0 Hz, 3H, pyridine 3-CH3), 2.85 (m, 1H, pyridine
3-CH), 2.93 (dd, J = 12.5/4.6 Hz, 1H, pyridine 2-CH2), 3.23 (dd, J = 12.5/4.8 Hz,
1H, pyridine 2-CH2), 3.52 (s, 1H, NH), 3.57 (t, J = 2.6 Hz, 2H, pyridine 6-CH2), 3.81
(s, 3H, O-CH3), 5.89 (dd, J = 3.4/2.3 Hz, 1H, pyridine 5-CH), 6.81 (dd, J = 8.0/2.1
Hz, 1H, phenol 6-CH), 6.84 (t, J = 2.0 Hz, 1H, phenol 2-CH), 6.89 (dt, J = 7.7/1.2
Hz, 1H, phenol 4-CH), 7.24 (t, J = 7.9 Hz, 1H, phenol 5-CH)




To a solution of 4-(3-methoxyphenyl)-3-methyl-1,2,3,6-tetrahydropyridine
(156) (157 mg, 0.772 mmol) in dichloroethane (5.5 mL) was added 37%
aqueous formaldehyde (23mg, 0.06 ml, 0.772 mmol, 1 eq) followed by the slow
addition of sodium triacetoxyborohydride (665 mg, 3.089 mmol, 4 eq) at room
temperature. After 90 minutes of stirring, acetic acid (0.04 mL, 43.4 mg, 0.723
mmol, 1 eq) was added and the reaction was left to stir for a further 30 minutes.
The solution was basified by the addition of saturated sodium bicarbonate
solution (10 mL) and extracted with dichloromethane (10 mL x3). The combined
organic phases were dried with magnesium sulfate and solvents evaporated off
under vacuum. Column chromatography (10% 1M NH3/ MeOH in
dichloromethane) afforded 157 as a yellow oil (149 mg, 89%).
1H NMR (CDCl3): δ 1.00 (d, J = 7.0 Hz, 3H, pyridine 3-CH3), 2.38 (s, 3H, N-CH3),
2.39 (dd, J = 11.2/5.2 Hz, 1H, pyridine 6-CH2), 2.69 (dd, J = 11.2/4.9 Hz, 1H,
pyridine 6-CH2), 2.91 (m, 1H, pyridine 3-CH), 2.99 (dt, J = 16.8/3.0 Hz, 1H,
pyridine 2-CH2), 3.10 (dt, J = 16.8/3.0 Hz, 1H, pyridine 2-CH2), 3.81 (s, 3H, O-
CH3), 5.85 (td, J = 3.6/1.2 Hz, 1H, pyridine 5-CH), 6.79 (ddd, J = 8.2/2.7/0.8 Hz,
1H, phenol 6-CH), 6.85 (t, J = 2.0 Hz, 1H, phenol 2-CH), 6.90 (dt, J = 7.7/1.2 Hz,
1H, phenol 4-CH), 7.22 (t, J = 8.0 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 18.8, 32.3, 45.9, 55.2, 55.5, 60.3, 112.0, 112.1, 118.8, 122.7, 
129.1, 141.0, 142.6, 159.5.
4-(3-isopropoxyphenyl)-1,3-dimethylpiperidin-4-ol (159)
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To a solution of 1-bromo-3-isopropoxybenzene (3.76 mL, 5 g, 23.25 mmol, 1.35
eq) in tetrahydrofuran (50 mL) at -75°C was added n-butyllithium (1.48M in
hexanes) (15.1 mL, 22.39 mmol, 1.3 eq). The reaction was allowed to stir at -
75°C for 1 hr before the dropwise addition of 1,3-dimethyl-4-piperidone (2.30
mL, 2.187 g, 17.22 mmol, 1 eq). The reaction was left to stir at -75°C until
complete by TLC. The reaction mixture was diluted with heptane (100 mL)
followed by the addition of saturated ammonium chloride solution (50 mL). The
layers were separated and the organic layer was washed with water (25 mL)
and brine (25 mL). It was then dried with magnesium sulfate and solvents
evaporated off under vacuum. Column chromatography (10% 1M NH3/MeOH
in EtOAc) afforded 159 as a colourless oil (4.099 g, 94%).
1H NMR (CDCl3): δ 0.65 (d, J = 6.8 Hz, 3H, piperidine 3-CH3), 1.34 (d, J = 6.0 Hz,
6H, i-Pr CH3), 1.72 (dt, J = 14.1, 2.5 Hz, 1H, piperidine 5-CH2), 2.11-2.23 (m, 2H,
piperidine 2-CH2 and 5-CH2), 2.23-2.33 (m, 1H, piperidine 3-CH), 2.36 (s, 3H, N-
CH3), 2.42 (dd, J = 12.9, 2.5 Hz, 1H, piperidine 6-CH2), 2.70 (ddd, J = 11.2, 4.0,
1.6 Hz, 1H, piperidine 2-CH2), 2.77 (ddt, J = 11.3, 4.3, 1.9 Hz, 1H, piperidine 6-
CH2), 4.56 (hept, J = 6.1 Hz, 1H, i-Pr CH), 6.78 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H,
phenol 6-CH), 7.01 (dt, J = 7.9, 1.5 Hz, 1H, phenol 2-CH), 7.04 (t, J = 2.1 Hz, 1H,
phenol 4-CH), 7.25 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 12.3, 22.1, 22.1, 39.3, 40.6, 46.2, 51.5, 58.8, 69.8, 73.4, 
112.7, 113.9, 116.9, 129.2, 149.0, 157.9.
m/z: LCMS C16H25NO2 [MH]+ calc 264.2, found 264.2 with tR of 2.48 min.
Ethyl (4-(3-isopropoxyphenyl)-1,3-dimethylpiperidin-4-yl) carbonate (160)
To a solution of 4-(3-isopropoxyphenyl)-1,3-dimethylpiperidin-4-ol (159)
(4.000 g, 15.19 mmol) and triethylamine (2.96 mL, 2.151 g, 21.26 mmol, 1.4 eq)
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in ethyl acetate (100 mL) at 0°C was added ethyl chloroformate (2.03 mL, 2.307
g, 21.26 mmol, 1.4 eq) dropwise over 15 minutes. The reaction was allowed to
stir and warm to room temperature over 24 hrs. 2M NaOH (100 mL) and
additional EtOAc (100 mL) were added and the layers separated. The aqueous
layer was extracted with further EtOAc (2 x 50 mL). The combined organic
phases were then washed with water (50 mL) and brine (50 mL). It was then
dried with magnesium sulfate and solvents evaporated off under vacuum.
Column chromatography (5-10% 1M NH3/MeOH in EtOAc) afforded 160 as a
colourless oil (4.044 g, 79%).
1H NMR (CDCl3): δ 0.75 (d, J = 6.8 Hz, 3H, piperidine 3-CH3), 1.30 – 1.38 (m, 9H,
i-Pr CH3 and Et CH3), 1.88 – 2.02 (m, 1H, piperidine 3-CH), 2.17 – 2.33 (m, 2H,
piperidine 2-CH2 and 6-CH2), 2.36 (s, 3H, N-CH3), 2.35 – 2.47 (m, 1H, piperidine
5-CH2), 2.69 (ddd, J = 11.5, 4.1, 1.5 Hz, 1H, piperidine 2-CH2), 2.83 (br d, J = 11.4
Hz, 1H, piperidine 6-CH2), 3.00 (dt, J = 14.2, 2.5 Hz, 1H, piperidine 5-CH2), 4.19
(ddq, J = 15.2, 10.7, 7.1 Hz, 2H, Et CH2), 4.52 (hept, J = 6.0 Hz, 1H, i-Pr CH), 6.74
– 6.84 (m, 3H, Ph 2-CH, Ph 4-CH and Ph 6-CH), 7.24 (t, J = 7.9 Hz, 1H, Ph 5-CH).
13C NMR (CDCl3): δ 12.6, 14.4, 22.0, 22.1, 32.8, 42.6, 45.9, 51.0, 58.8, 63.5, 69.9, 
84.3, 113.2, 114.3, 117.3, 129.0, 143.4, 153.2, 157.7.
m/z: LCMS C19H29NO4 [MH]+ calc 336.2, found 336.1 with tR of 2.20 min.
4-(3-isopropoxyphenyl)-1,3-dimethyl-1,2,3,6-tetrahydropyridine (161)
To a two-neck flask containing ethyl (4-(3-isopropoxyphenyl)-1,3-
dimethylpiperidin-4-yl) carbonate (160) (8.650 g, 25.79 mmol) was added
anhydrous decalin (100 ml). The reaction was heated to reflux (195°C) for 24
hrs or until the reaction was complete by TLC. Ethanol produced in the reaction
was removed by evaporation under vacuum. The decalin was washed with 2M
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HCl (4 x 25 mL) and the combined aqueous phases were basified with 2M NaOH
(200 mL) and the product extracted with EtOAc (3 x 50 mL). The organic phase
was finally washed with water (50 mL) and brine (50 mL), dried with magnesium
sulfate and solvents evaporated off under vacuum. Column chromatography
(5% 1M NH3/MeOH in EtOAc) afforded 161 as a pale yellow oil (6.248 g, 99%).
(R)-4-(3-isopropoxyphenyl)-1,3-dimethyl-1,2,3,6-tetrahydropyridine (161a)
[α]19D: -79.7 (MeOH, c 1.00).
1H NMR (CDCl3): δ 1.00 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.33 (d, J = 6.1 Hz,
6H, i-Pr CH3), 2.38 (s, 3H, N-CH3), 2.39 (dd, J = 10.9, 5.1 Hz, 1H, piperidine 2-
CH2), 2.68 (dd, J = 11.2, 4.9 Hz, 1H, piperidine 2-CH2), 2.87 – 2.97 (m, 1H,
piperidine 3-CH), 2.98 (dt, J = 16.8, 3.0 Hz, 1H, piperidine 6-CH2), 3.09 (dt, J =
16.8, 3.0 Hz, 1H, piperidine 6-CH2), 4.55 (hept, J = 6.0 Hz, 1H, i-Pr CH), 5.86 (td,
J = 3.6, 1.2 Hz, 1H, piperidine 5-CH), 6.76 (ddd, 8.2, 2.5, 0.9 Hz, 1H, phenol 6-
CH), 6.83 (t, J = 2.1 Hz, 1H phenol 2-CH), 6.87 (dt, J = 7.7, 1.2 Hz, 1H, phenol 4-
CH), 7.20 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 18.9, 22.2, 22.3, 32.4, 46.1, 55.6, 60.4, 69.9, 114.2, 114.2, 
118.7, 122.7, 129.3, 141.2, 142.7, 158.0.
m/z: LCMS C16H23NO [MH]+ calc 246.2, found 246.2 with tR of 2.07 min.
(S)-4-(3-isopropoxyphenyl)-1,3-dimethyl-1,2,3,6-tetrahydropyridine (161b)
[α]19D: +79.7 (MeOH, c 1.00).
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1H NMR (CDCl3): δ 1.00 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.33 (d, J = 6.1 Hz,
6H, i-Pr CH3), 2.38 (s, 3H, N-CH3), 2.39 (dd, J = 10.9, 5.1 Hz, 1H, piperidine 2-
CH2), 2.68 (dd, J = 11.2, 4.9 Hz, 1H, piperidine 2-CH2), 2.87 – 2.97 (m, 1H,
piperidine 3-CH), 2.98 (dt, J = 16.8, 3.0 Hz, 1H, piperidine 6-CH2), 3.09 (dt, J =
16.8, 3.0 Hz, 1H, piperidine 6-CH2), 4.55 (hept, J = 6.0 Hz, 1H, i-Pr CH), 5.86 (td,
J = 3.6, 1.2 Hz, 1H, piperidine 5-CH), 6.76 (ddd, 8.2, 2.5, 0.9 Hz, 1H, phenol 6-
CH), 6.83 (t, J = 2.1 Hz, 1H phenol 2-CH), 6.87 (dt, J = 7.7, 1.2 Hz, 1H, phenol 4-
CH), 7.20 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 18.9, 22.2, 22.3, 32.4, 46.1, 55.6, 60.4, 69.9, 114.2, 114.2, 
118.7, 122.7, 129.3, 141.2, 142.7, 158.0.
m/z: LCMS C16H23NO [MH]+ calc 246.2, found 246.2 with tR of 2.07 min.
(3R,4S)-4-(3-isopropoxyphenyl)-1,3,4-trimethyl-1,2,3,4-tetrahydropyridine
(162a)
To a solution of I-4-(3-isopropoxyphenyl)-1,3-dimethyl-1,2,3,6-
tetrahydropyridine (161a) (588 mg, 2.40 mmol) in THF (10 ml) at -10°C was
added n-Butyllithium (1.56 ml of a 1.48M solution in hexanes, 3.59 mmol, 1.5
eq) dropwise. The dark red solution was allowed to stir at -10°C for 30 minutes.
The flask was then cooled to -50°C and dimethylsulphate (0.25 ml, 332 mg,
2.636 mmol, 1.1 eq) was added dropwise over 15 minutes. The reaction was
then allowed to stir at -50°C until complete by TLC and LCMS (I hour). A dilute
solution of ammonium hydroxide (1:3 35% NH4OH/water, 5 ml) and heptane (5
ml) were added at 0°C and stirred for a further 1 hour, allowing the solution to
warm to room temperature. The layers were then separated and the aqueous
phase extracted with EtOAc (25 mL). The combined organic phases were
washed with water (10 mL) and brine (10 mL), dried over MgSO4 and
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evaporated under vacuum. Column chromatography (1% 1M NH3/MeOH in
EtOAc) afforded 162a as a pale yellow oil (481 mg, 77%).
[α]19D: -59.7 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.60 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.34 (d, J = 6.1 Hz,
6H, i-Pr CH3), 1.44 (s, 3H, piperidine 4-CH3), 1.92 (dqd, J = 10.5, 6.9, 3.4 Hz, 1H,
piperidine 3-CH), 2.47 (dd, J = 11.6, 10.4 Hz, 1H, piperidine 2-CH2), 2.67 (dd, J =
11.5, 3.6 Hz, 1H, piperidine 2-CH2), 2.67 (s, 3H, N-CH3), 4.34 (d, J = 7.8 Hz, 1H,
piperidine 5-CH), 4.53 (hept, J = 6.0 Hz, 1H i-Pr CH), 5.98 (d, J = 7.8 Hz, 1H,
piperidine 6-CH), 6.72 (ddd, J = 8.2, 2.5, 1.1 Hz, 1H, phenol 6-CH), 6.94 – 6.98
(m, 2H, phenol 2-CH, 4-CH), 7.17 (t, J = 8.2 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 15.2, 22.3, 22.3, 28.2, 38.9, 40.3, 42.6, 52.9, 69.9, 106.3, 
112.8, 117.4, 121.4, 127.9, 135.3, 148.1, 157.1.
m/z: LCMS C17H25NO [MH]+ calc 260.2, found 260.3 with tR of 2.12 min.
(3S,4R)-4-(3-isopropoxyphenyl)-1,3,4-trimethyl-1,2,3,4-tetrahydropyridine
(162b)
Experimental method unchanged from that described for the synthesis of
(3R,4S)-4-(3-isopropoxyphenyl)-1,3,4-trimethyl-1,2,3,4-tetrahydropyridine
(162a) yielding 162b as a pale yellow oil (78%).
[α]19D: +59.7 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.60 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.34 (d, J = 6.1 Hz,
6H, i-Pr CH3), 1.44 (s, 3H, piperidine 4-CH3), 1.92 (dqd, J = 10.5, 6.9, 3.4 Hz, 1H,
piperidine 3-CH), 2.47 (dd, J = 11.6, 10.4 Hz, 1H, piperidine 2-CH2), 2.67 (dd, J =
11.5, 3.6 Hz, 1H, piperidine 2-CH2), 2.67 (s, 3H, N-CH3), 4.34 (d, J = 7.8 Hz, 1H,
piperidine 5-CH), 4.53 (hept, J = 6.0 Hz, 1H i-Pr CH), 5.98 (d, J = 7.8 Hz, 1H,
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piperidine 6-CH), 6.72 (ddd, J = 8.2, 2.5, 1.1 Hz, 1H, phenol 6-CH), 6.94 – 6.98
(m, 2H, phenol 2-CH, 4-CH), 7.17 (t, J = 8.2 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 15.2, 22.3, 22.3, 28.2, 38.9, 40.3, 42.6, 52.9, 69.9, 106.3, 
112.8, 117.4, 121.4, 127.9, 135.3, 148.1, 157.1.
m/z: LCMS C17H25NO [MH]+ calc 260.2, found 260.3 with tR of 2.12 min.
(3R,4R)-4-(3-isopropoxyphenyl)-1,3,4-trimethylpiperidine (163a)
To a solution of (3R,4S)-4-(3-isopropoxyphenyl)-1,3,4-trimethyl-1,2,3,4-
tetrahydropyridine (162a) (465 mg, 1.79 mmol) in methanol (10 mL) at 0°C was
added sodium borohydride (109 mg, 2.87 mmol, 1.6 eq). It was stirred while
warming to room temperature until complete by TLC. The solution was
quenched with 1:1 acetone/sat. NaHCO3 solution (10 mL). The solvents were
evaporated off under vacuum and the remaining mixture re-dissolved in EtOAc
(20 mL). This was then washed with water (10 mL) and brine (10 mL), dried over
MgSO4 and evaporated under vacuum. Column chromatography (5% 1M
NH3/MeOH in EtOAc) afforded 163a as a pale yellow oil (332 mg, 71%).
[α]19D: -69.4 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.80 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.31 (s, 3H,
piperidine 4-CH3), 1.34 (dd, J = 6.0, 1.9 Hz, 6H, i-Pr CH3), 1.60 (ddd, J = 10.3, 3.4,
1.7 Hz, 1H, piperidine 6-CH2), 1.94-2.05 (m, 1H, piperidine 3-CH), 2.28 (s, 3H, N-
CH3), 2.32 (dt, J = 9.0, 3.1 Hz, 2H, piperidine 5-CH2), 2.53 (d, J = 2.9 Hz, 2H,
piperidine 2-CH2), 2.76-2.82 (m, 1H, piperidine 6-CH2), 4.54 (hept, J = 6.1 Hz,
1H, i-Pr CH), 6.70 (dd, J = 8.2, 2.2 Hz, 1H, phenol 4-CH), 6.82 (t, J = 2.2 Hz, 1H,
phenol 2-CH), 6.86 (ddd, J = 7.8, 1.8, 0.9 Hz, 1H, phenol 6-CH), 7.20 (t, J = 8.0
Hz, 1H, phenol 5-CH).
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13C NMR (CDCl3): δ 16.5, 22.1, 22.2, 27.6, 38.0, 38.8, 46.7, 52.3, 58.6, 69.7, 
112.1, 114.4, 118.1, 128.9, 151.9, 157.8.
LCMS m/z for C17H27NO [MH]+ calc 262.2, found 262.2 with tR of 2.14 min.
(3S,4S)-4-(3-isopropoxyphenyl)-1,3,4-trimethylpiperidine 163)
Experimental method unchanged from that described for the synthesis of
(3R,4R)-4-(3-isopropoxyphenyl)-1,3,4-trimethylpiperidine (163a) yielding 163b
as a pale yellow oil (69%).
[α]19D: +69.4 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.80 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.31 (s, 3H,
piperidine 4-CH3), 1.34 (dd, J = 6.0, 1.9 Hz, 6H, i-Pr CH3), 1.60 (ddd, J = 10.3, 3.4,
1.7 Hz, 1H, piperidine 6-CH2), 1.94-2.05 (m, 1H, piperidine 3-CH), 2.28 (s, 3H, N-
CH3), 2.32 (dt, J = 9.0, 3.1 Hz, 2H, piperidine 5-CH2), 2.53 (d, J = 2.9 Hz, 2H,
piperidine 2-CH2), 2.76-2.82 (m, 1H, piperidine 6-CH2), 4.54 (hept, J = 6.1 Hz,
1H, i-Pr CH), 6.70 (dd, J = 8.2, 2.2 Hz, 1H, phenol 4-CH), 6.82 (t, J = 2.2 Hz, 1H,
phenol 2-CH), 6.86 (ddd, J = 7.8, 1.8, 0.9 Hz, 1H, phenol 6-CH), 7.20 (t, J = 8.0
Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 16.5, 22.1, 22.2, 27.6, 38.0, 38.8, 46.7, 52.3, 58.6, 69.7, 
112.1, 114.4, 118.1, 128.9, 151.9, 157.8.




To a solution of (3R,4R)-4-(3-isopropoxyphenyl)-1,3,4-trimethylpiperidine
(163a) (403 mg, 1.542 mmol) in anhydrous toluene (20 mL) at 85°C was added
phenyl chloroformate (0.23 mL, 290 mg, 1.850 mmol, 1.2 eq) dropwise. The
solution was heated to reflux and stirred for 2 hours. It was then cooled to 45°C
and quenched with 1.4 M NaOH (5 mL) before allowing it to cool to room
temperature. The layers were partitioned and the organic washed with 1:1
MeOH/1M HCl (10 mL x3), 1:1 MeOH/1M NaOH (10 mL), water (10 mL) and
brine (10 mL), dried over MgSO4 and evaporated under vacuum. Column
chromatography (5% 1M NH3/MeOH in EtOAc) afforded phenyl 164a as an
orange oil (423 mg, 75%).
[α]19D: -65.1 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.71-0.82 (m, 3H, piperidine 3-CH3), 1.35 (d, J = 6.1 Hz, 6H, i-
Pr CH3), 1.42 (s, 3H, piperidine 4-CH3), 1.61-1.70 (m, 1H, piperidine 5-CH2), 2.00-
2.15 (m, 1H, piperidine 3-CH), 2.32 (dd, J = 13.0, 5.0 Hz, 1H, piperidine 5-CH2),
3.13-3.60 (m, 2H, piperidine 2-CH2, piperidine 6-CH2), 3.94- 4.14 (m, 1H,
piperidine 2-CH2), 4.25-4.39 (m, 1H, piperidine 6-CH2), 4.56 (septet, J = 6.1 Hz,
1H, i-Pr CH), 6.74 (ddd, J = 8.2, 2.5, 0.8 Hz, 1H, phenol 4-CH), 6.82 (t, J = 3.6 Hz,
1H, phenol 2-CH), 6.85 (d, J = 8.1 Hz, 1H, phenol 6-CH), 7.06 – 7.31 (m, 3H,
phenol 5-CH, phenyl 2-CH, phenyl 6-CH), 7.32 – 7.48 (m, 3H, phenyl 3-CH,
phenyl 4-CH, phenyl 5-CH).
13C NMR (CDCl3): δ 14.3, 22.0, 26.4, 29.1, 29.6, 38.3, 38.4, 38.7, 40.3, 40.7, 45.9, 
46.5, 69.6, 112.1, 112.2, 113.9, 117.5, 120.8, 121.6, 125.0, 126.2, 129.1, 129.4,
150.9, 157.8.




Experimental method unchanged from that described for the synthesis of
phenyl (3R,4R)-4-(3-isopropoxyphenyl)-3,4-dimethylpiperidine-1-carboxylate
(164a) yielding phenyl 164b as an orange oil (74%).
[α]19D: +65.1 (MeOH, c 1.00).
1H NMR (CDCl3): δ 0.71-0.82 (m, 3H, piperidine 3-CH3), 1.35 (d, J = 6.1 Hz, 6H, i-
Pr CH3), 1.42 (s, 3H, piperidine 4-CH3), 1.61-1.70 (m, 1H, piperidine 5-CH2), 2.00-
2.15 (m, 1H, piperidine 3-CH), 2.32 (dd, J = 13.0, 5.0 Hz, 1H, piperidine 5-CH2),
3.13-3.60 (m, 2H, piperidine 2-CH2, piperidine 6-CH2), 3.94- 4.14 (m, 1H,
piperidine 2-CH2), 4.25-4.39 (m, 1H, piperidine 6-CH2), 4.56 (septet, J = 6.1 Hz,
1H, i-Pr CH), 6.74 (ddd, J = 8.2, 2.5, 0.8 Hz, 1H, phenol 4-CH), 6.82 (t, J = 3.6 Hz,
1H, phenol 2-CH), 6.85 (d, J = 8.1 Hz, 1H, phenol 6-CH), 7.06 – 7.31 (m, 3H,
phenol 5-CH, phenyl 2-CH, phenyl 6-CH), 7.32 – 7.48 (m, 3H, phenyl 3-CH,
phenyl 4-CH, phenyl 5-CH).
13C NMR (CDCl3): δ 14.3, 22.0, 26.4, 29.1, 29.6, 38.3, 38.4, 38.7, 40.3, 40.7, 45.9, 
46.5, 69.6, 112.1, 112.2, 113.9, 117.5, 120.8, 121.6, 125.0, 126.2, 129.1, 129.4,
150.9, 157.8.
m/z: LCMS C23H29NO3 [MH]+ calc 368.5, found 368.3 with tR of 2.30 min.
3-((3R,4R)-3,4-dimethylpiperidin-4-yl)phenol (146a)
171
A solution of phenyl (3R,4R)-4-(3-isopropoxyphenyl)-3,4-dimethylpiperidine-1-
carboxylate (15a) (500 mg, 1.36 mmol) in glacial acetic acid (0.84 ml) and 48%
hydrobromic acid (0.84 ml) were heated to reflux for 16 hours. The solution
was cooled to room temperature and extracted with methyl tert-butyl ether
(x3) to remove any phenol by-product. The aqueous phase was titrated to pH
10 and extracted with 1:3 toluene/butan-1-ol until no further compound could
be detected in the extracts. The combined extracts were evaporated under
vacuum. Column chromatography (30% 1M NH3/MeOH in EtOAc) afforded
146a as an orange oil (240 mg, 86%) which dried into a foam at room
temperature.
[α]19D: +118.7 (MeOH, c 1.00).
1H NMR (MeOD): δ 0.84 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.44 (s, 3H,
piperidine 4-CH3), 1.86 (dt, J = 14.0, 3.6 Hz, 1H, piperidine 5-CH2), 2.26 – 2.34
(m, 1H, piperidine 3-CH), 2.39 (ddd, J = 14.5, 11.1, 6.2 Hz, 1H, piperidine 5-CH2),
3.16 (dd, J = 13.1, 3.2 Hz, 1H, piperidine 6-CH2), 3.26 – 3.39 (m, 2H, piperidine
2-CH2), 3.50 (dd, J = 13.0, 3.8 Hz, 1H, piperidine 6-CH2), 6.66 (dd, J = 7.9, 2.2 Hz,
1H, phenol 6-CH), 6.76 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.80 (dd, J = 8.0, 1.7 Hz,
1H, phenol 4-CH), 7.16 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (MeOD): δ 14.8, 24.2, 27.4, 37.4, 38.8, 41.7, 47.2, 113.5, 114.1, 117.5, 
130.6, 150.2, 158.8.
m/z: LCMS C13H19NO [MH]+ calc 206.3, found 206.3 with tR of 0.84 min.
3-((3S,4S)-3,4-dimethylpiperidin-4-yl)phenol (146b)
Experimental method unchanged from that described for the synthesis of 3-
((3R,4R)-3,4-dimethylpiperidin-4-yl)phenol (146a) yielding 146b as an orange
oil (82%) which dried into a foam at room temperature.
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[α]19D: -118.7 (MeOH, c 1.00).
1H NMR (MeOD): δ 0.84 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.44 (s, 3H,
piperidine 4-CH3), 1.86 (dt, J = 14.0, 3.6 Hz, 1H, piperidine 5-CH2), 2.26 – 2.34
(m, 1H, piperidine 3-CH), 2.39 (ddd, J = 14.5, 11.1, 6.2 Hz, 1H, piperidine 5-CH2),
3.16 (dd, J = 13.1, 3.2 Hz, 1H, piperidine 6-CH2), 3.26 – 3.39 (m, 2H, piperidine
2-CH2), 3.50 (dd, J = 13.0, 3.8 Hz, 1H, piperidine 6-CH2), 6.66 (dd, J = 7.9, 2.2 Hz,
1H, phenol 6-CH), 6.76 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.80 (dd, J = 8.0, 1.7 Hz,
1H, phenol 4-CH), 7.16 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (MeOD): δ 14.8, 24.2, 27.4, 37.4, 38.8, 41.7, 47.2, 113.5, 114.1, 117.5, 
130.6, 150.2, 158.8.
m/z: LCMS C13H19NO [MH]+ calc 206.3, found 206.3 with tR of 0.84 min.
Ethyl 3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoate
(167a)
To a solution of 3-((3R,4R)-3,4-dimethylpiperidin-4-yl)phenol (146a) (240 mg,
1.17 mmol) in anhydrous tetrahydrofuran (10 mL) at 50 °C was added ethyl
acrylate (0.25 mL, 235 mg, 2.33 mmol, 2 eq) dropwise. The reaction was left to
stir for 20 hours at 50°C. The solution was cooled to room temperature and
filtered through celite, washing with MeOH before the solvents were
evaporated under vacuum. Column chromatography (5% 1M NH3/MeOH in
EtOAc) afforded 167a as a white solid (300 mg, 84%).
1H NMR (CDCl3) δ 0.73 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.25 (t, J = 7.2 Hz,
3H, Et-CH3), 1.30 (s, 3H, piperidine 4-CH3), 1.58 (d, J = 12.9 Hz, 1H, piperidine 5-
CH2), 1.93 – 2.01 (m, 1H, piperidine 3-CH), 2.29 (td, J = 12.4, 4.6 Hz, 1H,
piperidine 5-CH2), 2.41 (td, J = 11.5, 2.6 Hz, 1H, piperidine 6-CH2), 2.51 (t, J = 7.1
Hz, 2H, propanoate α-CH2), 2.58 (t, J = 3.4 Hz, 2H, piperidine 2-CH2), 2.61-2.80
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(m, 2H, propanoate β-CH2), 2.85 (dt, J = 10.8, 3.7 Hz, 1H, piperidine 6-CH2), 4.13
(qd, J = 7.1, 2.0 Hz, 2H, Et-CH2), 6.63 (dd, J = 7.8, 2.3 Hz, 1H, phenol 4-CH), 6.74
(t, J = 2.1 Hz, 1H, phenol 2-CH), 6.83 (d, J = 8.0 Hz, 1H, phenol 6-CH), 7.16 (t, J =
7.9 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3) δ 16.1, 27.5, 30.8, 32.0, 38.4, 38.9, 49.9, 51.7, 53.9, 55.8, 112.6, 
113.2, 117.7, 129.2, 151.6, 156.1, 173.4.
m/z: LCMS C18H27NO3 [MH]+ calc 306.4, found 306.2 with tR of 1.89 min.
Ethyl 3-((3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoate
(167b)
Experimental method unchanged from that described for the synthesis of ethyl
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoate (167a)
yielding 167b as a white solid (84%).
1H NMR (CDCl3): δ 0.73 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.25 (t, J = 7.2 Hz,
3H, Et-CH3), 1.30 (s, 3H, piperidine 4-CH3), 1.58 (d, J = 12.9 Hz, 1H, piperidine 5-
CH2), 1.93 – 2.01 (m, 1H, piperidine 3-CH), 2.29 (td, J = 12.4, 4.6 Hz, 1H,
piperidine 5-CH2), 2.41 (td, J = 11.5, 2.6 Hz, 1H, piperidine 6-CH2), 2.51 (t, J = 7.1
Hz, 2H, propanoate α-CH2), 2.58 (t, J = 3.4 Hz, 2H, piperidine 2-CH2), 2.61-2.80
(m, 2H, propanoate β-CH2), 2.85 (dt, J = 10.8, 3.7 Hz, 1H, piperidine 6-CH2), 4.13
(qd, J = 7.1, 2.0 Hz, 2H, Et-CH2), 6.63 (dd, J = 7.8, 2.3 Hz, 1H, phenol 4-CH), 6.74
(t, J = 2.1 Hz, 1H, phenol 2-CH), 6.83 (d, J = 8.0 Hz, 1H, phenol 6-CH), 7.16 (t, J =
7.9 Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ 16.1, 27.5, 30.8, 32.0, 38.4, 38.9, 49.9, 51.7, 53.9, 55.8, 
112.6, 113.2, 117.7, 129.2, 151.6, 156.1, 173.4




To a solution of ethyl 3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoate (167a) (40 mg, 0.913 mmol) in dioxane (1 mL) was added 4M HCl
(in dioxane and water) (0.5 mL) and heated to reflux (105°C) for 2 hours. Once
cooled to room temperature the solvents were evaporated in vacuo to give
165a as a white solid (39 mg, 95%).
1H NMR (MeOD): δ 0.83 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.45 (s, 3H,
piperidine 4-CH3), 1.93 (d, J = 14.8 Hz, 1H, piperidine 5-CH2), 2.34 – 2.44 (m, 1H,
piperidine 3-CH), 2.49 (td, J = 14.1, 4.4 Hz, 1H, piperidine 5-CH2), 2.91 (t, J = 7.0
Hz, 2H, propanoate α-CH2), 3.42 (dt, J = 14.2, 2.7 Hz, 1H, piperidine 6-CH2), 3.49
(t, J = 7.1 Hz, 2H, propanoate β-CH2), 3.53 – 3.62 (m, 3H, piperidine 2-CH2,
piperidine 6-CH2), 6.66 (dd, J = 8.0, 2.4 Hz, 1H, phenol 6-CH), 6.73 (t, J = 2.1 Hz,
1H, phenol 2-CH), 6.77 (dd, J = 7.7, 1.8 Hz, 1H, phenol 4-CH), 7.16 (t, J = 7.8 Hz,
1H, phenol 5-CH).
13C NMR (MeOD): δ 15.1, 27.0, 28.7, 29.3, 38.3, 38.4, 43.7, 50.9, 54.1, 56.0, 
113.27, 114.2, 117.3, 130.7, 150.2, 158.8, 173.6.




Experimental method unchanged from that described for the synthesis of 3-
((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) yielding 165b as a white solid (98%).
1H NMR (MeOD): δ 0.83 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.45 (s, 3H,
piperidine 4-CH3), 1.93 (d, J = 14.8 Hz, 1H, piperidine 5-CH2), 2.34 – 2.44 (m, 1H,
piperidine 3-CH), 2.49 (td, J = 14.1, 4.4 Hz, 1H, piperidine 5-CH2), 2.91 (t, J = 7.0
Hz, 2H, propanoate α-CH2), 3.42 (dt, J = 14.2, 2.7 Hz, 1H, piperidine 6-CH2), 3.49
(t, J = 7.1 Hz, 2H, propanoate β-CH2), 3.53 – 3.62 (m, 3H, piperidine 2-CH2,
piperidine 6-CH2), 6.66 (dd, J = 8.0, 2.4 Hz, 1H, phenol 6-CH), 6.73 (t, J = 2.1 Hz,
1H, phenol 2-CH), 6.77 (dd, J = 7.7, 1.8 Hz, 1H, phenol 4-CH), 7.16 (t, J = 7.8 Hz,
1H, phenol 5-CH).
13C NMR (MeOD): δ 15.1, 27.0, 28.7, 29.3, 38.3, 38.4, 43.7, 50.9, 54.1, 56.0, 
113.27, 114.2, 117.3, 130.7, 150.2, 158.8, 173.6.
m/z: HRMS C16H23NO3 [MH]+ calc 278.1751, found 278.1754.
General procedure 2 – amide coupling of 3-(4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanoic acids to amino acid methyl esters
To a solution of a 3-(4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic
acid (165a or 165b) (1 eq) in DMF was added HBTU (0.5 eq), HOBt (1 eq) and
amino acid methyl ester hydrochloride (1 eq). TEA (4 eq) was then added
dropwise and the solution was stirred at room temperature for 24 hours. The
DMF was evaporated off under vacuum and before re-dissolving in toluene and
further evaporation under vacuum to remove any residual DMF. Column
chromatography (5% 1M NH3/MeOH in EtOAc) of the product afforded the
product. Where necessary, further purification was carried out using reverse




The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (23 mg, 0.072 mmol, 1 eq) and glycine methyl ester
hydrochloride (9 mg, 0.072 mmol, 1 eq) to give 166a as a white solid (4 mg,
16%).
1H NMR (MeOD) δ 0.77 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.32 (s, 3H,
piperidine 4-CH3), 1.63 (d, J = 13.2 Hz, 1H, piperidine 5-CH2), 2.02 – 2.10 (m, 1H,
piperidine 3-CH), 2.35 (td, J = 12.6, 4.2 Hz, 1H, piperidine 5-CH2), 2.41 – 2.51
(m, 1H, piperidine 6-CH2), 2.47 (t, J = 6.6 Hz, 2H, propanamide α-CH2), 2.61 –
2.77 (m, 4H, piperidine 2-CH2, propanamide β-CH2), 2.93 (dt, J = 11.0, 4.0 Hz,
1H, piperidine 6-CH2), 3.71 (s, 3H, O-CH3), 3.92 (d, J = 17.8 Hz, 1H, glycine CH2),
3.99 (d, J = 17.8 Hz, 1H, glycine CH2), 6.59 (dd, J = 8.0, 2.4 Hz, 1H, phenol 6-CH),
6.75 (d, J = 2.2 Hz, 1H, phenol 2-CH), 6.78 (d, J = 8.4 Hz, 1H, phenol 4-CH), 7.11
(t, J = 7.9 Hz, 1H, phenol 5-CH).




The title compound was synthesised as described in general procedure 2, using
3-((3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (146b) (23 mg, 0.072 mmol, 1 eq) and glycine methyl ester
hydrochloride (9 mg, 0.072 mmol, 1 eq) to give 166b as a white solid (4 mg,
16%).
1H NMR (MeOD) δ 0.77 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.32 (s, 3H,
piperidine 4-CH3), 1.63 (d, J = 13.2 Hz, 1H, piperidine 5-CH2), 2.02 – 2.10 (m, 1H,
piperidine 3-CH), 2.35 (td, J = 12.6, 4.2 Hz, 1H, piperidine 5-CH2), 2.41 – 2.51
(m, 1H, piperidine 6-CH2), 2.47 (t, J = 6.6 Hz, 2H, propanamide α-CH2), 2.61 –
2.77 (m, 4H, piperidine 2-CH2, propanamide β-CH2), 2.93 (dt, J = 11.0, 4.0 Hz,
1H, piperidine 6-CH2), 3.71 (s, 3H, O-CH3), 3.92 (d, J = 17.8 Hz, 1H, glycine CH2),
3.99 (d, J = 17.8 Hz, 1H, glycine CH2), 6.59 (dd, J = 8.0, 2.4 Hz, 1H, phenol 6-CH),
6.75 (d, J = 2.2 Hz, 1H, phenol 2-CH), 6.78 (d, J = 8.4 Hz, 1H, phenol 4-CH), 7.11
(t, J = 7.9 Hz, 1H, phenol 5-CH).
m/z: HRMS C19H28N2O4 [MH]+ calc 349.2122, found 349.2112.
General procedure 3 – Ester hydrolysis of 3-(4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanoylamido methyl esters
To a solution of the 3-(4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoylamido methyl ester in dioxane (0.5 mL) was added 4M HCl (in
dioxane and water) (0.1 mL) and heated to reflux (105°C) for 2 hours. Once






The title compound was synthesised as described in general procedure 3, using
methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)glycinate (166a) (5 mg, 0.014 mmol) to give 136a as a white solid
(5 mg, 100%).
1H NMR (MeOD) δ 0.82 (d, J = 7.4 Hz, 3H, piperidine 3-CH3), 1.45 (s, 3H,
piperidine 4-CH3), 1.94 (d, J = 14.8 Hz, 1H, piperidine 5-CH2), 2.35 – 2.44 (m, 1H,
piperidine 3-CH), 2.49 (td, J = 14.1, 4.5 Hz, 1H, , piperidine 5-CH2), 2.85 (t, J =
6.4 Hz, 2H, propanamide α-CH2), 3.38 – 3.70 (m, 5H, propanamide β-CH2,
piperidine 2-CH2, piperidine 6-CH2), 3.75 (dd, J = 11.4, 6.4 Hz, 1H, piperidine 6-
CH2), 6.66 (dd, J = 8.0, 2.3 Hz, 1H, phenol 6-CH), 6.73 (t, J = 2.2 Hz, 1H, phenol
2-CH), 6.78 (d, J = 7.8 Hz, 1H, phenol 4-CH), 7.17 (t, J = 7.9 Hz, 1H, phenol 5-CH).
m/z HRMS C18H26N2O4 [MH]+ calc 335.1965, found 335.1955.
(3-((3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)glycine hydrochloride (136b)
The title compound was synthesised as described in general procedure 3, using
methyl (3-((3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)glycinate (166b) (5 mg, 0.014 mmol) to give 136b as a white solid
(5 mg, 100%).
1H NMR (MeOD) δ 0.82 (d, J = 7.4 Hz, 3H, piperidine 3-CH3), 1.45 (s, 3H,
piperidine 4-CH3), 1.94 (d, J = 14.8 Hz, 1H, piperidine 5-CH2), 2.35 – 2.44 (m, 1H,
piperidine 3-CH), 2.49 (td, J = 14.1, 4.5 Hz, 1H, , piperidine 5-CH2), 2.85 (t, J =
6.4 Hz, 2H, propanamide α-CH2), 3.38 – 3.70 (m, 5H, propanamide β-CH2,
piperidine 2-CH2, piperidine 6-CH2), 3.75 (dd, J = 11.4, 6.4 Hz, 1H, piperidine 6-
CH2), 6.66 (dd, J = 8.0, 2.3 Hz, 1H, phenol 6-CH), 6.73 (t, J = 2.2 Hz, 1H, phenol
2-CH), 6.78 (d, J = 7.8 Hz, 1H, phenol 4-CH), 7.17 (t, J = 7.9 Hz, 1H, phenol 5-CH).
179
m/z HRMS C18H26N2O4 [MH]+ calc 335.1965, found 335.1958.
Methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-alaninate (166c)
The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-alanine methyl ester
hydrochloride (11 mg, 0.080 mmol, 1 eq) to give 166c as a white solid (4 mg,
14%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.22 (s, 3H,
piperidine 4-CH3), 1.23 (d, J = 7.6 Hz, 3H, alanine CH3), 1.51 (d, J = 12.8 Hz, 1H,
piperidine 5-CH2), 1.96 (d, J = 7.3 Hz, 1H, piperidine 3-CH), 2.14 (dt, J = 12.7, 6.4
Hz, 1H, piperidine 5-CH2), 2.22 – 2.35 (m, 2H, piperidine 2-CH2, piperidine 6-
CH2), 2.28 (t, J = 6.9 Hz, 2H, propanamide α-CH2), 2.47 – 2.58 (m, 3H,
propanamide β-CH2, piperidine 2-CH2), 2.82 (d, J = 10.7 Hz, 1H, piperidine 6-
CH2), 3.62 (s, 3H, O-CH3), 4.29 (p, J = 7.2 Hz, 1H, alanine α-CH), 6.55 (dd, J = 7.7,
2.3 Hz, 1H, phenol 6-CH), 6.66 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.71 (d, J = 8.0
Hz, 1H, phenol 4-CH), 7.08 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.21 (s, 1H, phenol
OH), 8.55 (d, J = 7.3 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 16.1, 17.4, 27.2, 29.1, 32.6, 37.9, 47.2, 49.0, 50.9, 53.5, 
54.7, 112.2, 112.4, 116.0, 128.8, 157.1, 163.8, 171.2, 173.2.




The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-valine methyl ester
hydrochloride (13 mg, 0.080 mmol, 1 eq) to give 166d as a white solid (5 mg,
16%).
1H NMR (MeOD): δ 0.85 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 0.97 (dd, J = 6.8,
1.0 Hz, 6H, valine CH3), 1.42 (s, 3H, piperidine 4-CH3), 1.89 (dt, J = 13.6, 3.8 Hz,
1H, piperidine 5-CH2), 2.15 (dp, J = 7.0, 6.6 Hz, 1H, valine β-CH), 2.27 – 2.37 (m, 
1H, piperidine 3-CH), 2.46 (ddd, J = 15.6, 12.1, 4.3 Hz, 1H, piperidine 5-CH2),
2.80 (t, J = 6.7 Hz, 2H, propanamide α-CH2), 3.13 – 3.31 (m, 2H, piperidine 2-
CH2, piperidine 6-CH2), 3.32 – 3.41 (m, 3H, propanamide β-CH2, piperidine 2-
CH2), 3.45 (d, J = 12.4 Hz, 1H, piperidine 6-CH2), 3.72 (s, 3H, O-CH3), 4.35 (d, J =
5.9 Hz, 1H, valine α-CH), 6.65 (ddd, J = 8.1, 2.4, 0.9 Hz, 1H, phenol 6-CH), 6.75
(t, J = 2.1 Hz, 1H, phenol 2-CH), 6.79 (dt, J = 7.8, 1.5 Hz, 1H, phenol 4-CH), 7.16
(t, J = 7.9 Hz, 1H, phenol 5-CH), 8.45 (s, 1H, phenol OH).
13C NMR (MeOD): δ 15.2, 18.5, 19.4, 27.6, 30.0, 30.7, 38.8, 38.9, 50.6, 52.5, 
54.6, 55.9, 59.4, 113.7, 114.1, 117.7, 130.6, 158.7, 169.0, 173.1, 173.5.




The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-phenylalanine methyl
ester hydrochloride (17 mg, 0.080 mmol, 1 eq) to give 166e as a white solid (6
mg, 17%).
1H NMR (CDCl3): δ 0.60 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.28 (s, 3H,
piperidine 4-CH3), 1.58 (dd, J = 10.5, 3.9 Hz, 1H, piperidine 5-CH2), 1.87 – 2.02
(m, 1H, piperidine 3-CH), 2.21 – 2.36 (m, 2H, piperidine 5-CH2, piperidine 6-
CH2), 2.40 (qt, J = 16.7, 5.4 Hz, 2H, propanamide β-CH2), 2.50 – 2.62 (m, 4H,
propanamide α-CH2, piperidine 2-CH2), 2.88 – 2.97 (m, 1H, piperidine 6-CH2),
3.00 (dd, J = 13.9, 6.9 Hz, 1H, phenylalanine CH2), 3.11 (dd, J = 13.9, 6.1 Hz, 1H,
phenylalanine CH2), 3.68 (s, 3H, O-CH3), 4.92 (dt, J = 8.2, 6.5 Hz, 1H,
phenylalanine α-CH), 6.67 (dd, J = 7.9, 2.4 Hz, 1H, phenol 6-CH), 6.77 (t, J = 2.1
Hz, 1H, phenol 2-CH), 6.80 (dd, J = 7.9, 1.7 Hz, 1H, phenol 4-CH), 7.06 – 7.11 (m,
2H, phenylalanine ortho-CH), 7.13 – 7.25 (m, 3H, phenylalanine para-CH,
phenylalanine meta-CH), 7.16 (t, J = 7.9 Hz, 1H, phenol 5-CH), 9.10 (d, J = 8.4
Hz, 1H, amide NH).
13C NMR (CDCl3): δ 16.3, 27.6, 30.4, 31.9, 38.3, 38.6, 38.6, 49.2, 52.3, 53.2, 54.3, 
56.1, 112.6, 113.1, 117.8, 127.0, 128.5, 129.3, 129.4, 136.6, 151.7, 156.2, 172.2,
172.8.




The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-cyclohexylalanine
methyl ester hydrochloride (18 mg, 0.080 mmol, 1 eq) to give 166f as a white
solid (6 mg, 17%).
1H NMR (MeOD): δ 0.85 (d, J = 7.4 Hz, 3H, piperidine 3-CH3), 0.88 – 1.05 (m, 2H,
cyclohexyl 2-CH2, cyclohexyl 6-CH2), 1.14 – 1.40 (m, 4H, cyclohexyl 3-CH2,
cyclohexyl 4-CH2, cyclohexyl 5-CH2), 1.42 (s, 3H, piperidine 4-CH3), 1.50 – 1.82
(m, 7H, cyclohexylalanine β-CH2, cyclohexyl 1-CH, cyclohexyl 2-CH2, cyclohexyl
3-CH2, cyclohexyl 5-CH2, cyclohexyl 6-CH2), 1.88 (d, J = 14.5 Hz, 1H, piperidine
5-CH2), 2.26 – 2.37 (m, 1H, piperidine 3-CH), 2.46 (td, J = 12.6, 4.2 Hz, 1H,
piperidine 5-CH2), 2.76 (t, J = 6.6 Hz, 2H, propanamide α-CH2), 3.10 – 3.24 (m,
2H, piperidine 2-CH2, piperidine 6-CH2), 3.24 – 3.40 (m, 3H, piperidine 2-CH2,
propanamide β-CH2), 3.44 (d, J = 12.0 Hz, 1H, piperidine 6-CH2), 3.70 (s, 3H, O-
CH3), 4.48 (dd, J = 9.9, 5.1 Hz, 1H, cyclohexylalanine α-CH), 6.65 (ddd, J = 8.1,
2.4, 0.8 Hz, 1H, phenol 6-CH), 6.75 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.79 (dt, J =
7.9, 1.3 Hz, 1H, phenol 4-CH), 7.16 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.43 (s, 1H,
OH)
13C NMR (MeOD): δ 15.3, 27.1, 27.3, 27.5, 30.2, 30.7, 33.2, 34.7, 35.4, 38.8, 
39.0, 40.0, 50.7, 51.6, 52.7, 54.5, 55.9, 113.7, 114.1, 117.7, 130.5, 158.7, 168.7,
173.1, 174.7.




The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-homophenylalanine
ethyl ester hydrochloride (18 mg, 0.080 mmol, 1 eq) to give 166g as a white
solid (6 mg, 16%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.15 (t, J = 6.3
Hz, 3H, Et-CH3) 1.22 (s, 3H, piperidine 4-CH3), 1.51 (d, J = 12.7 Hz, 1H, piperidine
5-CH2), 1.74 (m, 4H, homophenylalanine β-CH2, propanamide α-CH2), 2.05 –
2.10 (m, 1H, piperidine 3-CH), 2.15 (td, J = 12.7, 4.2 Hz, 1H, piperidine 5-CH2),
2.22 – 2.41 (m, 4H, propanamide β-CH2, piperidine 2-CH2, piperidine 6-CH2),
2.44 – 2.68 (m, homophenylalanine γ-CH2, piperidine 2-CH2), 2.85 (d, J = 11.1
Hz, 1H, piperidine 6-CH2), 4.09 (qd, J = 6.3, 2.2 Hz, 2H, Et-CH2), 4.26 (td, J = 8.7,
4.8 Hz, 1H, homophenylalanine α-CH), 6.54 (dd, J = 7.9, 1.6 Hz, 1H, phenol 6-
CH), 6.64 – 6.71 (m, 2H, phenol 2-CH, phenol 4-CH), 7.07 (t, J = 7.8 Hz, 1H,
phenol 5-CH), 7.13 – 7.21 (m, 3H, phenyl ortho-CH, phenyl para-CH), 7.22 – 7.30
(m, 2H, phenyl meta-CH), 8.27 (s, 1H, phenol OH), 8.58 (d, J = 7.9 Hz, 1H, amide
NH)
13C NMR (DMSO-d6): δ 15.4, 16.6, 27.7, 31.7, 33.3, 33.6, 38.4, 49.1, 49.6, 51.5, 
52.3, 54.5, 55.6, 56.0, 112.6, 112.9. 116.5, 126.4, 128.8, 129.4, 141.3, 152.1,
157.6, 172.1, 173.1.
m/z: HRMS C27H36N2O4 [MH]+ calc 467.2904, found 466.2901.
Methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-tyrosinate (166h)
The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
184
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and L-tyrosine methyl ester
hydrochloride (19 mg, 0.080 mmol, 1 eq) to give 166g as a white solid (5 mg,
14%).
1H NMR (MeOD): δ 0.76 (d, J = 7.2 Hz, 3H, piperidine 3-CH3), 1.37 (s, 3H,
piperidine 4-CH3), 1.80 (d, J = 14.1 Hz, 1H, piperidine 5-CH2), 2.22 (d, J = 7.7 Hz,
1H, piperidine 3-CH), 2.37 (td, J = 14.0, 10.1 Hz, 1H, piperidine 5-CH2), 2.52 –
2.71 (m, 2H, propanamide α-CH2), 2.84 (dd, J = 14.0, 9.2 Hz, 1H, tyrosine β-CH2),
2.91 – 3.05 (m, 2H, piperidine 2-CH2, piperidine 6-CH2), 3.07 – 3.19 (m, 4H,
tyrosine β-CH2, piperidine 2-CH2, propanamide β-CH2), 3.24 (d, J = 14.6 Hz, 1H,
piperidine 6-CH2), 3.70 (s, 3H, O-CH3), 4.69 (ddd, J = 9.3, 5.3, 2.1 Hz, 1H, tyrosine
α-CH), 6.64 (ddd, J = 8.1, 2.4, 0.8 Hz, 1H, phenol 6-CH), 6.67 – 6.77 (m, 3H,
phenol 2-CH, tyrosine phenol ortho-CH), 6.78 (dd, J = 8.1, 1.9 Hz, 1H, phenol 4-
CH), 7.02 (d, J = 8.5 Hz, 2H, tyrosine meta-CH), 7.15 (t, J = 7.9 Hz, 1H, phenol 5-
CH).
13C NMR (MeOD): δ 15.4, 27.6, 30.5, 31.6, 36.9, 37.8, 38.9, 50.5, 52.8, 54.5, 
55.3, 56.0, 113.7, 114.0, 116.3, 116.3, 117.8, 128.6, 130.5, 131.3, 151.1, 157.5,
158.6, 169.4, 173.0, 173.5.
m/z: HRMS C26H34N2O5 [MH]+ calc 455.2640, found 455.2548.
Methyl N6-(tert-butoxycarbonyl)-N2-(3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanoyl)-L-lysinate (168i)
The title compound was synthesised as described in general procedure 2, using
3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoic acid
hydrochloride (165a) (25 mg, 0.080 mmol, 1 eq) and Nε-Boc-L-lysine methyl
ester hydrochloride (24 mg, 0.080 mmol, 1 eq) to give 166g as a white solid (5
mg, 12%).
185
1H NMR (MeOD): δ 0.81 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.34 – 1.54 (m, 4H,
lysine γ-CH2, lysine δ-CH2), 1.43 (s, 9H, tBu-CH3), 1.45 (s, 3H, piperidine 4-CH3),
1.65 – 1.78 (m, 1H, lysine β-CH2), 1.79 – 1.91 (m, 1H, lysine β-CH2), 1.95 (d, J =
14.5 Hz, 1H, piperidine 5-CH2), 2.36 – 2.53 (m, 2H, piperidine 5-CH2, piperidine
3-CH), 2.83 (t, J = 6.7 Hz, 2H, propanamide α-CH2), 3.02 (t, J = 6.8 Hz, 2H, lysine
ε-CH2), 3.29 – 3.38 (m, 1H, piperidine 6-CH2), 3.40 – 3.56 (m, 4H, piperidine 2-
CH2, propanamide β-CH2), 3.60 (d, J = 14.4 Hz, 1H, piperidine 6-CH2), 3.73 (s,
3H, O-CH3), 4.41 (dd, J = 8.8, 5.1 Hz, 1H, lysine α-CH), 6.66 (ddd, J = 8.1, 2.4, 0.8
Hz, 1H, phenol 6-CH), 6.73 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.78 (dt, J = 7.9, 1.5
Hz, 1H, phenol 4-CH), 7.17 (t, J = 7.9 Hz, 1H, phenol 5-CH).
13C NMR (MeOD): δ 13.4, 22.7, 25.6, 27.4, 27.7, 29.1, 30.6, 36.8, 37.1, 39.6, 




The title compound was synthesised as described in general procedure 3, using
methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-alaninate (166c) (3 mg, 0.008 mmol) to give 136c as a white
solid (3 mg, 100%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.22 (s, 3H,
piperidine 4-CH3), 1.23 (d, J = 7.6 Hz, 3H, alanine CH3), 1.51 (d, J = 12.8 Hz, 1H,
piperidine 5-CH2), 1.96 (d, J = 7.3 Hz, 1H, piperidine 3-CH), 2.14 (dt, J = 12.7, 6.4
Hz, 1H, piperidine 5-CH2), 2.22 – 2.35 (m, 2H, piperidine 2-CH2, piperidine 6-
CH2), 2.28 (t, J = 6.9 Hz, 2H, propanamide α-CH2), 2.47 – 2.58 (m, 3H,
propanamide β-CH2, piperidine 2-CH2), 2.82 (d, J = 10.7 Hz, 1H, piperidine 6-
186
CH2), 4.29 (p, J = 7.2 Hz, 1H, alanine α-CH), 6.55 (dd, J = 7.7, 2.3 Hz, 1H, phenol
6-CH), 6.66 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.71 (d, J = 8.0 Hz, 1H, phenol 4-CH),
7.08 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.21 (s, 1H, phenol OH), 8.55 (d, J = 7.3 Hz,
1H, amide NH).
13C NMR (DMSO-d6): δ 16.1, 17.4, 27.2, 29.1, 32.6, 37.9, 47.2, 49.0, 53.5, 54.7, 
112.2, 112.4, 116.0, 128.8, 157.1, 163.8, 171.2, 173.2.
m/z: HRMS C19H28N2O4 [MH]+ calc 349.2122, found 349.2130.
(3-((3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoyl)-L-
valine (136d)
The title compound was synthesised as described in general procedure 3, using
methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-valinate (166d) (3 mg, 0.008 mmol) to give 136d as a white solid
(3 mg, 100%).
1H NMR (DMSO-d6): δ 0.68 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 0.85 (dd, J = 6.8,
3.5 Hz, 6H, valine CH3), 1.23 (s, 3H, piperidine 4-CH3), 1.51 (d, J = 12.6 Hz, 1H,
piperidine 5-CH2), 1.91 – 2.09 (m, 2H, valine β-CH, piperidine 3-CH), 2.18 (td, J
= 12.7, 4.2 Hz, 1H, piperidine 5-CH2), 2.24 – 2.43 (m, 3H, propanamide α-CH2,
piperidine 6-CH2), 2.52 – 2.63 (m, 4H, propanamide β-CH2, piperidine 2-CH2),
2.87 (d, J = 11.8 Hz, 1H, piperidine 6-CH2), 4.17 (dd, J = 8.7, 5.6 Hz, 1H), 6.55
(dd, J = 7.9, 2.3 Hz, 1H, phenol 6-CH), 6.66 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.70
(d, J = 7.9 Hz, 1H, phenol 4-CH), 7.08 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.19 (s, 1H,
phenol OH), 8.31 (d, J = 8.7 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 16.6, 18.5, 19.6, 27.7, 30.3, 30.7, 33.0, 38.4, 38.4, 49.5, 
54.7, 55.7, 57.4, 112.6, 113.0, 116.5, 129.4, 152.0, 157.6, 164.0, 171.9, 173.7.
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m/z: HRMS C21H32N2O4 [MH]+ calc 377.2435, found 377.2427.
(3-((3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoyl)-L-
phenylalanine (136e)
The title compound was synthesised as described in general procedure 3, using
methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-phenylalaninate (166e) (5 mg, 0.011 mmol) to give 136e as a
white solid (5 mg, 100%).
1H NMR (MeOD): δ 0.77 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 1.42 (s, 3H,
piperidine 4-CH3), 1.90 (d, J = 10.5 Hz, 1H, piperidine 5-CH2), 2.30 – 2.47 (m, 2H,
piperidine 3-CH, piperidine 5-CH2), 2.69 (dt, J = 17.0, 6.7 Hz, 1H, phenylalanine
β-CH2), 2.79 (dt, J = 16.9, 6.4 Hz, 1H, phenylalanine β-CH2), 2.94 (dd, J = 13.9,
9.9 Hz, 2H, propanamide α-CH2), 3.20 – 3.29 (m, 1H, piperidine 6-CH2), 3.36 –
3.42 (m, 2H, propanamide β-CH2), 3.43 – 3.52 (m, 2H, piperidine 2-CH2), 3.61 –
3.73 (m, 1H, piperidine 6-CH2), 4.72 (dd, J = 9.7, 4.7 Hz, 1H, phenylalanine α-
CH), 6.66 (dd, J = 8.1, 2.3 Hz, 1H, phenol 6-CH), 6.72 (d, J = 2.3 Hz, 1H, phenol
2-CH), 6.76 (d, J = 7.8 Hz, 1H, phenol 4-CH), 7.17 (t, J = 7.9 Hz, 1H, phenol 5-CH),
7.19 – 7.35 (m, 5H, phenyl CH).
13C NMR (DMSO-d6): δ 15.2, 26.4, 26.9, 29.3, 36.3, 36.6, 37.0, 43.6, 60.2, 70.5, 
72.2, 112.2, 122.8, 115.7, 126.5, 128.2, 129.1, 129.3, 137.7, 149.5, 157.4, 169.2,
172.9.




The title compound was synthesised as described in general procedure 3, using
methyl (S)-3-cyclohexyl-2-(3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanamido)propanoate (166f) (5 mg, 0.011 mmol) to
give 136f as a white solid (5 mg, 100%).
1H NMR (DMSO-d6): δ 0.77 (d, J = 7.3 Hz, 3H, piperidine 3-CH3), 0.80 – 0.99 (m,
2H, cyclohexyl 2-CH2, cyclohexyl 6-CH2), 1.05 – 1.31 (m, 4H, cyclohexyl 3-CH2,
cyclohexyl 4-CH2, cyclohexyl 5-CH2), 1.35 (s, 3H, piperidine 4-CH3), 1.47 – 1.72
(m, 7H, cyclohexylalanine β-CH2, cyclohexyl 1-CH, cyclohexyl 2-CH2, cyclohexyl
3-CH2, cyclohexyl 5-CH2, cyclohexyl 6-CH2), 1.76 (d, J = 14.2 Hz, 1H, piperidine
5-CH2), 2.20 – 2.29 (m, 1H, piperidine 3-CH), 2.26 (td, J = 14.1, 3.0 Hz, 1H,
piperidine 5-CH2), 2.80 (t, J = 7.5 Hz, 2H, propanamide α-CH2), 3.19 – 3.43 (m,
6H, propanamide α-CH2, piperidine 2-CH2, piperidine 6-CH2), 4.25 (q, J = 7.6 Hz,
1H, cyclohexylalanine α-CH), 6.61 (dd, J = 7.9, 2.2 Hz, 1H, phenol 6-CH), 6.66 (t,
J = 2.0 Hz, 1H, phenol 2-CH), 6.70 (d, J = 8.1 Hz, 1H, phenol 4-CH), 7.12 (t, J = 7.9
Hz, 1H, phenol 5-CH), 8.48 (d, J = 7.8 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 15.1, 25.6, 25.8, 26.0, 26.4, 27.0, 29.2, 31.5, 33.1, 33.6, 
36.3, 37.1, 38.3, 43.6, 48.6, 49.7, 52.3, 53.3, 112.2, 112.8, 115.7, 129.2, 149.4,
157.4, 169.2, 174.0.




The title compound was synthesised as described in general procedure 3, using
ethyl (S)-2-(3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanamido)-4-phenylbutanoate (166g) (5 mg, 0.011 mmol) to give 136g as
a white solid (5 mg, 100%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.22 (s, 3H,
piperidine 4-CH3), 1.51 (d, J = 12.7 Hz, 1H, piperidine 5-CH2), 1.74 (m, 4H,
homophenylalanine β-CH2, propanamide α-CH2), 2.05 – 2.10 (m, 1H, piperidine
3-CH), 2.15 (td, J = 12.7, 4.2 Hz, 1H, piperidine 5-CH2), 2.22 – 2.41 (m, 4H,
propanamide β-CH2, piperidine 2-CH2, piperidine 6-CH2), 2.44 – 2.68 (m,
homophenylalanine γ-CH2, piperidine 2-CH2), 2.85 (d, J = 11.1 Hz, 1H, piperidine
6-CH2), 4.26 (td, J = 8.7, 4.8 Hz, 1H, homophenylalanine α-CH), 6.54 (dd, J = 7.9,
1.6 Hz, 1H, phenol 6-CH), 6.64 – 6.71 (m, 2H, phenol 2-CH, phenol 4-CH), 7.07
(t, J = 7.8 Hz, 1H, phenol 5-CH), 7.13 – 7.21 (m, 3H, phenyl ortho-CH, phenyl
para-CH), 7.22 – 7.30 (m, 2H, phenyl meta-CH), 8.27 (s, 1H, phenol OH), 8.58
(d, J = 7.9 Hz, 1H, amide NH)
13C NMR (DMSO-d6): δ 16.6, 27.7, 31.7, 33.3, 33.6, 38.4, 49.1, 49.6, 51.5, 52.3, 
54.5, 55.6, 1126, 112.9. 116.5, 126.4, 128.8, 129.4, 141.3, 152.1, 157.6, 172.1,
173.1.




The title compound was synthesised as described in general procedure 3, using
methyl (3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl)propanoyl)-L-tyrosinate (166h) (4 mg, 0.009 mmol) to give 136h as a white
solid (4 mg, 100%).
1H NMR (DMSO-d6): δ 0.59 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.22 (s, 3H,
piperidine 4-CH3), 1.50 (d, J = 13.3 Hz, 1H, piperidine 5-CH2), 1.85 – 1.99 (m, 1H,
piperidine 3-CH), 2.15 (td, J = 12.8, 4.4 Hz, 1H, piperidine 5-CH2), 2.24 – 2.42
(m, 3H, propanamide α-CH2, piperidine 6-CH2), 2.52 – 2.65 (m, 3H,
propanamide β-CH2, piperidine 2-CH2), 2.72 (dd, J = 13.8, 8.4 Hz, 1H, tyrosine
β-CH2), 2.86 (d, J = 11.4 Hz, 1H, piperidine 6-CH2), 2.91 (dd, J = 13.9, 5.0 Hz, 1H,
tyrosine β-CH2), 4.38 (td, J = 8.2, 5.0 Hz, 1H, tyrosine α-CH), 6.55 (dd, J = 7.9,
1.6 Hz, 1H, phenol 6-CH), 6.59 – 6.67 (m, phenol 2-CH, tyrosine phenol ortho-
CH), 6.69 (d, J = 8.6 Hz, 1H, phenol 4-CH), 6.92 – 7.01 (m, 2H, tyrosine phenol
meta-CH), 7.08 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.18 (s, 1H, phenol OH), 8.42 (d,
J = 8.1 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 15.7, 27.2, 29.5, 32.1, 36.3, 37.7, 37.8, 48.9, 53.6, 53.8, 
54.9, 112.2, 112.5, 114.9, 116.1, 127.5, 129.0, 130.0, 151.3, 155.9, 157.1, 163.4,
170.8, 173.2.




The title compound was synthesised as described in general procedure 3, using
methyl N6-(tert-butoxycarbonyl)-N2-(3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanoyl)-L-lysinate (168i) (4 mg, 0.009 mmol) to give
136i as a white solid (2 mg, 50%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.23 (s, 3H,
piperidine 4-CH3), 1.32 (tq, J = 13.7, 8.5 Hz, 2H, lysine γ-CH2), 1.43 – 1.60 (m,
4H, lysine δ-CH2, lysine β-CH2, piperidine 5-CH2), 1.67 (ddt, J = 11.4, 9.6, 5.5 Hz,
1H, lysine β-CH2), 1.91 – 2.00 (m, 1H, piperidine 3-CH), 2.13 (td, J = 12.6, 4.3 Hz,
1H, piperidine 5-CH2), 2.22 – 2.34 (m, 3H, propanamide α-CH2, piperidine 6-
CH2), 2.47 – 2.57 (m, 4H, lysine ε-CH2, piperidine 2-CH2), 2.69 (t, J = 7.6 Hz, 2H,
propanamide β-CH2), 2.82 (dd, J = 9.9, 5.7 Hz, 1H, piperidine 6-CH2), 4.27 (ddd,
J = 9.1, 7.8, 5.0 Hz, 1H, lysine α-CH), 6.55 (ddd, J = 8.0, 2.4, 0.8 Hz, 1H, phenol
6-CH), 6.68 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.71 (dt, J = 7.9, 1.2 Hz, 1H, phenol
4-CH), 7.09 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.39 (s, 1H, phenol OH), 8.56 (d, J =
7.9 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 16.6, 22.8, 27.7, 27.8, 30.3, 31.3, 33.2, 38.4, 38.4, 39.1, 
49.6, 51.9, 54.5, 55.5, 112.7, 112.9, 116.4, 129.4, 152.2, 157.7, 165.5, 172.1,
173.1.




The title compound was synthesised as described in general procedure 3, using
methyl N6-(tert-butoxycarbonyl)-N2-(3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-
dimethylpiperidin-1-yl)propanoyl)-L-lysinate (168i) (4 mg, 0.009 mmol) to give
166i, a white solid as a biproduct of 136i (2 mg, 50%).
1H NMR (DMSO-d6): δ 0.67 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.23 (s, 3H,
piperidine 4-CH3), 1.32 (tq, J = 13.7, 8.5 Hz, 2H, lysine γ-CH2), 1.43 – 1.60 (m,
4H, lysine δ-CH2, lysine β-CH2, piperidine 5-CH2), 1.67 (ddt, J = 11.4, 9.6, 5.5 Hz,
1H, lysine β-CH2), 1.91 – 2.00 (m, 1H, piperidine 3-CH), 2.13 (td, J = 12.6, 4.3 Hz,
1H, piperidine 5-CH2), 2.22 – 2.34 (m, 3H, propanamide α-CH2, piperidine 6-
CH2), 2.47 – 2.57 (m, 4H, lysine ε-CH2, piperidine 2-CH2), 2.69 (t, J = 7.6 Hz, 2H,
propanamide β-CH2), 2.82 (dd, J = 9.9, 5.7 Hz, 1H, piperidine 6-CH2), 3.63 (s, 3H,
O-CH3), 4.27 (ddd, J = 9.1, 7.8, 5.0 Hz, 1H, lysine α-CH), 6.55 (ddd, J = 8.0, 2.4,
0.8 Hz, 1H, phenol 6-CH), 6.68 (t, J = 2.1 Hz, 1H, phenol 2-CH), 6.71 (dt, J = 7.9,
1.2 Hz, 1H, phenol 4-CH), 7.09 (t, J = 7.9 Hz, 1H, phenol 5-CH), 8.39 (s, 1H,
phenol OH), 8.56 (d, J = 7.9 Hz, 1H, amide NH).
13C NMR (DMSO-d6): δ 16.6, 22.8, 27.7, 27.8, 30.3, 31.3, 33.2, 38.4, 38.4, 39.1, 
49.6, 51.9, 52.3, 54.5, 55.5, 112.7, 112.9, 116.4, 129.4, 152.2, 157.7, 165.5,
172.1, 173.1.





yl)propanoate (167) (278 mg, 0.91 mmol) and imidazole (124 mg, 1.820 mmol,
2 eq) in DMF (25 ml) was added tert-butyldimethylsilyl chloride (206 mg, 1.365
mmol, 1.5 eq) and stirred at rt for 4 hours. The solution was diluted with water
(200 ml) and extracted with EtOAc (3 x 50 ml). The combined organics were
washed with brine (50 ml) and dried over Na2SO4. Column chromatography (5%
MeOH in EtOAc) yielded 179 as a pale orange oil (344 mg, 90%)
1H NMR (CDCl3): δ 0.18 (s, 6H, silyl CH3), 0.74 (d, J = 7.0 Hz, 3H, piperidine 3-
CH3), 0.98 (s, 9H, tBu CH3), 1.25 (t, J = 7.1 Hz, 3H, Et CH3), 1.29 (s, 3H, piperidine
4-CH3), 1.56 (d, J = 12.3 Hz, 1H, piperidine 5-CH2), 1.91 – 1.99 (m, 1H, piperidine
3-CH), 2.26 (td, J = 12.4, 4.3 Hz, 1H, piperidine 5-CH2), 2.40 (td, J = 11.7, 2.3 Hz,
1H, piperidine 6-CH2), 2.49 (t, J = 7.2 Hz, 2H, propanoate α-CH2), 2.54 – 2.58 (m,
2H, piperidine 2-CH2), 2.70 (ddt, J = 26.5, 12.4, 7.1 Hz, 2H, propanoate β-CH2),
2.83 (dd, J = 7.6, 3.6 Hz, 1H, piperidine 6-CH2), 4.13 (qd, J = 7.1, 2.6 Hz, 2H, Et
CH2), 6.65 (ddd, J = 8.0, 2.4, 0.8 Hz, 1H, phenol 6-CH), 6.75 (t, J = 2.0 Hz, 1H,
phenol 2-CH), 6.86 (ddd, J = 7.9, 1.7, 0.9 Hz, 1H, phenol 4-CH), 7.14 (t, J = 7.9
Hz, 1H, phenol 5-CH).
13C NMR (CDCl3): δ -4.2, 14.4, 16.2, 18.4, 25.9, 27.6, 30.8, 32.8, 38.5, 39.0, 50.1,
54.0, 55.7, 60.5, 117.2, 117.9, 118.8, 129.0, 152.0, 155.6, 172.9.





yl)propanoate (167) (88 mg, 0.288 mmol) and K2CO3 (119 mg, 0.864 mmol, 3
eq) under N2 was added dry DMF (10 ml) and stirred at rt for 10 mins. Benzyl
bromide (38 µl, 0.317 mmol, 1.1 eq) was added dropwise and the reaction was
left to stir at rt overnight. Solvent was removed under high vacuum and the
residue was partitioned between water (50 ml) and EtOAc (50 ml). The organic
was washed with brine (20 ml) and dried over Na2SO4. Column chromatography
(5% MeOH in EtOAc) yielded 180 as an orange oil (80 mg, 70%).
1H NMR (CDCl3): δ 0.66 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 1.16 (t, J = 7.1 Hz,
3H, Et CH3), 1.21 (s, 3H, piperidine 4-CH3), 1.50 (d, J = 11.3 Hz, 1H, piperidine 5-
CH2), 1.85 – 1.94 (m, 1H, piperidine 3-CH), 2.19 (td, J = 12.4, 4.4 Hz, 1H,
piperidine 5-CH2), 2.33 (td, J = 11.5, 2.7 Hz, 1H, piperidine 6-CH2), 2.41 (t, J = 7.2
Hz, 2H, propanoate α-CH2), 2.44 – 2.53 (m, 2H, piperidine 2-CH2), 2.53 – 2.70
(m, 2H, propanoate β-CH2), 2.74 (dt, J = 10.8, 4.1 Hz, 1H, piperidine 6-CH2), 4.04
(qd, J = 7.1, 2.3 Hz, 2H, Et CH2), 4.96 (s, 2H, benzyl CH2), 6.71 (dd, J = 8.4, 2.5 Hz,
1H, phenol 6-CH), 6.77 – 6.85 (m, 2H, phenol 2-CH, phenol 4-CH), 7.14 (t, J = 7.9
Hz, 1H, phenol 5-CH), 7.19 – 7.42 (m, 5H, benzyl CH).
13C NMR (CDCl3): δ 14.3, 16.2, 27.7, 30.9, 32.7, 38.7, 38.9, 50.1, 53.9, 55.7, 60.4, 
70.1, 111.1, 113.5, 118.6, 127.7, 128.0, 128.7, 129.1, 137.3, 152.0, 158.8, 172.9.




To a solution of ethyl 3-((3R,4R)-4-(3-(benzyloxy)phenyl)-3,4-
dimethylpiperidin-1-yl)propanoate (180) (72 mg, 0.182 mmol) in dioxane (5
mL) was added 4M HCl (in dioxane and water) (2.5 mL) and heated to reflux
(105°C) for 2 hours. Once cooled to room temperature the solvents were
evaporated in vacuo to give 182 as a white solid (70 mg, 100%).
1H NMR (CDCl3): δ 0.76 (d, J = 7.1 Hz, 3H, piperidine 3-CH3), 1.30 (s, 3H,
piperidine 4-CH3), 1.71 (d, J = 13.9 Hz, 1H, piperidine 5-CH2), 2.01 – 2.15 (m, 1H,
piperidine 3-CH), 2.34 (td, J = 11.8 Hz, 1H, piperidine 5-CH2), 2.41 (t, J = 7.2 Hz,
2H, propanoate α-CH2), 2.33 (td, J = 11.5, 2.7 Hz, 1H, piperidine 6-CH2), 2.73 –
2.95 (m, 4H, piperidine 2-CH2, propanoate β-CH2), 3.09 (s, 1H, piperidine 6-
CH2), 4.04 (qd, J = 7.1, 2.3 Hz, 2H, Et CH2), 4.98 (s, 2H, benzyl CH2), 6.72 – 6.83
(m, 3H, phenol 6-CH, phenol 2-CH, phenol 4-CH), 7.14 (t, J = 8.2 Hz, 1H, phenol
5-CH), 7.22 – 7.41 (m, 5H, benzyl CH).
13C NMR (CDCl3): δ 15.8, 29.2, 29.8, 38.3, 48.8, 53.8, 55.2, 70.2, 111.7, 127.7, 
128.2, 128.7, 129.6, 137.1, 159.0, 174.0.
m/z: LCMS C23H29NO3 [MH]+ calc 368.5, found 368.2 with tR of 2.85 min.
General procedure 4 – solid phase peptide synthesis.
Novagel rink amide resin (0.69 mmol/g) (290 mg, 0.2 mmol) was swelled in
DMF in a filtered column for 1 hour before draining. 20% v/v piperidine in DMF
(5 ml) was added and the column gently agitated over 1 hour. The column was
drained and then washed with DMF (3 x 5 ml). Separately, a coupling solution
of HCTU (414 mg, 1.0 mmol, 5 eq), Fmoc-amino acid (1.0 mmol, 5 eq) and DIPEA
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(174 µl, 1.0 mmol, 5 eq) were stirred in DMF for 15 min at rt. The coupling
solution was added to the column and the column gently agitated over 4 hours.
The resin was drained, washed with DMF (3 x 5 ml), a 3:2 v/v mixture of acetic
anhydride/pyridine (5 ml) was added and the column was gently agitated over
1 hour. The column was drained and then washed with DMF (3 x 5 ml). The
Fmoc-deprotection in 20% v/v piperidine in DMF, Fmoc-amino acid coupling,
and capping steps were repeated twice more, with DMF washing (3 x 5ml)
between each step. This was followed by washing in DMF (3 x 5 ml), Fmoc-
deprotection in 20% v/v piperidine in DMF (5 ml), and further washing in DMF
(3 x 5 ml). A coupling mixture of HCTU (414 mg, 1.0 mmol, 5 eq), acrylic acid
(69 µl, 1.0 mmol, 5 eq) and DIPEA (174 µl, 1.0 mmol, 5 eq) were stirred in DMF
for 15 min at rt. This coupling mixture was then added to the column and the
column gently agitated over 4 hours. Washing in DMF (3 x 5 ml) was followed
by washing with DCM (3 x 5 ml) and the resin was dried under a stream of
nitrogen. The product was cleaved from the resin using an 18:1:1 v/v/v mixture
of TFA, TIPS and water (5 ml). The filtrate solvent was evaporated in vacuo.
Column chromatography (10% MeOH in EtOAc) yielded the product as a pale
yellow oil.
General procedure 5 – Michael addition of 3-((3R,4R)-3,4-dimethylpiperidin-
4-yl)phenol (146a) to acrylamido tripeptides.
3-((3R,4R)-3,4-dimethylpiperidin-4-yl)phenol (146a) (5 eq) and acrylamido
tripeptide (1 eq) were dissolved in minimal NMP and stirred at 85°C until
complete by TLC or LCMS (2-3 days). NMP was removed under high vacuum
and the residue was taken up in a 20% v/v solution of MeOH/EtOAc. It was then
was passed through a silica plug with additional washing with EtOAc and
purified by HPLC (system 3), to give the product as a pale yellow oil. Unreacted





The title compound was synthesised as described in general procedure 5, using
N-((2S)-1-((2-((1-amino-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)acrylamide (177a) (5 mg, 0.01
mmol), which was synthesised using general procedure 4. This yielded 170a as
a white solid (7 mg, 100%).
1H NMR (DMSO-d6): δ 0.62 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.19 (s, 3H,
piperidine 4-CH3), 1.45 (d, J = 12.5 Hz, 1H piperidine 5-CH2), 1.85 – 1.96 (m, 1H,
piperidine 3-CH), 2.08 (td, J = 12.6, 4.2 Hz, 1H, piperidine 5-CH2), 2.13 – 2.30
(m, 3H, propanamide α-CH2, piperidine 6-CH2), 2.34 – 2.46 (m, 4H,
propanamide β-CH2, piperidine 2-CH2), 2.69 – 2.77 (m, 1H, piperidine 6-CH2),
2.73 (dd, J = 13.7, 9.6 Hz, 1H, Phe3 β-CH2), 2.81 (dd, J = 13.8, 9.6 Hz, 1H, Phe1 β-
CH2), 3.00 (dd, J = 14.4, 5.2 Hz, 1H, Phe3 β-CH2), 3.04 (dd, J = 14.1, 4.9 Hz, 1H,
Phe1 β-CH2), 3.55 (dd, J = 16.6, 5.4 Hz, 1H, Gly2 CH2), 3.78 (dd, J = 16.7, 6.1 Hz,
1H, Gly2 CH2), 4.41 (td, J = 9.0, 4.5 Hz, 1H, Phe1 α-CH), 4.50 (td, J = 8.9, 4.5 Hz,
1H, Phe3 α-CH), 6.55 (dd, J = 8.0, 2.3 Hz, 1H, phenol 6-CH), 6.66 (s, 1H, phenol
2-CH), 6.69 (d, J = 8.0 Hz, 1H, phenol 4-CH), 7.08 (t, J = 7.9 Hz, 1H, phenol 5-CH),
7.12 (s, 1H, amide NH2), 7.15 – 7.30 (m, 10H, phenyl CH), 7.43 (s, 1H, amide
NH2), 8.02 (d, J = 8.5 Hz, 1H, Pr-Phe1 amide NH), 8.26 (t, J = 5.8 Hz, 1H, Phe1-
Gly2 amide NH), 8.41 (s, 1H, phenol OH), 8.46 (d, J = 8.0 Hz, 1H, Gly2-Phe3 amide
NH).
13C NMR (DMSO-d6): δ 16.1, 27.3, 29.9, 32.8, 37.5, 37.6, 37.9, 40.4, 42.0, 49.0, 
53.9, 54.0, 55.1, 112.1, 112.5, 116.1, 126.3, 128.0, 128.1, 128.9, 129.1, 129.1,
137.9, 138.1, 151.7, 157.2, 165.1, 168.5, 171.6, 172.9.
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The title compound was synthesised as described in general procedure 5, using
N-((2S)-1-(((2S)-1-((1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-
2-yl)amino)-1-oxo-3-phenylpropan-2-yl)acrylamide (177b) (5 mg, 0.01 mmol),
which was synthesised using general procedure 4. This yielded 170b as a white
solid (7 mg, 100%).
1H NMR (DMSO-d6): δ 0.61 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.16 (d, J = 7.1
Hz, 3H, Ala2 β-CH3), 1.19 (s, 3H, piperidine 4-CH3), 1.45 (d, J = 12.2 Hz, 1H
piperidine 5-CH2), 1.84 – 1.95 (m, 1H, piperidine 3-CH), 2.08 (td, J = 12.5, 4.0
Hz, 1H, piperidine 5-CH2), 2.13 – 2.27 (m, 3H, propanamide α-CH2, piperidine 6-
CH2), 2.29 – 2.45 (m, 4H, propanamide β-CH2, piperidine 2-CH2), 2.66 (dd, J =
13.9, 10.1 Hz, 1H, Phe3 β-CH2), 2.73 (d, J = 10.8 Hz, 1H, piperidine 6-CH2), 2.83
(dd, J = 13.8, 8.6 Hz, 1H, Phe1 β-CH2), 2.96 (dd, J = 14.4, 5.2 Hz, 1H, Phe3 β-CH2),
3.01 (dd, J = 14.1, 4.9 Hz, 1H, Phe1 β-CH2), 4.21 (p, J = 7.0 Hz, 1H, Ala2 α-CH), 
4.40 (td, J = 8.4, 5.0 Hz, 1H, Phe1 α-CH), 4.54 (td, J = 9.7, 4.1 Hz, 1H, Phe3 α-CH), 
6.54 (dd, J = 8.0, 2.3 Hz, 1H, phenol 6-CH), 6.65 (t, J = 2.0 Hz, 1H, phenol 2-CH),
6.68 (d, J = 8.0 Hz, 1H, phenol 4-CH), 7.07 (t, J = 7.8 Hz, 1H, phenol 5-CH), 7.09
(s, 1H, Phe3 amide NH2), 7.11 – 7.26 (m, 10H, phenyl CH), 7.36 (s, 1H, Phe3
amide NH2), 7.84 (d, J = 8.2 Hz, 1H, Pr-Phe1 amide NH), 8.18 (d, J = 7.2 Hz, 1H,
Phe1-Ala2 amide NH), 8.30 (s, 1H, phenol OH), 8.33 (d, J = 8.4 Hz, 1H, Ala2-Phe3
amide NH).
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13C NMR (DMSO-d6): δ 16.1, 18.0, 27.3, 29.9, 32.8, 37.4, 37.6, 37.9, 40.2, 48.5, 
49.0, 53.3, 53.6, 54.0, 55.1, 112.2, 112.5, 116.0, 126.2, 126.2, 127.9, 128.0,
128.9, 129.1, 129.2, 137.8, 137.9, 151.7, 157.1, 171.1, 171.3, 171.8, 172.6.




The title compound was synthesised as described in general procedure 5, using
(2S)-2-((S)-2-acrylamido-3-phenylpropanamido)-N-(1-amino-1-oxo-3-
phenylpropan-2-yl)-3-methylbutanamide (177c) (5 mg, 0.01 mmol), which was
synthesised using general procedure 4. This yielded 170c as a white solid (7
mg, 100%).
1H NMR (DMSO-d6): δ 0.62 (d, J = 7.0 Hz, 3H, piperidine 3-CH3), 0.76 (dd, J = 6.7,
2.4 Hz, 6H, Val2 CH3), 1.19 (s, 3H, piperidine 4-CH3), 1.45 (d, J = 12.4 Hz, 1H
piperidine 5-CH2), 1.86 – 1.98 (m, 3H, Val2 β-CH, piperidine 3-CH), 2.08 (td, J =
12.5, 4.2 Hz, 1H, piperidine 5-CH2), 2.13 – 2.27 (m, 3H, propanamide α-CH2,
piperidine 6-CH2), 2.33 – 2.46 (m, 4H, propanamide β-CH2, piperidine 2-CH2),
2.68 (dd, J = 14.1, 10.1 Hz, 1H, Phe3 β-CH2), 2.73 (dt, J = 11.4, 3.6 Hz, 1H,
piperidine 6-CH2), 2.81 (dd, J = 13.9, 9.0 Hz, 1H, Phe1 β-CH2), 2.95 (dd, J = 14.0,
4.3 Hz, 1H, Phe3 β-CH2), 2.99 (dd, J = 13.8, 5.2 Hz, 1H, Phe1 β-CH2), 4.11 (dd, J =
8.8, 6.8 Hz, 1H, Val2 α-CH), 4.48 (td, J = 8.6, 5.2 Hz, 1H, Phe1 α-CH), 4.61 (td, J =
9.2, 4.2 Hz, 1H, Phe3 α-CH), 6.55. (dd, J = 7.9, 2.5 Hz, 1H, phenol 6-CH), 6.64 –
6.72 (m, 2H, phenol 2-CH, phenol 4-CH), 7.06 (s, 1H, Phe3 amide NH2), 7.08 (t, J
= 7.8 Hz, 1H, phenol 5-CH), 7.12 – 7.27 (m, 10H, phenyl CH), 7.35 (s, 1H, Phe3
amide NH2), 7.92 (d, J = 9.0 Hz, 1H, Phe1-Ala2 amide NH), 8.00 (d, J = 8.3 Hz, 1H,
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Pr-Phe1 amide NH), 8.35 (d, J = 8.5 Hz, 1H, Ala2-Phe3 amide NH), 8.43 (s, 1H,
phenol OH).
13C NMR (DMSO-d6): δ 14.4, 16.1, 18.1, 19.1, 26.5, 27.3, 29.3, 30.6, 32.9, 37.5, 
37.6, 38.0, 38.3, 49.0, 53.3, 53.6, 54.0, 55.1, 112.2, 112.5, 116.0, 126.2, 126.2,
127.9, 128.0, 128.9, 129.1, 129.2, 137.8, 137.9, 151.7, 157.1, 171.1, 171.3,
171.8, 172.6.




The title compound was synthesised as described in general procedure 5, using
N-((2S)-1-(((2S)-1-((1-amino-1-oxo-3-phenylpropan-2-yl)amino)-3-hydroxy-1-
oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)acrylamide (177d) (5 mg,
0.01 mmol), which was synthesised using general procedure 4. This yielded
170d as a white solid (7 mg, 100%).
1H NMR (DMSO-d6): δ 0.62 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.19 (s, 3H,
piperidine 4-CH3), 1.46 (d, J = 12.3 Hz, 1H piperidine 5-CH2), 1.85 – 1.94 (m, 1H,
piperidine 3-CH), 2.10 (td, J = 12.5, 4.0 Hz, 1H, piperidine 5-CH2), 2.14 – 2.27
(m, 3H, propanamide α-CH2, piperidine 6-CH2), 2.29 – 2.47 (m, 4H,
propanamide β-CH2, piperidine 2-CH2), 2.68 (dd, J = 14.1, 10.1 Hz, 1H, Phe3 β-
CH2), 2.74 (d, J = 11.2 Hz, 1H, piperidine 6-CH2), 2.84 (dd, J = 13.9, 9.2 Hz, 1H,
Phe1 β-CH2), 2.97 (dd, J = 13.9, 4.1 Hz, 1H, Phe3 β-CH2), 3.08 (dd, J = 14.0, 4.5
Hz, 1H, Phe1 β-CH2), 3.48 (dd, J = 10.9, 6.2 Hz, 1H, Ser2 β-CH2), 3.59 (dd, J = 10.7,
6.0 Hz, 1H, Ser2 CH2), 4.27 (q, J = 6.4 Hz, 1H, Ser2 α-CH), 4.41 (td, J = 8.7, 4.5 Hz,
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1H, Phe1 α-CH), 4.59 (td, J = 9.2, 4.0 Hz, 1H, Phe3 α-CH), 6.56 (dd, J = 8.0, 2.3 Hz,
1H, phenol 6-CH), 6.65 – 6.72 (m, 2H, phenol 2-CH, phenol 4-CH), 7.08 (t, J = 7.8
Hz, 1H, phenol 5-CH), 7.12 – 7.29 (m, 11H, Phe3 amide NH2, phenyl CH), 7.40 (s,
1H, Phe3 amide NH2), 8.06 (d, J = 8.2 Hz, 1H, Pr-Phe1 amide NH), 8.19 (d, J = 7.5
Hz, 1H, Phe1-Ala2 amide NH), 8.37 (d, J = 8.4 Hz, 1H, Ala2-Phe3 amide NH), 8.44
(s, 1H, phenol OH).
13C NMR (DMSO-d6): δ 16.1, 27.3, 32.9, 37.0, 37.8, 37.9, 37.9, 49.0, 53.4, 54.0, 
54.0, 55.1, 55.1, 61.7, 112.2, 112.5, 116.0, 126.1, 126.2, 127.9, 128.0, 128.9,
129.1, 129.1, 137.9, 138.0, 151.7, 157.2, 165.6, 169.8, 171.3, 171.5, 172.8.




The title compound was synthesised as described in general procedure 5, using
(2S)-2-((S)-2-acrylamido-3-phenylpropanamido)-N1-(1-amino-1-oxo-3-
phenylpropan-2-yl)succinimide (177e) (6 mg, 0.01 mmol), which was
synthesised using general procedure 4. This yielded 170e as a white solid (8
mg, 100%).
1H NMR (DMSO-d6): δ 0.63 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.20 (s, 3H,
piperidine 4-CH3), 1.46 (d, J = 11.8 Hz, 1H piperidine 5-CH2), 1.85 – 1.96 (m, 1H,
piperidine 3-CH), 2.03 – 2.30 (m, 4H, propanamide α-CH2, piperidine 5-CH2,
piperidine 6-CH2), 2.31 – 2.46 (m, 5H, propanamide β-CH2, piperidine 2-CH2,
Asn2 β-CH2), 2.52 – 2.66 (m, 2H, Asn2 β-CH2, Phe3 β-CH2), 2.73 (d, J = 10.5 Hz,
1H, piperidine 6-CH2), 2.82 (dd, J = 14.2, 9.7 Hz, 1H, Phe1 β-CH2), 2.87 (dd, J =
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13.9, 3.9 Hz, 1H, Phe3 β-CH2), 3.11 (dd, J = 14.1, 4.2 Hz, 1H, Phe1 β-CH2), 4.34
(td, J = 8.9, 4.1 Hz, 1H, Phe1 α-CH), 4.44 – 4.58 (m, 2H, Asn2 α-CH, Phe3 α-CH), 
6.55 (dd, J = 7.9, 2.3 Hz, 1H, phenol 6-CH), 6.67 (t, J = 2.1 Hz, 1H, phenol 2-CH),
6.70 (d, J = 7.8 Hz, 1H, phenol 4-CH), 6.99 (s, 1H, Asn2 NH2), 7.09 (t, J = 7.9 Hz,
1H, phenol 5-CH), 7.13 – 7.30 (m, 11H, Phe3 amide NH2, phenyl CH), 7.43 (s, 1H,
Phe3 amide NH2), 7.47 (s, 1H, Asn2 NH2), 8.06 (d, J = 8.3 Hz, 1H, Pr-Phe1 amide
NH), 8.30 (s, 1H, phenol OH), 8.33 (d, J = 7.8 Hz, 1H, Phe1-Ala2 amide NH), 8.36
(d, J = 8.4 Hz, 1H, Ala2-Phe3 amide NH).
13C NMR (DMSO-d6): δ 16.1, 27.3, 29.9, 32.8, 36.8, 36.9, 37.8, 37.9, 37.9, 40.2, 
48.9, 49.7, 53.4, 54.0, 55.2, 112.2, 112.5, 116.1, 126.1, 126.2, 127.9, 128.1,
128.9, 129.0, 129.1, 137.8, 138.2, 151.7, 157.1, 170.5, 171.3, 171.3, 171.9,
172.8.


















The title compound was synthesised as described in general procedure 5, using
(3S)-3-((S)-2-acrylamido-3-phenylpropanamido)-4-((1-amino-1-oxo-3-
phenylpropan-2-yl)amino)-4-oxobutanoic acid (177f) (6 mg, 0.01 mmol), which
was synthesised using general procedure 4. This yielded 170f as a white solid
(8 mg, 100%).
1H NMR (DMSO-d6): δ 0.63 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.20 (s, 3H,
piperidine 4-CH3), 1.46 (d, J = 12.1 Hz, 1H piperidine 5-CH2), 1.86 – 1.96 (m, 1H,
piperidine 3-CH), 2.06 – 2.31 (m, 4H, propanamide α-CH2, piperidine 5-CH2,
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piperidine 6-CH2), 2.34 – 2.49 (m, 5H, propanamide β-CH2, piperidine 2-CH2,
Asn2 β-CH2), 2.52 – 2.70 (m, 2H, Asp2 β-CH2, Phe3 β-CH2), 2.77 (d, J = 10.8 Hz,
1H, piperidine 6-CH2), 2.83 (dd, J = 13.9, 9.2 Hz, 1H, Phe1 β-CH2), 2.92 (dd, J =
14.0, 4.2 Hz, 1H, Phe3 β-CH2), 3.06 (dd, J = 14.0, 4.5 Hz, 1H, Phe1 β-CH2), 4.34
(td, J = 8.7, 4.4 Hz, 1H, Phe1 α-CH), 4.45 (q, J = 7.0 Hz, 1H, Asn2 α-CH), 4.51 (td, 
J = 9.6, 4.2 Hz, 1H, Phe3 α-CH), 6.54 (dd, J = 8.8, 1.9 Hz, 1H, phenol 6-CH), 6.64
– 6.72, phenol 2-CH, phenol 4-CH), 7.00 – 7.29 (m, 12H, phenol 5-CH, Phe3
amide NH2, phenyl CH), 7.40 (s, 1H, Phe3 amide NH2), 8.02 (d, J = 8.2 Hz, 1H, Pr-
Phe1 amide NH), 8.30 (s, 1H, phenol OH), 8.37 (d, J = 7.6 Hz, 1H, Phe1-Ala2 amide
NH), 8.41 (d, J = 8.4 Hz, 1H, Ala2-Phe3 amide NH).
13C NMR (DMSO-d6): δ 16.1, 27.2, 29.8, 32.6, 37.0, 37.3, 37.6, 37.9, 40.2, 48.9, 
50.0, 53.5, 53.8, 54.0, 55.1, 112.2, 112.6, 116.1, 126.1, 126.2, 128.0, 128.1,
128.9, 129.1, 129.1, 137.9, 138.1, 151.5, 157.2, 170.6, 171.2, 171.2, 171.4,
172.6, 172.8.




The title compound was synthesised as described in general procedure 5, using
(2S)-2-((S)-2-acrylamido-3-phenylpropanamido)-6-amino-N-(1-amino-1-oxo-3-
phenylpropan-2-yl)hexanamide (177g) (7 mg, 0.015 mmol), which was
synthesised using general procedure 4. This yielded 170g as a white solid (10
mg, 100%).
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1H NMR (DMSO-d6): δ 0.61 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.19 (s, 3H,
piperidine 4-CH3), 1.14 – 1.27 (m, 2H, lysine γ-CH2), 1.40 – 1.63 (m, 5H,
piperidine 5-CH2, Lys2 β-CH2, Lys2 δ-CH2), 1.83 – 1.98 (m, 1H, piperidine 3-CH),
2.07 (td, J = 12.8, 4.2 Hz, 1H, piperidine 5-CH2), 2.13 – 2.31 (m, 3H, propanamide
α-CH2, piperidine 6-CH2), 2.36 – 2.48 (m, 4H, propanamide β-CH2, piperidine 2-
CH2), 2.62 – 2.78 (m, 4H, Lys2 ε-CH2, Phe3 β-CH2, piperidine 6-CH2), 2.82 (dd, J =
13.8, 9.1 Hz, 1H, Phe1 β-CH2), 2.96 (dd, J = 14.0, 4.0 Hz, 1H, Phe3 β-CH2), 3.02
(dd, J = 13.9, 4.9 Hz, 1H, Phe1 β-CH2), 4.16 (td, J = 8.1, 5.4 Hz, 1H, Lys2 α-CH), 
4.43 (td, J = 8.6, 4.9 Hz, 1H, Phe1 α-CH), 4.52 (ddd, J = 10.1, 8.2, 4.1 Hz, 1H, Phe3
α-CH), 6.55 (dd, J = 8.0, 2.2 Hz, 1H, phenol 6-CH), 6.62 – 6.72, phenol 2-CH,
phenol 4-CH), 7.08 (t, J = 8.0 Hz, 1H, phenol 5-CH), 7.10 (s, 1H, Phe3 amide NH2),
7.12 – 7.27 (m, 10H, phenyl CH), 7.41 (s, 1H, Phe3 amide NH2), 7.96 (d, J = 8.2
Hz, 1H, Pr-Phe1 amide NH), 8.25 (d, J = 7.8 Hz, 1H, Phe1-Ala2 amide NH), 8.33 (s,
1H, phenol OH), 8.44 (d, J = 8.2 Hz, 1H, Ala2-Phe3 amide NH).
13C NMR (DMSO-d6): δ 16.1, 22.1, 26.7, 27.4, 29.9, 31.2, 32.8, 37.5, 37.6, 37.9, 
38.0, 38.6, 40.2, 49.1, 52.8, 53.8, 53.8, 54.0, 55.1, 112.3, 112.6, 116.1, 126.3,
126.4, 128.1, 128.1, 129.0, 129.2, 129.3, 137.8 ,137.9, 151.7, 157.3, 165.1
,171.3, 171.6, 171.6, 173.0.



















The title compound was synthesised as described in general procedure 5, using
(2S)-2-((S)-2-acrylamido-3-phenylpropanamido)-N-(1-amino-1-oxo-3-
phenylpropan-2-yl)-5-guanidinopentanamide (177h) (7 mg, 0.015 mmol),
which was synthesised using general procedure 4. This yielded 170h as a white
solid (10 mg, 100%).
1H NMR (DMSO-d6): δ 0.61 (d, J = 6.9 Hz, 3H, piperidine 3-CH3), 1.19 (s, 3H,
piperidine 4-CH3), 1.32 – 1.42 (m, 2H, Arg2 γ-CH2), 1.45 (d, J = 12.6 Hz, 1H,
piperidine 5-CH2), 1.40 – 1.71 (m, 2H, Arg2 β-CH2), 1.83 – 1.95 (m, 1H, piperidine
3-CH), 2.08 (td, J = 13.1, 6.5 Hz, 1H, piperidine 5-CH2), 2.12 – 2.30 (m, 3H,
propanamide α-CH2, piperidine 6-CH2), 2.34 – 2.45 (m, 4H, propanamide β-CH2,
piperidine 2-CH2), 2.64 – 2.77 (m, 2H, Phe3 β-CH2, piperidine 6-CH2), 2.82 (dd, J
= 13.8, 9.0 Hz, 1H, Phe1 β-CH2), 2.92 – 3.09 (m, 4H, Arg2 δ-CH2, Phe1 β-CH2, Phe3
β-CH2), 4.19 (td, J = 8.0, 5.1 Hz, 1H, Arg2 α-CH), 4.42 (td, J = 8.5, 4.9 Hz, 1H, Phe1
α-CH), 4.53 (ddd, J = 9.8, 8.1, 4.2 Hz, 1H, Phe3 α-CH), 6.55 (dd, J = 8.0, 2.2 Hz,
1H, phenol 6-CH), 6.63 – 6.73, phenol 2-CH, phenol 4-CH), 7.07 (t, J = 7.8 Hz,
1H, phenol 5-CH), 7.09 (s, 1H, Phe3 amide NH2), 7.10 – 7.27 (m, 10H, phenyl
CH), 7.37 (s, 1H, Phe3 amide NH2), 8.00 (d, J = 8.2 Hz, 1H, Pr-Phe1 amide NH),
8.36 (d, J = 7.5 Hz, 1H, Phe1-Ala2 amide NH), 8.37 (s, 1H, phenol OH), 8.42 (d, J
= 8.0 Hz, 1H, Ala2-Phe3 amide NH), 8.65 (t, J = 5.1 Hz, 1H, Arg2 δ-NH). 
13C NMR (DMSO-d6): δ 16.1, 24.6, 27.3, 28.8, 29.9, 32.9, 37.5, 37.5, 37.9, 49.0, 
51.4, 53.7, 53.8, 54.0, 55.1, 112.2, 112.5, 116.0, 126.2, 128.0, 128.0, 128.9,
129.1, 129.1, 137.8, 137.9, 151.7, 157.2, 157.3, 165.8, 171.0, 171.5, 171.6,
172.7.









phenylpropanamido)hexanamide (170g) (1.17 mg, 1.5 µmol, 1.0 eq) in DMF
(0.5 ml) was added BODIPY 630/650-X NHS ester (1.0 mg, 1.5 µmol, 1.0 eq) in
DMF (0.5 ml). The reaction mixture was stirred at room temperature for 90
min. Solvent was removed under high vacuum and purification by reverse
phase HPLC (system 3) yielded 192, a blue solid (1.0 mg, 53%).







To BODIPY 630/650 (0.68 mg, 1.5 µmol) in DMF (0.5 ml) was added PyBOP (0.78
mg, 1.5 µmol, 1.0 eq) and DIPEA (0.26 µl, 1.5 µmol, 1.0 eq). The reaction
mixture was stirred at room temperature for 15 min after which (2S)-6-amino-
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(3-((3R,4R)-4-(3-
hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)-3-
phenylpropanamido)hexanamide (170g) (0.73 mg, 1.5 µmol, 1.0 eq) in DMF
(0.5 ml) was added. The reaction mixture was then stirred at room temperature
for 90 min. Solvent was removed under high vacuum and purification by
reverse phase HPLC (system 3) yielded 193, a blue solid (0.6 mg, 35%).








phenylpropanamido)hexanamide (170g) (1.05 mg, 1.5 µmol, 1.0 eq) in DMF
(0.5 ml) was added sulfo-Cy5 NHS ester (1.17 mg, 1.5 µmol, 1.0 eq) in DMF (0.5
ml). The reaction mixture was stirred at room temperature for 90 min. Solvent
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was removed under high vacuum and purification by reverse phase HPLC
(system 3) yielded 194, a blue solid (0.8 mg, 40%).
m/z: HRMS C72H90N8O12S2 [M-H]- calcd 1321.6047; found 1321.6037.
5.2 General pharmacology
Cell culture
MOR-expressing HEK293 cells and SNAP-MOR-expressing HEK293 cells were
obtained from Dr Arisbel Gondin, who performed the transfections and
isolated stable clones as described in Gondin et al.149 Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and maintained at 37 °C in a humidified incubator containing
5% CO2.
Cells were grown to confluence in 75 cm2 tissue culture treated flasks (T75s).
Passaging of cells proceeded with removal of the DMEM and washing with
phosphate buffered saline (PBS). Cells were lifted from the flask by 1 mL 1x
trypsin-EDTA and removed from the flask with PBS. Following this, the cells
were centrifuged at 1000 rpm for 5 min and the supernatant discarded. The
pellet was resuspended in DMEM and a portion (typically 1/5 or 1/10)
transferred into a new T75 flask containing DMEM.
Preparation of Lumi4-Tb-labelled membranes
SNAP-MOR-expressing HEK293 cells were seeded into poly-D-Lysine-coated
175 cm2 tissue culture treated flasks (T175s) and grown to confluence. DMEM
was aspirated and the cells were washed with PBS. SNAP tag labelling was
performed by addition of 12 ml of 100 nM Lumi4-Tb (CisBio, Bagnols-sur-Ce’ze,
France) in Tag-lite labelling medium to the cells and the cells incubated at 37
°C in a humidified incubator containing 5% CO2 for 1 hour. The labelling solution
was removed, and the cells washed with PBS. Cells were then removed from
the flask by scraping and washing with further PBS. The cells were transferred
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to a 50 ml tube and centrifuged at 1500 rpm for 10 min. The supernatant was
removed, and the resulting pellets stored at -80°C.
Membranes were prepared from the defrosted cell pellets which were
resuspended in 20 ml PBS and homogenised using an electrical homogeniser in
20 × 2 sec bursts. The resultant homogenate was centrifuged at 1500 x g for 20
min to remove unbroken cells and nuclei. The supernatant was decanted and
subsequently centrifuged at 41415 x g for 30 min, the supernatant discarded,
and the pellet resuspended in PBS. Further homogenisation was carried out by
20 passes of a glass homogeniser. Protein concentration was determined using
a BCA protein assay and membranes were stored at оϴϬΣƵŶƟůƌĞƋƵŝƌĞĚ͘
Whole cell competition binding assays
Cells were seeded into poly-D-Lysine-coated thin clear bottomed black wall 96
well plates (Greiner Bio-One Ltd, Stonehouse, UK) 24 hours prior to the assay.
On the day of the experiment, DMEM was aspirated and the cells washed with
room temperature PBS. The cells were incubated in duplicate with increasing
concentrations of unlabelled ligand and 50 nM fluorescent ligand 51 in a final
volume of 100 µl of HEPES-buffered saline solution (HBSS: 145 mmol/L NaCl, 5
mmol/L KCl, 1.7 mmol/L CaCl2, 1 mmol/L MgSO4, 10 mmol/L HEPES, 2 mmol/L
sodium pyruvate, 1.5 mmol/L NaHCO3, 10 mmol/L D-glucose, pH 7.4) for 1 hour
at 37 °C in a humidified incubator. Plates were imaged using an ImageXpress
Ultra confocal plate reader which captured four images per well. Excitation of
51 used a 635 nm laser (20 % laser power) with emission collected through a
640-685 nm bandpass filter. The focus and laser gain settings used were
adjusted for each plate. Values for fluorescence intensity were obtained using
a multi-wavelength cell scoring algorithm within the MetaXpress software,
normalised as a percentage of maximal integrated intensity per plate (where
fluorescence intensity in the absence of unlabelled competitor was defined at
100%) from mean total well intensity.
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Results were fitted to a competition binding curve in GraphPad Prism 8.4.3
using non-linear regression analysis (variable slope – four parameters). IC50
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Where [fluorescent ligand] = concentration of free fluorescent ligand used in the assay. KD =
the dissociation constant of the fluorescent ligand for the receptor. IC50 = the concentration of
unlabelled ligand that displaces 50% of the specific binding of the fluorescent ligand.
Membrane-based competition binding assays
To each well of an opaque bottomed 96-well plate were added increasing
concentrations of unlabelled ligand and fluorescent ligand at a concentration
equal to its KD, followed by 2.5 µg of Lumi4-Tb-labelled SNAP-MOR-expressing
HEK293 cell membrane, in a final volume of 100 µl of HBSS. Membranes were
incubated in duplicate or triplicate for 90 mins at 37 °C, after which plates were
read in a TR-FRET competition binding assay using a PHERAstar FS plate reader
(BMG Labtech, Offenberg, Germany) with the terbium (donor) excited with 30
flashes of laser at 337 nm and emission collected at 620 nm (terbium) and 665
nm (Cy5/BY630) 400 ms after excitation.
Competition binding curves were fitted from the percentage of maximal
measured HTRF emission ratio (665/620 nm) (where HTRF emission ratio in the
absence of unlabelled competitor was defined at 100%, and the mean of the
lowest duplicate or triplicate sample set on the plate was defined as 0%) in
GraphPad Prism 8.4.3 using non-linear regression analysis. IC50 values were
used to determine Ki using the Cheng-Prusoff equation (see above).122
Saturation binding assays
Saturation binding assays were carried out using Lumi4-Tb-labelled SNAP-
MOR-expressing HEK293 cell membranes. Increasing concentrations of
fluorescent ligand followed 2.5 µg of membrane were added to each well of an
opaque bottomed 96-well plate in HBSS, both in the absence (total binding)
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and presence (non-specific binding) of 10 µM naloxone, in a final volume of 100
µl of HBSS. Membranes were incubated in duplicate or triplicate for 90 mins at
37 °C, after which plates were read in a TR-FRET saturation binding assay using
a PHERAstar FS plate reader as described above.
Total and non-specific binding curves were fitted from the measured HTRF
emission ratio (665/620 nm) (where HTRF emission ratio in the absence of
unlabelled competitor was defined at 100%, and the mean of the lowest
duplicate or triplicate sample set on the plate was defined as 0%) in GraphPad
Prism 8.4.3 using a one site – total and non-specific binding model, from which
KD of specific binding curve was determined.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 8.4.3 software by one-
way ANOVA and post-hoc analysis as described.
5.3 In silico modelling
The three dimensional model of MOR (PDB: 4DKL)33 was obtained from GPCRdb
(https://www.gpcrdb.org) and loaded into the online docking software
DockingServer (http://www.dockingserver.com/web). Prior to docking, the
binding site was established using the bound ligand β-FNA (74). Compounds of
the structures 92 (Figure 2-15) and 93 (Figure 2-20) were drawn and docked.
Twenty docking poses of each congener which visually met the criteria
described in Figure 2-16, were inspected for 6-substituent interactions.
Outputs were visualised on DockingServer as no export file was available.
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